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 Trastuzumab targets the ErbB2 (HER2) receptor on breast cancer cells to 
attenuate HER2 driven tumor formation. Trastuzumab reduces both downstream 
PI3K/Akt and MAPK pathway signaling as well as the breast cancer stem cell 
(BCSC) population. BCSCs are hypothesized to be responsible for tumor 
recurrence, metastasis, as well as drug resistance. Today, resistance to 
trastuzumab remains a major clinical problem for women diagnosed with HER2+ 
breast cancer. Attenuation of PI3K/Akt and MAPK pathways may occur through 
the tumor suppressor, PTEN. Women with HER2+ breast tumors expressing less 
PTEN and increased PI3K/Akt or MAPK activity have worse overall outcome. 
Previously we have shown that trastuzumab resistant cells have increased 
expression of Notch-1 which drives cell proliferation in vitro as well as tumor 
recurrence in vivo. Here, we show, to our knowledge for the first time, that Notch-
1 directly represses PTEN transcript RNA expression to promote trastuzumab 
resistant HER2+ breast cancer cell proliferation at least in part through activation 
of ERK1/2. Furthermore, we demonstrate that Notch-1 mediated inhibition of PTEN 







Breast Development and Anatomy. 
 At birth, the mammary gland is identical in both males and females as it is 
comprised a series of ducts to form a tree-like structure (Moore and Persaud, 1998; 
Pandya and Moore, 2011). In females, the mammary gland develops into an 
exocrine gland that produces milk for the purpose of weening children. Thelarche 
is the onset of breast development which occurs primarily during puberty. At this 
time, an increase in ovarian estrogen and progesterone production in combination 
with somatotropin (human growth hormone) secretion from the pituitary gland 
promotes mammary gland formation inside the developing breast. Mammary gland 
development is completed upon the onset of pregnancy. During pregnancy, the 
breast enlarges due to estrogen, progesterone, prolactin, growth hormone, and 
placental hormones. This burst of female hormones drives proliferation of the 
glandular epithelium that replace breast tissue stromal elements. During the third 
trimester of pregnancy, the epithelium differentiates into secretory cells for the 
synthesis and secretion of milk. After birth, the release of oxytocin promotes 
myoepithelial cell proliferation and differentiation in preparation for the nursing of 
young (Beesley and Johnson, 2008). After delivery, estrogen and progesterone 





Milk secretion is induced reflexively by a suckling infant and regulated by oxytocin. 
As nursing of the infant decreases, the glandular, stromal, and ductal elements of 
the breast atrophy resulting in reduced breast size. Similarly, there is an overall 
reduction in mammary gland ducts and lobules as well as fat and stromal elements 
resulting in a reduction in breast size and volume during menopause (Macias and 
Hinck, 2012).  
During embryogenesis, mammary glands develop from the primary 
epidermal ectoderm layer cells invading the underlying mesenchymal tissue (Drew 
et al., 2007). As the mammary gland develops, the primary bud of the mammary 
gland branches into 15 to 20 secondary buds that become lactiferous ducts. The 
breast tissue is comprised of 15 to 20 lobes that are divided into 4 lobules and 
each lobe is comprised of branched tubuloalveolar glands. The lobes drain into 
major lactiferous ducts that then drain into a lactiferous sinus which can be 
accessed through the nipple orifice. Similarly, the breast is divided into four 
quadrants: upper inner, upper outer, lower inner, and lower outer. The most 
common place for the development of breast tumors is in the upper outer quadrant 
where a majority of the breast volume exists (Clough et al., 2010).  
Breast Cancer. 
 Breast cancer remains the leading cause of cancer-related deaths among 
women world-wide (ACS, 2015). In the United States, it is estimated that 246,660 
women will be diagnosed with invasive breast cancer and 61,000 women will be 





Society. Additionally, it is estimated that 40,450 women in the U.S. will succumb 
to breast cancer. For men, it is estimated that there will be 2,600 new cases of 
invasive breast cancer as they tend to ignore breast cancer symptoms resulting in 
breast cancer diagnosis at a later stage compared to women. Women have a 1 in 
8 risk of developing invasive breast cancer within their lifetime. This statistic has 
risen since 1975 (1 in 11 risk of breast cancer) mainly due to an increase in early 
detection and breast cancer awareness (breastcancer.org). 
 Cancer is not a single disease but a group of diseases that causes cells in 
the body to uncontrollably grow and proliferate compared to normal, healthy cells. 
Unregulated proliferation of cancer cells can form a tumor which is named after the 
tissue in which it originates; hence breast cancer is dubbed so due to the formation 
of tumors in the breast tissue. Breast cancer can have several different forms 
depending on the type of breast tissue that the tumor develops in as well as the 
expression of various biomarkers by the breast cancer cell. Breast cancer typically 
forms from cells of the lactiferous ducts (ductal carcinoma) or the lobules (lobular 
carcinoma) that supply the milk. There are over 18 sub-types of breast cancer 
which include tubular, medullary, mucinous, and papillary ductal carcinoma 
depending on the tumor origin. Using histopathology techniques, breast cancer 
grade as well as stage can help determine the progression of the disease. Cancer 
grade indicates the amount of disorganization occurring in the cancer cell. Cancer 
stage indicates the degree of invasiveness of the cancer. Both grade and stage of 





course that will be taken. Several factors can affect breast cancer diagnosis 
including differences in race, diet, alcohol consumption, smoking, physical activity, 
hormone replacement therapy, and family history.  
Breast Cancer Subtypes. 
 The intrinsic heterogeneity of breast cancer becomes apparent when 
determining how to organize the various subtypes of breast cancer that can be 
present in each woman. Beyond grading and staging of breast cancer, 
determination of the biological features of the breast cancer provides a better 
understanding of its cellular processes which in turn improves the treatment 
strategy for the particular breast cancer subtype. Today, there are three major 
classes of breast cancer: luminal, human epidermal receptor 2 (ErbB2, HER2), 
and triple negative (TNBC) which lacks detectable overexpression of 
pharmacologically targetable receptors. The first breast cancer “molecular 
portraits” were pioneered by Perou et al. and Sorlie et al. (Perou et al., 2000; Sørlie 
et al., 2001). These two research groups used microarray technology to establish 
the five intrinsic subtypes of breast cancer that persist today. The five subtypes of 
breast cancer are: Luminal A which overexpresses hormone receptors, estrogen 
and / or progesterone (ER+/PR+); Luminal B, or triple positive, which 
overexpresses hormone receptors as well as the HER2 receptor 
(ER+/PR+/HER2+); HER2 positive (HER2+) which overexpresses the HER2 
receptor; triple negative breast cancer (TNBC), or basal breast cancer, which lack 





like breast cancer which has gene expression patterns much like those displayed 
by cells in normal breast tissue. Many studies have been done to reinforce the 
predominance of these molecular subtypes as well as continue to define subtypes 
within these subtypes thereby further classifying breast cancer into specific 
categories. Tissue Microarrays (TMAs) by Abd El-Rehim et al. validate the 
categorization of breast cancer into five subtypes by further characterization of 
protein expression pertinent to cell differentiation, epithelial cell lineage, hormone 
and growth factor receptors, as well as proteins known to be altered in some breast 
cancer subtypes (Abd El-Rehim et al., 2005). Breast cancer can be further 
classified according to disease aggressiveness by comparing differences in: cell 
proliferation markers Ki-67 (MKI67) (Cheang et al., 2009), Mitotic Index (MI), 
Proliferating Cell Nuclear Antigen (PCNA) (Stuart-Harris et al., 2008); as well as 
relapse-free and overall survival (Hu et al., 2006). 
 Formation of different biological characteristics for each breast cancer 
subtype segregates these subtypes by distinct biological behaviors that lead to a 
variety of treatment responses. Continued analysis of the different breast cancer 
subtypes may complicate our understanding of the disease by diverging the 
subtypes into more refined groups as well as converging the major subtypes. 
Further assessment of breast cancer heterogeneity allows clinicians to gain insight 






     Luminal A. Luminal A is the most common breast cancer subtype, affecting 
nearly 70% of women (breastcancer.org). Luminal A breast cancer is categorized 
by it is overexpression of ER and/or PR, low proliferation index (low Ki67), and 
low tumor grade. Oncogenic mutations have been identified in the luminal A 
subtype affecting multiple signaling pathways such as, PI3K (PIK3CA: 49%), p53 
(TP53: 12%), MAPK (MAP3K1: 14%), as well as cell differentiation (GATA3: 14%) 
which can be used as predictors for the luminal A subtype (TCGA, 2012). The 
luminal A subtype has the best prognosis among the five breast cancer subtypes. 
Luminal A breast cancer is commonly treated with endocrine disrupting therapies 
such as aromatase inhibitors (AIs) or tamoxifen in conjunction with surgery such 
as a lumpectomy, quandrantectomy, partial mastectomy, mastectomy, or double 
mastectomy in an effort to reduce breast cancer recurrence.  
 The aromatase enzyme synthesizes forms of estrogen by converting 
testosterone to 17-estradiol, or androstenedione to esterone (Santen and Harvey, 
1999). There are two types of AIs, the irreversible (exemestane) and reversible 
(anastrozole or letrozole) that act as competitive inhibitors by binding to the 
aromatase enzyme.  An AI is used to treat luminal A (ER+/PR+) breast cancer by 
selectively targeting the enzymatic activity of the aromatase enzyme thereby 
blocking estrogen synthesis. Tamoxifen is classified as a selective estrogen-
receptor modulator (SERM) indicating that it acts directly on estrogen receptor  
(ER). Tamoxifen is a prodrug that is metabolized by the liver (Desta et al., 2004). 





abundant are 4-hydroxytamoxifen (4-OHT) and endoxifen which compete with 
17-estradiol for ER resulting in reduced ER-mediated transcription in the 
breast cancer cell. An aromatase inhibitor or tamoxifen is given as an adjuvant 
therapy to prevent potential breast cancer relapse after surgery. Aromatase 
inhibitors are primarily given to post-menopausal women who have hormone 
sensitive tumors while tamoxifen is given to premenopausal women as AIs can 
promote a compensational increase in estrogen production in younger women 
(Mathew and Davidson, 2015). Anti-hormonal therapies have been proven 
successful for the treatment of the luminal A subtype but current work shows that 
approximately 50% of women may not benefit from adjuvant endocrine therapy 
(Ejlertsen et al., 2010). Also, of the 50% of women that do show a response, about 
40% will develop resistance to the AI or tamoxifen resulting in tumor recurrence or 
metastatic spread. 
     Luminal B. The luminal B breast cancer subtype affects 10 to 20% of women 
with breast cancer (ACS, 2015). Luminal A and B breast cancer cells are derived 
from the luminal epithelium of ducts in the breast tissue. Luminal B breast cancer 
is categorized by an increase in ER/PR expression as well as a high Ki67 
positivity (Ades et al., 2014). Increased HER2 receptor expression occurs in 
approximately 50% of women with the luminal B subtype causing this subtype to 
also be referred to as the triple positive subtype. Luminal B breast cancer is a more 
aggressive subtype compared to luminal A with similar DNA mutations except for 





chromatin hypermethylation compared to luminal A (TCGA, 2012). The luminal B 
subtype has the second best prognosis and can be treated with targeted therapies 
such as the anti-hormonal therapies used for luminal A as well as HER2 targeted 
therapies. The targeted therapies are often combined with chemo- and/or radiation 
therapy. Common chemotherapeutics used to treat breast cancer are tubulin-
destabilizing taxanes (docetaxel, paclitaxel), DNA stabilizers (doxorubicin, 
camptothecin), DNA untangling (topoisomerase II), or DNA damaging alkylating / 
methylating agents (cyclophosphamide, temozolomide). 
     Triple negative breast cancer. Triple Negative Breast Cancer (TNBC) affects 
15 to 20% of women with breast cancer (ACS, 2015). TNBC is categorized by its 
lack of ER, PR, and HER2 receptor overexpression and thus cannot be treated 
with anti-hormonal or HER2-targeted agents. TNBCs have a high incidence of p53 
mutations (TP53: 84%), loss of DNA repair protein expression (i.e. BRCA-1/2), as 
well as chromatin hypomethylation to further distinguish TNBC from the other BC 
subtypes (TCGA, 2012). TNBC includes basal-like and normal-like cancers which 
also lack targetable receptor overexpression (Perou et al., 2000). Basal-like tumor 
cells are similar to basal cells which surround the mammary duct and are also 
known as myoepithelial cells. Basal-like tumor cells are so named because of their 
expression of basal cell markers such as cytokeratin (CK) 5, 6, 14, and 17 (Perou 
et al., 2000; Sotiriou et al., 2003). While most TNBCs are basal-like and most 
basal-like are classified as TNBC, this is not true for all TNBC and basal-like BCs, 





therapies for TNBC, it has the worst prognosis among the five BC subtypes. The 
first line therapy for TNBC is surgery combined with chemo- and/or radiation 
therapy.  
 Research continues to further classify TNBC in hopes of finding new 
treatable targets for the disease. Thus far, six new subtypes of TNBC have been 
established: Basal-like 1 and 2 (BL1, 2), immunomodulatory (IM), mesenchymal 
(M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) 
(Lehmann et al., 2011). The basal-like 1 and 2 subtypes are classified by increased 
cell cycle associated genes (CENPA, CCNA2) and DNA damage response 
(BRCA/ATR) gene expression. BL1 and 2 show sensitivity to platinum-based 
chemotherapeutics such as cisplatin as well as the single strand DNA repair 
protein, poly-ADP ribose polymerase (PARP) inhibitor. The immunomodulatory 
subtype displays increased signaling through the immune cell signaling pathways 
(TH1, TH2, B cell, NK cell) and has a similar GEP to medullary BC, which is 
associated with a favorable diagnosis. Mesenchymal and mesenchymal stem-like 
subtypes have increased epithelial to mesenchymal transition (EMT) markers 
(TWIST, SNAI2, ZEB1) and growth factor pathways (PDGF, EGFR, GPCR) as well 
as a claudin-low (Claudin 3, 4, 7) gene signature. Claudin low is similar to the 
M/MSL subtypes of TNBC as they both have high expression of EMT markers, 
growth factor pathways (EGFR), and resemble basal breast cells (Prat et al., 
2010).  Both mesenchymal and mesenchymal stem-like subtypes show increased 





receptor (LAR) subtype is driven by increased androgen receptor signaling and is 
sensitive to an androgen receptor antagonist such as bicalutamide.  
     Normal-like breast cancer. Some reports fold normal-like breast cancer under 
the umbrella of TNBC as the normal-like breast cancer cells lack detectable 
overexpression of pharmacologically targetable receptors. Like its name suggests, 
normal-like breast cancer shares a GEP with normal cells in the breast tissue such 
as adipose or myoepithelial (basal) cells and dissimilarity to luminal cells (Perou et 
al., 2000). Normal-like breast cancer may be stratified by its overexpression of 
Alcohol Dehydrogenase 1B (ALDH1B) (Perou et al., 2000) as well as increased 
activation of the focal adhesion pathways (Smid et al., 2008). Normal-like breast 
cancers have a tendency to have a better prognosis than basal-like cancers (Fan  
et al., 2006), but typically do not respond to neoadjuvant chemotherapy (Rouzier 
et al., 2005). This subtype is consistently the smallest subtype among the five as 
it could be a luminal A subtype that is contaminated by normal breast cells during 
GEP analysis.  
HER2+ Breast Cancer. 
 HER2 activity has been shown to promote ductal elongation, ductal 
branching, and modification of terminal end bud structures during pubertal 
mammary gland development (Andrechek et al., 2004; Jackson-Fisher et al., 
2004). The role of HER2 during mammary gland development indicates that it is 
also plays a role in breast cancer. Approximately 15 to 25% of breast cancers 





transduction networks that become dysregulated in cancer cells (Slamon et al., 
1987). Increased HER2 expression in cancer cells is mostly due to amplification of 
the ERBB2 gene located on chromosome 17. Overexpression of HER2 can drive 
oncogenesis making HER2 a bonafide proto-oncogene. The oncogenic activity of 
HER2 confers a strong proliferative advantage to tumor cells, which promotes an 
increase in tumor size (van de Vivjer et al., 1988), lymph node invasion (Berger et 
al., 1988), aneuploidy (Babiak et al., 1991) percentage of cells in S-phase (O’Reilly 
et al., 1991), and tumor grade (Tsuda et al., 1990). HER2 overexpression has been 
associated with aggressive disease and a worse, overall prognosis in women 
(Adair et al., 2008). Several types of human solid tumors have displayed HER2 
overexpression, including breast cancer, in which a majority of HER2 oncogenic 
activity has been studied. Patient samples of the HER2+ subtype have undergone 
further evaluation to begin separating the HER2+ subtype into HER2 low, medium, 
and high expression profiles to better facilitate targeted treatment of HER2 
expressing cancers (Wulfkuhle et al., 2012). ER status has been shown to induce 
expression of different genes when coupled with HER2 overexpression creating 
two distinct subgroups: HER2+/ER+ and HER2+/ER- within the HER2+ breast 
cancer subtype (TCGA, 2012). Fortunately, HER2 overexpression primarily occurs 






     EGFR/HER pathway. HER2 is a type 1 transmembrane protein receptor 
tyrosine kinase (RTK) and member of the Epidermal Growth Factor Receptor 
(EGFR)/HER family of receptors (Reviewed in Yarden and Sliwkowski, 2001). 
EGFR/HER receptors are expressed on the cell surface and activated by members 
of the Epidermal Growth Factor (EGF) family of extracellular ligands. The 
EGFR/HER family of receptors are comprised of four structurally related RTKs with 
EGFR as the original member of the family. In humans, these include: EGFR 
(EGFR, ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). The gene 
symbol for HER2, ERBB2, is derived from a homologous viral oncogene, 
Erythroblastic Leukemia Viral Oncogene, and has the official name: V-Erb-B2 
Avian Erythroblastic Leukemia Viral Oncogene Homolog or HER2 consequently 
(USNLM, 2011). The HER2 gene has been mapped on chromosome 17q21 which 
can be transcribed and translated into the 1225 amino acids to form the 185kD 
(p185HER) transmembrane glycoprotein known as the HER2 receptor (Coussens 
et al., 1985).  
 The EGFR/HER family of receptors are activated through receptor homo- 
or hetero-dimerization induced by binding of a soluble, growth factor ligand. 
EGFR/HER receptor ligands are produced by ectodomain shedding of the 
membrane anchored ligand precursors from the surface of the cell by matrix 
metalloproteinases such as MMP9 or ADAM12 (Reviewed in Higashiyama et al., 
2008). EGFR/HER receptor activation results in activation of downstream 





EGFR is activated by at least 11 different growth factor-ligands including EGF, 
Heparin binding EGF (HB-EGF), amphiregulin (AREG), or Transforming Growth 
Factor alpha (TGFα). In contrast, HER3 and HER4 are activated by the heregulin 
(neuregulin) family of growth factors (Hrg/Nrg 1, 2, 3, 4) (Figure 1). The EGFR/HER 
receptor ligands are classified by their epidermal growth factor-like domain which 
is comprised of three intramolecular loops formed by disulfide bonds (Harris et al., 
2003). The EGFR/HER receptors contain an extracellular, transmembrane, and 
intracellular domain. The extracellular domain is made up of four subdomains, I-
IV. The ligand binds to extracellular subdomains I-III which take on a “C” shape to 
receive the ligand (Ogiso et al., 2002; Garrett et al., 2003) (Figure 2). The ligand 
binds to subdomains I and III which result in the conformation of the receptor to 
“open” in preparation for dimerization. Dimerization of ligand bound receptors is 
facilitated by a β-hairpin structure from the cysteine rich subdomain II otherwise 
known as the “dimerization loop”. The dimerization loop holds the neighboring 
receptor by making specific contacts that stabilize dimerization of the two 
receptors. Dimerization is also stabilized by interactions between subdomain IV, 
the transmembrane domain, and the intracellular domain (Dawson et al., 2005). 
EGFR/HER receptors unbound by a ligand are in a “closed” or “autoinhibited” state 
in which subdomain II and IV interactions sequester the dimerization loop 








Figure 1: EGFR/HER Receptors 
Members of the EGFR/HER family of receptors: EGFR/HER1, HER2, HER3, and 
HER4. Each receptor is composed of 4 extracellular domains (I-VI) and a tyrosine 
rich (Tyr) intracellular domain. Growth factor ligands such as amphiregulin 
(AREG), Epidermal Growth Factor (EGF), heparin binding EGF (HB-EGF), and 
heregulins 1-4 bind to and activate the EGFR/HER1 and HER3/4 receptors, 
respectively. Ligand binding causes rearrangement of the receptor exposing the 
dimerization domain (D.D.) to assume an open and active conformation. The 
HER2 receptor takes on a fixed active conformation while HER3 has a truncated, 
inactive intracellular domain. HER receptor activity can be blocked by small 
tyrosine kinase inhibitors [(TKIs) Gefitinib or Lapatinib], antibodies (pertuzumab or 









Figure 2: EGFR/HER Receptor Dimerization 
EGFR/HER binding of a ligand exposes the dimerization domain (D.D.) of the 
receptor enabling the formation of homodimers (left: EGFR-EGFR) or 
heterodimers (right: HER2-HER3).  
 EGFR/HER receptors have a highly conserved tyrosine kinase domain in 
the intracellular domain of the receptor. After ligand-mediated dimerization of 
EGFR/HER receptors, the dimerized receptors autophosphorylate then 
transphosphorylate tyrosine residues in the tyrosine kinase domain (Figure 3). 
Tyrosine phosphorylation enables the activation of downstream pathways through 
the recruitment of adaptor proteins containing phosphotyrosine binding (PTB) or 
Src homology 2 (SH2) domains. Adaptor protein docking to the EGFR/HER 
receptors is able to elicit the activation of several downstream pathways including 





pathway (Figure 4). Activation of downstream pathways is dictated by the tyrosine 
phosphorylation pattern of the tyrosine kinase domain as 5 to 8 amino acids around 
the phosphorylated tyrosine residues confer specificity of PTB or SH2 binding 
(Songyang et al., 1995). Ligands can regulate RTK dimerization as well as the 
strength and duration of downstream signaling by influencing the tyrosine 
phosphorylation pattern (Olayioye et al., 1998; Sweeney et al., 2000). EGFR/HER-
mediated activation of downstream pathways enables a ligand to elicit proliferation, 
survival, and/or migration signals to the cancer cell. 
 
Figure 3: EGFR/HER Receptor Phosphorylation 
EGFR/HER dimerization promotes auto-phosphorylation then 






Figure 4: EGFR/HER Receptor Activation of Downstream PI3K/Akt and 
MAPK Pathways. 
Activated EGFR/HER receptors are able to activate downstream PI3K/Akt (left) 
and/or MAPK (right) pathways. 
 All four members of the EGFR/HER family of RTKs share structural 
similarities, but they each have specific features that confer unique regulatory 
characteristics. Unlike EGFR, the extracellular region of HER2 resembles a ligand 
activated or “open” state, making HER2 an orphan receptor as there is no known 
ligand that binds to HER2 with high affinity. Thus the constitutively active state of 
HER2 does not necessitate ligand binding for its activation and is primed for 
dimerization with other RTKs (Cho et al., 2003; Garrett et al., 2003). HER3 is a 





activity and can only potentiate downstream signaling when dimerized with another 
HER receptor. The fixed state of HER2 makes it the preferred dimerization partner 
of the HER receptors, particularly HER3. HER2-partnered heterodimers are more 
stable and display increased ligand binding and kinase activity compared to other 
heterodimers. In addition, HER2 has been shown to dimerize with other RTKs, 
such as Insulin-like Growth Factor-1 Receptor (IGF-1R) (Nahta et al., 2005). HER2 
dimerization requires one ligand whereas dimers without HER2 require two ligands 
for downstream signaling. Therefore, dimerization with HER2 lowers the amount 
of ligands necessary for activation of downstream pathways (Graus-Porta et al., 
1997). Together, EGFR/HER signaling is a complex mechanism capable of 
activating a number of downstream pathways. HER2 can act as a lateral signal 
transmission between other HER receptors (Graus-Porta, et al., 1997) as well as 
amplifying activation and strength of other RTKs (Karunagaran et al., 1996).                       
     HER2 activation of downstream PI3K/Akt and MAPK pathways. An 
important trait of the HER family of receptors is their ability to activate protein 
kinase B (PKB/Akt) and MAPK pathways. Activation of downstream pathways is 
executed through a series phosphorylation events. HER2:HER3 dimerization 
preferentially activates the PI3K/Akt pathway (Graus-Porta et al., 1997). PI3K is a 
heterodimer comprised of the regulatory subunit, p85, bound to the catalytic 
subunit, p110. The p85 subunit uses its SH2 domain to dock to specific 
phosphotyrosine residues on the activated HER receptor [Figure 4 (on EGFR)]. 





3 (SH3).  PI3K is now fully activated and it phosphorylates the 3’OH of 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3, 4, 5)-
trisphosphate (PIP3). PIP3 can be dephosphorylated by the Phosphate and Tensin 
Homolog Deleted on chromosome TEN (PTEN) phosphatase back to PIP2 thereby 
attenuating PI3K signaling. PIP3 interacts with the Plekstrin homology domain 
(PHD) within the catalytic domain of phosphoinositol dependent kinase-1 (PDK1) 
thus activating the kinase. The lipid binding PHD recruits Akt to the intracellular 
surface of the plasma membrane where it docks to PIP3. It is important to note that 
the physical interactions and activations of PI3K, PTEN, PDK1, and Akt occur at 
the outer surface of the plasma membrane inside the cell. PDK1 is able to 
phosphorylate Akt at the threonine308 residue and mTORC2/PDKs is able to 
phosphorylate Akt at serine473. Phosphorylation of Akt at both threonine308 and 
serine473 is necessary for full activation of Akt. Activated Akt can activate the 
mechanistic target of rapamycin (mTOR) which is made up of two protein 
complexes: mammalian target of rapamycin complex 1 (mTORC1) and 2 
(mTORC2). Activated Akt is able to disrupt the formation of the tuberous sclerosis 
1/2 (TSC1/2) dimer. The TSC1/2 dimer inhibits hydrolyzation of the GTP binding 
protein, Ras homolog enriched in brain (Rheb). Akt-mediated inhibition of the 
TSC1/2 complex allows Rheb to activate mTORC1. The mTORC1 complex is able 
to promote cell growth, proliferation, and autophagy by directing protein translation 
through eukaryotic initiation factor 4F complex [eIF4F (eIF4E, G, B, etc.)] and 





initiate transcription and ribosomal protein synthesis, respectively. The mTORC2 
complex is involved in cellular metabolism but largely facilitates fluctuations in 
cytoskeletal formation and degradation throughout the cell via serum and 
glucocorticoid-regulated kinase 1 (SGK1).  
 Activation status of PI3K has been implicated in promoting tumorigenesis 
through the expression of PIK3CA (p110 gene) mutations. PIK3CA mutations 
constitutively activate PI3K which in turn increase oncogenic signaling by Akt. 
Additionally, increased PI3K activity can be promoted by loss of the PIP3 
phosphatase, PTEN. Due to the role of Akt in a variety of solid tumors and 
hematological malignancies, several therapies have been developed to target 
effectors of the Akt pathway in an attempt to diminish tumor survival. Akt pathway 
targeted therapies include: Wortmannin and LY294002, which are reversible and 
non-reversible inhibitors of PI3K, respectively; and Rapamycin which targets 
mTOR signaling downstream of Akt. 
 HER2 overexpression can result in homodimerization of HER2 which 
preferentially activates the MAPK pathway (Ghosh et al., 2011). Similar to p85, the 
SH2 domain of Grb-2 is able to dock to phosphorylated tyrosine residues on the 
intracellular domain of HER2 [Figure 4 (on HER2)]. Grb-2 is a scaffold protein that 
contains both SH2 and SH3 domains. Once Grb-2 is bound to phosphotyrosine 
residues on HER2, it can recruit the son of sevenless (SOS) protein. SOS contains 
a proline rich regions that binds to the SH3 domains of Grb-2. SOS is a guanine-





exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) 
binding to form Ras-GTP, and initiating the MAPK phosphorylation cascade. 
GTPase Activating Protein (GAP) reduces Ras GTPase activity by hydrolyzing 
GTP bound to Ras thereby returning Ras to its inactive state (Ras-GDP), and thus 
limiting downstream phosphorylation of the MAPK pathway. Ras activation initiates 
the MAPK phosphorylation cascade, which is executed through a series of 
serine/threonine specific kinases. The rapidly accelerating fibrosarcoma/mitogen 
activated protein kinase kinase kinase (Raf/MAPKKK), mitogen activated protein 
kinase kinase (MEK/MAPKK), and extracellular signal-related kinase 1/2 / mitogen 
activated protein kinase (ERK/MAPK) are the main MAPK proteins. Ras-GTP 
binds Raf and initiates activation of Raf. Subsequently, Raf phosphorylates MEK 
and active MEK phosphorylates ERK. Activation of ERK1/2 facilitates 
phosphorylation and activation of transcription factors such as c-Fos and c-Myc. 
Activation of c-Myc and c-Fos initiate transcription of cyclin D1 and many other 
genes critical for coordination of cell motility, invasiveness, and proliferation 
(Reviewed in Hynes and Lane, 2005).  
 Both the MAPK and Akt pathways are known as central nodes in cancer 
whose increased activity have been shown to trigger tumorigenesis and 
metastasis. Several inhibitors have been designed to target the MAPK pathway 
such as: vemurafenib which inhibits Raf or U0126 which inhibits MEK1/2. Inhibition 
of Raf or MEK1/2 reduces downstream ERK1/2 phosphorylation and subsequent 





survival pathways can result in cancer cells to become addicted to these pathways 
in order to maintain tumor growth and survival (Sharma et al., 2006).  
     HER2 crosstalk. It has come to light that cancer cells are able to become 
resistant to targeted therapies by increasing compensatory pathways that continue 
downstream activation of protein synthesis, i.e., the Akt pathway, and/or 
transcriptional up-regulation of survival genes mediated by the MAPK pathway. 
Crosstalk, or bidirectional communication, between pathways to sustain cancer 
cell growth and survival is one mechanism by which cancer cells evade targeted 
therapy. Extensive research has been done on G-Protein Coupled Receptor 
(GPCR) crosstalk with EGFR/HER2 as some GPCR agonists such as 
Lysophosphatidic acid, carbachol (muscarinic acetylcholine inhibitor), and 
thrombin are known to increase HER activation by two independent mechanisms 
(Reviewed in Carpenter, 1999). The first consists of a GPCR-dependent surge in 
ectodomain shedding of HER ligands thus releasing them to bind and activate HER 
signaling. The second includes GPCR activation of c-Src to facilitate 
phosphorylation of tyrosine residues on HERs. HER activation via GPCR may be 
necessary for GPCR-mediated mitogenic activity via the MAPK pathway. Both 
HER-MAPK pathway initiation, as well as activation of a number of steroid 
hormone receptors, can initiate the transcription of HER ligands and trigger a 
positive feedback loop. HER2 has been shown to increase p53 expression through 
an unknown mechanism in skin squamous-cell carcinoma (Casalini et al., 2001). 





which may attribute to changes in the Cyclin Dependent Kinase (CDK)/Cyclin 
activity and regulation of cell division. Mechanisms of crosstalk between the HER 
family of RTKs and several other pathways including the: Wnt/β-catenin (Ayyanan 
et al., 2006), TNFa/IKK/NF-κB (Cao et al., 2007), and Notch pathways (Yamaguchi 
et al., 2008) have been under investigation for nearly a decade. Current data 
indicate that new mechanisms of crosstalk have been implicated in treatment 
resistance, Epithelial to Mesenchymal Transition (EMT), as well as enrichment and 
survival of the breast cancer stem cell (BCSC) population.  
     Anti-HER2 Therapies. Trastuzumab. HER2 is an ideal target for cancer cells 
as targeting of HER2 was found to be highly specific and have little off-target 
effects through the use of a murine anti-p185 antibody against HER2 which was 
shown to selectively inhibit growth of murine-derived neu-transformed cells and 
not Ras-transformed cells (Drebin et al., 1986). Consequently, a humanized, 
monoclonal antibody against HER2 in humans was shown to be highly effective in 
reducing proliferation of HER2-amplified cells in vitro, and promoted the antitumor 
effect of doxorubicin and paclitaxel in HER2+ breast cancer tumor xenograft 
models in vivo (Pegram et al., 1998). Anti-HER2 therapies have significantly 
improved the outcome of women with HER2+ breast cancer (Hicks et al., 2015; 
Michiels et al., 2016).   
 Trastuzumab is a first generation, FDA-approved, HER2 targeted therapy 
for women with HER2+ breast cancer.  Primary therapy for HER2+ breast cancer 





which targets domain IV in the extracellular domain of the HER2 receptor. 
Trastuzumab as a monotherapy has shown poor efficacy as the first randomized 
trial was stopped early due to poor pathological complete response (pCR) in the 
trastuzumab group compared to the control group (Buzdar et al., 2005). The term 
pCR indicates an absence of residual invasive disease in the breast or lymph 
nodes upon completion of neoadjuvant treatment prior to definitive surgery. 
Trastuzumab gains significant efficacy when combined with a taxane-based 
therapy and/or the second generation of HER2 targeting antibodies, pertuzumab 
(Untch et al., 2011; Baselga et al., 2010). Trastuzumab is effective in early stage 
breast cancer, but approximately 15% of women treated with trastuzumab go on 
to develop metastatic disease within the first year of treatment (Piccart-Gebhart et 
al., 2005) and 20 to 50% of women develop trastuzumab resistance (Cobleigh et 
al., 1999; Slamon et al., 2001). So far, there are several potential mechanisms of 
HER inhibition by trastuzumab. The benefits of trastuzumab treatment are limited 
in some women due to intrinsic resistance to trastuzumab or the development of 
acquired resistance to trastuzumab treatment.  
 Trastuzumab and the immune response. The immune system response has 
proven to be important in the efficacy of antibody treatments such as trastuzumab. 
In the clinic, there is consistently a positive correlation between immune cell 
infiltration and positive patient prognosis in HER2+ breast cancer (Reviewed in 
Bianchini and Gianni, 2014). One such method of immune cell infiltration is 





receptors (FcR) on the surface of immune cells recognizing the IgG1 Fc heavy 
chain of a monoclonal antibody bound to the surface of the target cell. The BIG 02-
98 (Loi et al., 2013) and FinHER (Loi et al., 2012) clinical trials have shown that a 
correlation exists between the benefits of trastuzumab-based therapy in early 
stage breast cancer and tumor infiltrating lymphocytes. Building from this work 
which demonstrates that both cytotoxic and targeted cancer therapies can improve 
immune function, researchers have begun manipulating these therapies to 
enhance immune function in tumors.  
 Researchers have been modifying trastuzumab to improve its ability to 
direct the immune system against HER2 overexpressing tumor cells. Removal of 
the fucose group from trastuzumab creates afucosylated trastuzumab which has 
increased FcγIIIRa binding to enhance ADCC activity resulting in reduced tumor 
growth in a HER2+ xenograft tumor (Junttila et al., 2010a). Trastuzumab-activated 
ADCC can be reduced in tumors with high matrix metalloproteinase expression.  
The lower hinge region of trastuzumab can be cleaved by matrix 
metalloproteinases thereby inhibiting its ability to activate ADCC resulting in 
reduced trastuzumab efficacy (Fan et al., 2012). An IgE homolog of trastuzumab 
can initiate monocyte-mediated ADCC as well as induce mast cell degranulation 
to promote an anti-tumor response in vivo (Karagiannis et al., 2008; Karagiannis 
et al., 2011). Natural Killer (NK) cells can induce ADCC to improve trastuzumab 
treatment through the upregulation of CD137, a member of the tumor necrosis 





trastuzumab. To focus the lytic activity of NK cells on the trastuzumab coated 
tumor cells, an anti-CD137 antibody was used to enhance the killing function of 
the activated NK cells (Kohrt et al., 2012). The adaptive immune system plays a 
role in murine anti-HER2 treatment as tumor regression is dependent on cyctotoxic 
CD8+ T cell activation which is lowered when combined with chemotherapy. This 
finding suggests that trastuzumab may be more beneficial if administered after 
chemotherapy (Park et al., 2010a). Continued work is being done to develop 
vaccines against HER2 such as the peptide-based vaccine E75 which was shown 
to stimulate cytotoxic T lymphocytes against the HER2 peptide to improve disease 
free survival (DFS) and reduce tumor recurrence (Mittendorf et al., 2012).              
         Lapatinib. Lapatinib is a first generation small molecule tyrosine kinase 
inhibitor (TKI) that dually targets HER2 and EGFR. Lapatinib is administered to 
women with HER2+ breast cancer as a second line therapy. This is due to clinical 
evidence showing that lapatinib is effective against HER2+ breast cancer that has 
become resistant to trastuzumab (Scaltriti et al., 2010). Mechanistically, lapatinib 
is an ATP mimicking molecule that competitively blocks binding of ATP in the 
kinase pocket of HER2 or EGFR. Lapatinib is more effective than trastuzumab at 
attenuating both the PI3K/Akt and MAPK/ERK1/2 pathways in vivo (Xia et al., 
2002). One important advantage of lapatinib over trastuzumab is its ability to cross 
the blood-brain barrier to inhibit or treat brain metastases in women with metastatic 
HER2+ breast cancer (Gril et al., 2008). Combined trastuzumab and lapatinib 





metastatic HER2+ breast cancer compared to lapatinib alone (Blackwell et al., 
2012) suggesting that trastuzumab and lapatinib have complementary 
mechanisms of action. Surprisingly, lapatinib alone (Piccart-Gebhart et al., 2014) 
or combined lapatinib and trastuzumab (Gelmon et al., 2012) was unable to extend 
DFS. One major problem with lapatinib is its poor bioavailability and thus lapatinib 
requires high doses to achieve optimal kinase inhibition. These high doses have 
been shown to increase skin rash, gastrointestinal toxicity, and other side effects 
making it difficult to achieve anti-tumor efficacy.  
         Pertuzumab. A new anti-HER2 antibody has been developed that targets 
extracellular domain II of HER2 to inhibit HER2 heterodimerization with EGFR or 
HER3 and therefore activation (Cho, et al., 2003). Pertuzumab is able to block 
HER2:HER3 dimerization thus attenuating HER2 activation and has proven to be 
effective in HER2+ breast cancer cell lines as well as in both high and low HER2 
overexpressing breast tumor xenografts (Lee-Hoeflich et al., 2008). Combined 
trastuzumab and pertuzumab treatment resulted in significant regression of 
HER2+ breast tumor growth in vivo through blockade of HER2 dimerization and 
decreased formation of the truncated HER2 that evades trastuzumab treatment, 
p95HER2 (Scheuer et al., 2009). Currently, the combined trastuzumab plus 
pertuzumab therapy is standard of care for HER2+ breast cancer. Additionally, 
trastuzumab and pertuzumab combined with docetaxel for the treatment of 
metastatic HER2+ breast cancer significantly improved pCR and prolonged DFS 





         Trastuzumab-emtansine. Trastuzumab-emtansine (T-DM1) is an antibody-
drug conjugate in which cytotoxic emtansine is covalently linked to the trastuzumab 
antibody. Emtansine (Mertansine, DM1) is a maytansinoid that disrupts 
microtubule function by binding to tubulin resulting in cell cycle arrest of dividing 
cells. T-DM1 binds to the HER2 receptor on the surface of the cell. HER2 bound 
TDM-1 is internalized into the cytoplasm where emtansine is released from 
trastuzumab via lysosomal enzymes (Erickson et al., 2006). Besides the site 
directed anti-mitotic action of emtansine, T-DM1 retains trastuzumab mechanisms 
of action such as induction of ADCC, inhibition of PI3K activation, and prevention 
of p95HER2 truncation along with inhibiting growth of lapatinib resistant HER2+ 
breast cancer cell lines and tumor xenografts (Junttila et al., 2010b). TDM-1 is now 
used in the clinic as a second line therapy for metastatic, HER2+ breast cancer 
due to extending overall and progression free survival with less adverse side 
effects in clinical studies (Verma et al., 2012).  
Trastuzumab Resistance. 
 Unfortunately, cancers have become resistant to many types of therapies 
that specifically target HER2 or effectors of HER2-mediated downstream 
pathways. Resistance to targeted treatments leads to tumor recurrence and in 
some cases a more aggressive, metastatic cancer that invades vital organs and 
ultimately ends in death. Cancer cells can adapt to treatments using a variety of 
mutations that enable them to propagate under specific treatment conditions. 





suggesting that inherent resistance occurs in the other 50% that have no response 
to trastuzumab treatment. Roughly 40% of women with HER2+, metastatic breast 
cancer are inherently resistant to trastuzumab treatment and worst of all, most 
women who initially respond to trastuzumab treatment will develop acquired 
resistance to trastuzumab within a year (Marty et al., 2005; Slamon et al., 2001). 
Acquired resistance to trastuzumab leads to a more aggressive, recurrent tumor 
that is difficult to treat. The prevalence of resistance to trastuzumab underscores 
the need for more predictive biomarkers in addition to HER2 to accurately predict 
the course of resistance. 
     Mechanisms of trastuzumab resistance. Changes in HER2 status. Women 
can become insensitive to trastuzumab treatment due to changes in HER2 
expression in tumors. Primary and metastatic tumors can lose HER2+ expression 
status which is associated with a decrease in recurrence-free survival (Mittendorf 
et al., 2009; Niikura et al., 2012). Conversely, an increase in HER2 expression 
suggests that the tumor may be becoming more dependent on HER2 activity. 
However, this is not always the case as resistant cells in culture can display 
elevated levels of HER2 receptor expression and activation as measured by 
increased HER2 phosphorylation and sustained proliferation under trastuzumab 
treatment conditions (Ginestier et al., 2007a). Trastuzumab may inhibit HER2 
signaling through endocytosis or degradation of the receptor but some studies 
report that trastuzumab has no effect on HER2 receptor expression (Gennari et 





of HER2 expression throughout treatment in order to adjust and potentially improve 
therapeutic regimens. 
         Impaired HER2-Trastuzumab interaction. Resistance to trastuzumab can 
occur by masking of the HER2 receptor or disrupting trastuzumab binding. One 
such mechanism of HER2 alteration to evade trastuzumab occurs through 
expression of a HER2 splice variant, Δ16HER2. The Δ16HER2 splice variant is 
generated by exon 16 skipping of the HER2 gene resulting in a conformational 
change of the HER2 receptor that promotes stable HER2 homodimerization. 
Ectopic expression of the Δ16HER2 variant in vitro increased cell invasion, 
receptor dimerization, and trastuzumab resistance-mediated through direct 
interaction of Δ16HER2 to Src kinase (Mitra et al., 2009). Increased expression of 
Δ16HER2 in an in vivo mouse model as well as in patient samples correlated with 
increased tumorigenesis. Interestingly, the expression of the Δ16HER2 variant 
increased sensitivity to trastuzumab treatment compared to wild type HER2 
(Castagnoli et al., 2014). Given that expression of the Δ16HER2, as well as other 
HER2 splice variants such as Herstatin and p100, correlate to increased 
trastuzumab efficacy, detection of these variants could potentially change 
treatment options for women with HER2+ breast cancer.  
 An NH2 terminally-truncated form of the HER2 receptor, p95HER2, lacks 
extracellular subdomain IV resulting in resistance to trastuzumab treatment 
(Molina et al., 2001). The p95HER2 protein can be generated two ways. One is by 





metalloproteinase which is referred to as ectodomain shedding. HER2 shedding 
releases a portion of the HER2 ECD into the blood. HER2 ECD can be measured 
in patient serum and elevated HER2 ECD has been associated with poor 
prognosis and reduced response to both endocrine and chemotherapy in 
metastatic breast cancer (Colomer et al., 2000; Leitzel et al., 1995). Alternatively, 
p95HER2 can be expressed endogenously by an alternative translation initiation 
site on the HER2 mRNA which produces a 100-115 kDa size p95HER2 protein 
that is smaller than the wild type HER2 protein of 185 kDa. This p95HER2 protein 
is also referred to carboxyl terminal fragment (611CTF). The truncated form of the 
HER2 receptor is able to constitutively homodimerize and is considered a potent 
oncogene (Pedersen et al., 2009). Increased expression of p95HER2 is associated 
with worse overall patient outcome and importantly, trastuzumab resistance 
(Scaltriti et al., 2007). However, expression of p95HER2 in patient derived tumor 
xenografts and cell lines showed an increased sensitivity to chemotherapies such 
as doxorubicin. This increased sensitivity to chemotherapy also increased 
sensitivity to trastuzumab treatment (Parra-Palau et al., 2014). It is hypothesized 
that the doxorubicin treatment may have stabilized the HER2 protein in the cell 
membrane thereby increasing its sensitivity to trastuzumab treatment.  
 The HER2 receptor can be shielded from trastuzumab binding by interacting 
with other proteins to confer trastuzumab resistance. Mucin-4 (MUC4) is a high 
molecular weight membrane associated glycoprotein that has been shown to 





trastuzumab binding to HER2 yet has no effect on the level of HER2 expression 
(Price-Schiavi et al., 2002). MUC4 levels were shown to be elevated in a 
trastuzumab resistant cell lines as well as reduce trastuzumab binding compared 
to a trastuzumab sensitive cell line, JIMT-1. The resistance phenotype was shown 
to be reversible by MUC4 inhibition (Nagy et al., 2005). MUC4 was also shown to 
disrupt HER2 interaction with other HER receptors, HER3 and EGFR.  
Upregulation of MUC4 in a ER+/HER2+ tumor xenograft model resulted in 
resistance to anti-HER2 therapies, trastuzumab and lapatinib, as well as anti-
estrogen therapies, tamoxifen and estrogen deprivation (Chen et al., 2012).  
Interestingly, these tumors shifted their dependence from ER/PR expression to 
HER2 upon MUC4 upregulation. Trastuzumab resistance has also shown to be 
induced by increased expression of the MUC1 cleavage product, MUC1*. Both 
acquired and intrinsic trastuzumab resistance as well as chemotherapeutic 
resistance were reversed by MUC1* inhibition using a MUC1* antagonist (Fessler 
et al., 2009). These results suggest that the mucin family of glycoproteins may be 
heavily involved in trastuzumab resistance and could serve as potential markers 
of resistance. 
         Augmented signaling through the HER receptor family. HER2 can 
escape the effects of targeted trastuzumab treatment through activation of other 
members of the EGFR/HER family of receptors. Trastuzumab-mediated growth 
inhibition in BT474 and SkBr3 cells can be modulated by expression of the EGFR 





Trastuzumab resistant BT474 cells were shown to have increased EGFR 
expression as well as an elevated EGFR:HER2 heterodimerization suggesting that 
targeting of EGFR in HER2+ breast cancers may be a viable therapeutic option for 
some women (Ritter et al., 2007). Upregulation of EGFR expression was observed 
in 15% of HER2+, metastatic breast cancers and associated with worse overall 
survival in these women who received trastuzumab treatment (Gallardo et al., 
2012). Targeting EGFR with the TKI gefitinib reduced HER2 activation and HER2-
mediated cell proliferation in vitro (Moulder et al., 2001), yet trastuzumab combined 
with gefitinib failed to provide any clinical benefit to women with HER2+, metastatic 
breast cancer (Arteaga et al., 2008). Similar results were seen with the EGFR 
selective TKI, erlotinib (Dickler et al., 2008), yet the combination of gefitinib, 
trastuzumab, and docetaxel did improve progression free survival in some women 
(Somlo et al., 2012).   
 Trastuzumab has demonstrated the ability to inhibit the formation of HER2 
homodimers as well as the potent, oncogenic HER2:HER3 heterodimers (Ghosh 
et al., 2011; Junttila et al., 2009). Yet, Akt signaling can be activated in a 
compensatory manner by ligand stimulated HER2:HER3 heterodimers allowing 
evasion of HER2 targeted trastuzumab treatment. Attenuation of Akt signaling 
through inhibition of PI3K resulted in an increase in HER3 expression which 
amplified ERK1/2 activation in a compensatory manner. These data suggest that 
compensatory signaling in HER2+ cells may be overcome by dual targeting of 





with HER2+, metastatic breast cancer who received trastuzumab treatment was 
associated with shorter overall survival (Lipton et al., 2013) as well as shorter 
progression-free survival post trastuzumab and taxane treatment (Park et al., 
2014).  
 HER4 has been shown to play opposing roles in trastuzumab resistance. 
The fact that HER4 has 4 different splice variants may be the reason why its role 
in HER2+ breast cancer has been difficult to understand. Among the 4 variants, 
the JM-a/CYT1 and JM-a/CYT2 were associated with better event free survival in 
women with ER+ and HER2+ breast cancer (Machleidt et al., 2013). Localization 
of HER4 appears pertinent to its activity as cytoplasmic HER4 has been associated 
with increased survival while nuclear HER4 has been associated with trastuzumab 
resistance and may be a poor prognostic indicator for women with HER2+ breast 
cancer (Mohd Nafi et al., 2014). Interestingly, trastuzumab treatment was shown 
to promote upregulation of HER4, its cleavage, and nuclear translocation, 
suggesting that HER4 localization may be a potential therapeutic predictor of 
trastuzumab resistance.      
 Trastuzumab sensitivity can be affected by endogenous inhibitors of HER2 
such as mitogen-inducible gene 6 (MIG-6) [also known as ERBB receptor 
feedback inhibitor 1 (ERRFI1) or receptor-associated late transducer (RALT)]. 
MIG-6 is a cytoplasmic protein that is upregulated during cell growth, specifically 
during the G1 phase of the cell cycle. MIG-6 has been shown to interact with and 





EGFR/HER ligand-mediated trastuzumab resistance (Anastasi et al., 2005; 
Fiorentino et al., 2000).  
 Increased expression of EGFR/HER ligands such as heregulin-1 (Hrg-1) 
have been shown to confer resistance to cancer therapies. A subset of women 
with HER2low/HER2- breast cancer have displayed clinical benefit from 
trastuzumab treatment (Paik et al., 2008). These clinical data spurred the work that 
demonstrated that HER2:HER3 activation through Hrg-1 promotes BCSC survival 
and self-renewal in HER2- low expressing cells in vitro and in vivo (Lee et al., 
2013). BCSC from low HER2 expressing cells secreted Hrg-1 to form a positive 
feedback loop in which Hrg-1 activated HER3/HER4 dimers in BCSCs. Similar 
results were seen in head and neck cancer (Wilson et al., 2011) and melanoma in 
which Notch-1 was shown to directly activate transcription of Hrg-1 to perpetuate 
the autocrine feedback loop and progress cancer cell growth (Zhang et al., 2012).              
         HER2 interaction with other receptors. Trastuzumab resistance has been 
shown to be facilitated by the interaction of HER2 with other non-HER receptors. 
Trastuzumab resistant cell lines have displayed overexpression of the RTK, Ephrin 
type-A receptor 2 (EphA2). Inhibition of EphA2 in vivo increased sensitivity to 
trastuzumab treatment as elevated EphA2 expression correlated with worse 
overall survival in women with HER2+ breast cancer (Zhuang et al., 2010). Another 
RTK commonly overexpressed in HER2+ breast cancer is the c-Met receptor. 
Trastuzumab treatment in vitro resulted in a rapid upregulation of c-Met which 





trastuzumab treatment (Shattuck et al., 2008). Interestingly, the accelerated up-
regulation of c-Met by trastuzumab treatment results in resistance to trastuzumab. 
Increased expression of c-Met and its ligand, HGF, in HER2+, metastatic breast 
cancer correlates with failure of trastuzumab treatment as well as shorter time to 
cancer progression (Minuti et al., 2012).  
 HER2 has been shown to interact with growth factor receptors such as the 
insulin-like growth factor 1 receptor (IGF-1R) to promote trastuzumab resistance 
(Nahta et al., 2005). IGF-1R activation by its ligand, IGF-1, results in increased 
HER2 phosphorylation and activation of Akt and MAPK pathways in trastuzumab 
resistant cells compared to sensitive. IGF-1-mediated stimulation of IGF-1R is 
more prevalent in trastuzumab resistant cells and can promote downregulation of 
p27Kip1. The p27Kip1 protein is a cyclin dependent kinase (CDK) inhibitor that binds 
to CDKs to prevent CDK/Cyclin formation that is necessary for cell division. An 
increase in p27Kip1 activity stops cell cycle progression and results in the cell 
remaining in the G1 phase of the cell cycle. HER2 is able to heterodimerize with 
IGF-1R. Overexpression of IGF-1R amplifies trastuzumab resistance and 
correlates with shorter progression-free survival and increased probability of 
residual disease in women who received adjuvant trastuzumab treatment. 
Overexpression of IGF-1R was induced by epigenetic silencing of miR-375 
expression, a known regulator of IGF-1R expression. The re-expression of miR-
375 could be a potential method to re-sensitize HER2+ breast cancers to 





 Adipose tissue is a major component of the breast. In adipose tissue, it has 
been shown that adipocytes can secrete macrophage inhibitory cytokine 1 (MIC-
1), also known as growth differentiation factor 15 (GDF15), to reduce trastuzumab 
sensitivity (Ding et al., 2009). MIC-1 is related to TGF-β and can promote HER2 
phosphorylation through Src as well as trastuzumab resistance. Inhibition of MIC-
1, TGF-β, or Src restores trastuzumab sensitivity in resistant cells indicating that 
MIC-1 mediates TGF-β/Src crosstalk to evade trastuzumab treatment (Joshi et al., 
2011).  
         PIK3CA mutations in trastuzumab resistance. The most common 
pathway attributed to promoting drug resistance is the PI3K/Akt pathway. Elevated 
PI3K/Akt pathway activity has been identified as the source of resistance to 
targeting the HER2 pathway (Berns et al., 2007). Akt activity can be increased by 
expression of PIK3CA mutations, downregulation of PTEN, HER3 and HER2 
overexpression, Akt-1 mutations, and loss of inositol polyphosphate-4-
phosphatase type 2 (INPPB) expression. Activation of the Akt pathway results in 
resistance to apoptosis as well as increased cell migration, invasion, and survival.  
 In approximately 50% of HER2+ breast cancer cases, Akt signaling is 
activated by expression of PIK3CA mutations or loss of PTEN expression (Jensen 
et al., 2011). PIK3CA mutations confer trastuzumab resistance in vitro and in vivo 
(Cizkova et al., 2012; Dave et al., 2010; Razis et al., 2011) and have proven to be 
key biomarkers, and potential predictors, of trastuzumab resistance. PIK3CA 





lapatinib, trastuzumab, or combined neoadjuvant trastuzumab and lapatinib 
treatment, yet no difference was observed in overall patient survival (Majewski et 
al., 2015). Assessment of PIK3CA mutations in primary tumors predicted a worse 
clinical outcome for women with the PIK3CA mutation in the CLEOPATRA study 
which assessed pertuzumab, trastuzumab, and docetaxel treatment of HER2+, 
metastatic breast cancer but failed to predict for resistance to trastuzumab 
treatment (Baselga et al., 2014). As a potential biomarker, PIK3CA mutations were 
found to be positively associated with survival but not with trastuzumab treatment 
response (Loi et al., 2013; Pogue-Geile et al., 2015). These data indicate that the 
role of the PIK3CA mutations in HER2+ breast cancer is not straightforward and 
continued investigation is warranted. 
         Role of apoptotic and cell cycle regulators in trastuzumab resistance. 
Cells can control their proliferation rate through cell cycle arrest leading to cell 
quiescence and potentially programmed cell death or apoptosis. Cell cycle arrest 
can be mediated by stabilization of CDK inhibitors such as p27Kip1. Trastuzumab 
treatment of sensitive cells reduces Akt pathway activity and upregulates p27Kip1 
resulting in subsequent cell cycle arrest (Yakes et al., 2002). Conversely, 
trastuzumab resistant cells express less p27Kip1 protein as well as CDK2 which 
promotes an increased rate of cell cycle progression and proliferation (Nahta et 
al., 2004). Similarly, trastuzumab resistant cells display higher expression of cyclin 
E compared to trastuzumab sensitive cells (Scaltriti et al., 2011). Elevated cyclin 





reduced clinical benefit from trastuzumab treatment compared to women whose 
tumors express low levels of cyclin E. Interestingly, inhibition of CDK4/6 has no 
effect on cyclin E overexpression, hence tumors with heightened cyclin E 
expression may be resistant to CDK4/6 and HER2 targeted therapies. The p27Kip1 
protein is positively regulated by phosphorylation. The protein phosphatase 
PPM1H, encoded by the PPM1H gene, dephosphorylates serine/threonine 
residues and is able to dephosphorylate p27Kip1 leading to protein degradation and 
reversal of cell cycle inhibition. Inhibition of PPM1H resulted in increased 
proliferation of HER2+ cells in response to trastuzumab treatment. Importantly, low 
PPH1M expression correlates with worse patient outcome (Lee-Hoeflich et al., 
2011). These data suggest that p27Kip1 may be a marker of trastuzumab resistance 
and its re-expression may re-sensitive resistant cells to trastuzumab treatment. 
 Acquired trastuzumab resistant BT474 (BT474TR) cells display an increase 
in B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein. BT474TR cells have shown 
sensitivity to the Bcl-2 inhibitor, ABT-737, compared to trastuzumab sensitive 
(BT474TS) cells. Combined treatment of resistant cells with trastuzumab and ABT-
737 reduced cell proliferation. Bcl-2 activity was found to be mediated through 
PI3K/Akt and IKK/NFκB activity (Crawford and Nahta, 2011). Inhibition of both 
PI3K and IKK promoted downregulation of Bcl-2 thereby increasing sensitivity to 
trastuzumab treatment in the BT474TR cell model.  
 In culture, trastuzumab resistant cells were found to overexpress cyclin D1 





pathway activity. Elevated cyclin D1 results in an increase in CDK-mediated 
phosphorylation of cyclins to promote cell cycle progression and increase cell 
proliferation. Inhibition of cyclin D1 reduced HER2-driven breast tumorigenesis in 
vivo when MMTV-Neu (HER2) mice were crossed with cyclin D1-/- mice.  (Choi et 
al., 2012; Yu et al., 2001). CDK4/6 inhibition was shown to reduce resistant cell 
proliferation in vitro (Roberts et al., 2012) and tumorigenesis in vivo (Witkiewicz et 
al., 2014). Lapatinib has been shown to inhibit CDK4/6 and this may be one of the 
reasons it has an additive effect on cell growth inhibition when combined with 
trastuzumab treatment in HER2+ breast cancer.   
         Role of hormone receptors in trastuzumab resistance. Resistance to 
trastuzumab treatment in ER+/HER2+ breast cancers may occur through an 
escape route offered by ER activity (Giuliano et al., 2015). Conversely, HER2 
activity can reduce sensitivity to anti-hormonal treatments as ER+/HER2+ tumors 
have displayed resistance to endocrine therapy. The inverse relationship between 
ER and HER2 is mediated through a number of different bi-directional crosstalk 
mechanisms (Konecny et al., 2003). HER2 inhibition enables ER-mediated 
upregulation of HER signaling through increased expression of IGF-1 and TNFα 
ligands. ER can inhibit EGFR and HER2 as well as upregulate IGF-1R as a 
compensatory mechanism to evade the HER2 blockade. The inverse relationship 
between HER2 and ER suggests that targeting of both receptors may be 
necessary to suppress ER+/HER2+ tumorigenesis. The combined use of 





free survival compared to anastrozole alone (Kaufman et al., 2009). Increased ER 
activity has been associated with trastuzumab resistance in women with 
ER+/HER2+, metastatic breast cancer that received trastuzumab combined with 
chemotherapy. Interestingly, the addition of endocrine therapy post chemotherapy 
was shown to increase progression-free survival indicating that tumors can retain 
responsiveness to estrogen (Montemurro et al., 2012). These data suggest that 
the role of ER is to promote trastuzumab resistance in women with ER+/HER2+ 
tumors and careful consideration of treatment options must be made to avoid 
treatment resistance. 
         Role of microRNAs in trastuzumab resistance. MicroRNAs (miRNAs) are 
small, non-coding RNAs that regulate protein translation. Similar to silencing RNAs 
(siRNAs), microRNAs form base pairs with complementary mRNA to silence 
mRNA translation into a protein. Post transcriptional regulation by miRNAs can 
occur by: binding to the 3’ untranslated region (3’UTR) of mRNA causing truncation 
of the poly(A) tail and destabilization of mRNA, cleavage of the mRNA, or blocking 
ribosome binding to inhibit mRNA translation. Continued analysis of breast cancers 
by microarray expression profiles attempts to better assess potential promoters of 
breast cancer as well as future treatment options. Trastuzumab resistant, HER2+ 
cell lines have displayed upregulation of miR-21 which has been shown to reduce 
PTEN protein expression in liver cancer as well as programmed cell death 4 
(PDCD4) in colorectal and breast cancer cells (Talotta et al., 2008). Inhibition of 





cell proliferation as well as increased sensitivity to trastuzumab treatment (Gong 
et al., 2011). In BT474TR cells, miR-210 expression was higher compared to 
BT474TS cells and increased circulating levels of miR-210 in women with HER2+ 
breast cancer were found to be associated with lower response to trastuzumab 
treatment and increased lymph node metastases (Jung et al., 2012). Trastuzumab 
treatment was found to induce miR-30b and miR-26a expression in HER2+ cell 
lines, SkBr3 and BT474. miR-30b promotes G1 cell cycle arrest, apoptosis, as well 
as reduce cyclin E2 protein expression (Ichikawa et al., 2012). These data suggest 
that miRNA expression could provide important clues as to why some HER2+ 
breast cancers become resistant to trastuzumab.   
Biomarkers of Trastuzumab Resistance. 
 A number of clinical trials have been done to identify potential markers of 
anti-HER2 targeted resistance. Some of these trials include: NEO-ALTTO, 
CLEOPATRA, TRYPHAENA, Neo-Sphere, and EMILIA to name a few. These 
studies consistently show that HER2 expression is currently the only marker 
appropriate for selecting patients for anti-HER2 therapy (Baselga et al., 2014; 
Gianni et al., 2016; Schneeweiss et al., 2014). Nonetheless, previous markers 
such as: HER2/IGF-1R heterodimerization, Src activation, low PTEN, and 
increased p95HER2 expression were not consistently associated with overall or 
disease-free patient survival. Poor patient prognosis, and not necessarily 
trastuzumab resistance, was commonly associated with the presence of PIK3CA 





suitable for determining anti-HER2 treatment is gene amplification and 
overexpression of HER2 in breast cancer.  
Stem Cells and the Cancer Stem Cell Hypothesis. 
 Stem cells (SCs) are characterized by their ability to self-renew into 
undifferentiated stem cells and differentiate into specialized cells that can generate 
or regenerate tissue. There are two general types of stem cells: embryonic and 
adult stem cells. Embryonic SCs are retained in the inner mass of the blastocyst 
where they are able to differentiate into the three primordial germ layers: the 
ectoderm, endoderm, and mesoderm. Adult SCs are retained in various tissues 
throughout the body where they act as a repair system to maintain the body. Adult 
SCs are also critical for maintaining regenerative cells which can be found 
throughout the adult body in locations such as the bone marrow (periosteum), 
intestinal lining, or skin (epithelium) (Reviewed in Rumman et al., 2015). Adult SCs 
can be used for stem cell therapies such as bone marrow therapy in which donor 
adult SCs are extracted from the bone marrow or peripheral blood and used to 
rebuild a cancer patient’s ablated immune system. SCs can be harvested from 
previously collected umbilical cord blood for stem cell therapies. The continued 
development of stem cell therapies has driven the creation of stem cells from 
terminally differentiated somatic cells (dedifferentiation) or by nuclear transfer of 
an oocyte nucleus into a terminally differentiated somatic cell. A majority of stem 
cell work has been done in mice in which it has been shown that one multipotent 





in vivo (Shackleton et al., 2006). Cancer cells with stem like characteristics were 
first discovered in human acute myeloid leukemia (Bonnet and Dick, 1997) then in 
breast cancer (Al-Hajj et al., 2003) which laid the ground work to propose the 
cancer stem cell hypothesis. 
 The cancer stem cell hypothesis challenges the traditional concept of 
cancer development. Traditionally, the clonal evolution, or the stochastic model, of 
cancer hypothesizes that cancer develops from normal, somatic cells through an 
accumulation of mutations throughout the life time of the cell. These mutations give 
the cell a selective growth advantage over healthy cells enabling them to grow 
uncontrollably, invade neighboring tissues, become metastatic, resistant to 
treatments, and contribute to cancer recurrence. The acquisition of mutations 
creates a clonal subset of cancer cells in which any cancer cell can self-renew to 
produce the number of different cells within a tumor. Support for the clonal 
evolution model in breast cancer is exemplified by the most common mutation in 
breast cancer, the PIK3CAH1047R mutation (Koren et al., 2015). The PIK3CAH1047R 
mutation is able to induce cell dedifferentiation into a multipotent stem-like state 
which may be involved in the formation of multi-lineage, heterogeneous breast 
tumors.  
 The cancer stem cell hypothesis considers a small subset of stem cell-like 
cancer cells [also referred to as tumor initiating cells (TICs)] that are at the top of 
the cancer cell hierarchy. The CSCs are able to self-renew to create more 





comprise a tumor. The ability of a stem cell, or cancer stem cell, to differentiate 
into one or many different cell types is referred to as potency, such as pluripotent 
or multipotent cells.  Hypothetically, a single cancer stem cell can create all the 
cells required for the construction of a complete, heterogeneous tumor, much like 
a single totipotent stem cell can create an entire organ. Similarly, to stem cells, 
CSCs have shown reliance on the microenvironment as interactions with stromal 
or inflammatory cells can regulate their self-renewal or differentiation capabilities. 
The origin of CSCs remains contested as it is hypothesized that CSCs arise from 
transformed adult SCs or by lineage committed cells acquiring mutations resulting 
in dedifferentiation into CSCs. Though the two cancer models are considered 
mutually exclusive, as each fails to sufficiently address tumor heterogeneity, it is 
possible that the genetic and cancer stem cell models coincide by CSCs acquiring 
driver mutations during tumor progression (Reviewed in Kreso and Dick, 2014).  
An increase in CSC mutational burden may enhance CSC properties and result in 
enrichment of the CSC population residing within a tumor. In a heavily CSC 
populated tumor, tumor functionality becomes homogenous as a majority of the 
CSCs self-renew and few differentiate into progenitor cells.  
     CSC properties and BCSCs. Upon the discovery of cancer cells with stem cell 
characteristics, a lot of work has gone into discerning the phenotype of these cells 
and their role in tumor invasiveness, metastasis, therapeutic resistance, and 
recurrence. There are two types of cancer stem cells, the epithelial-like and 





primarily quiescent and at the invasive tumor front. In the breast, these cells are 
similar to basal stem cells found in the normal breast tissue that exist in the basal 
layer (myoepithelial layer) of mammary ducts. The mesenchymal-like CSCs are 
highly invasive yet largely non-proliferative. On the other hand, the proliferative 
epithelial-like CSCs are primarily retained in the hypoxic zones at the center of a 
solid tumor. This SC type has the multilineage capacity to differentiate into a wide 
variety of cells to construct a heterogenic tumor. Epithelial-like BCSCs are similar 
to luminal stem cells and can be found below luminal cells of mammary lobules. It 
is important to note the plasticity of these two stem cell types as the mesenchymal-
like CSCs can transition to epithelial-like CSCs by undergoing mesenchymal to 
epithelial transition (MET), Conversely epithelial-like CSCs can become 
mesenchymal-like CSCs via epithelial to mesenchymal transition (EMT). The 
ability of the CSCs to shift between epithelial and mesenchymal states perpetuates 
their ability to promote an aggressive cancer phenotype. Remarkably, both 
epithelial and mesenchymal-like BCSCs have similar GEPs across various breast 
cancer subtypes. CSCs have been shown to transdifferentiate into endothelial and 
vascular smooth muscle-like cells for improved tumor vascularization. Additionally, 
women whose tumors have high levels of CSC markers have poorer overall 
survival and these CSC markers may be used as prognostic factors for breast 
cancer progression in the clinic (Zhou et al., 2010).  
 Transit amplifying cells (TACs) differentiate from stem cells that have not 





state of TACs is between that of undifferentiated stem cells and terminally 
differentiated cells (Figure 5). TACs are highly proliferative yet short lived cells 
whose progeny differentiate into the various lineages of mature cells necessary to 
form a complete organ. Due to their high proliferation rate, TACs typically represent 
a greater portion of the cell population compared to stem cells. The limited 
proliferative nature of TACs can promote the accumulation of mutations, but these 
are usually repaired within the cell offspring. It is possible that some mutations 
remain in the TACs, resulting in dedifferentiation of this mutated TAC subset, 
thereby allowing these mutations to enter the SC population. Similarly, mutations 
retained by the TAC progeny may occur, in which they are more likely to transform 
into cancerous cells. Therefore, targeting TACs may be a viable option to reduce 
or prevent the initiation of tumorigenesis, in an effort to intercept the transition from 



































Figure 5: Breast Cancer Stem Cell Self-Renewal and Differentiation 
Pathways 
The tightly regulated process of BCSC self-renewal and differentiation into transit 
amplifying cells (TACs) then terminally differentiated cells can become 
dysregulated in breast cancer. Loss of PTEN or upregulation of Notch or HER2 
receptors can result in an increase in the BCSC population which is hypothesized 
to promote drug resistance, metastasis, and the generation of new, heterogeneous 
tumors. 
 Breast cancer cells with stem cell characteristics were first found in breast 
cancer patient samples by Al-Hajj et al. (Al-Hajj et al., 2003). Breast cancer cells 
with similar surface markers as multiprogenitor mammary stem cells [MaSCs 
(CD44+/CD24-/Low/Lin-)] may originate from BCSCs. As few as 100 breast cancer 





50,000 non cancer stem-like cells (CD44+/CD24+/Lin-) failed to form tumors. The 
discovery of BCSCs opens the door to further investigate the role of BCSCs in 
breast cancer.  
     BCSC markers. The first BCSCs were defined by their tumorigenicity in vivo 
using models of mouse BCSC tumor xenografts and in vitro by colony formation, 
sphere formation, migration, and invasion assays (Al-Hajj et al., 2003). These 
assays allow serial dilution of BCSCs to determine the ability of a logarithmically 
increasing amount of BCSCs, or non-BCSCs, to form tumors or display BCSC 
properties. Initially, BCSCs were isolated from patient samples by flow cytometry. 
Cell surface expression of CD44+/CD24-/low was the most common BCSC marker 
within patient samples. This subset of cells was used in BCSC colony forming 
assays and in an immunodeficient mouse model to determine tumorigenicity of 
serial diluted (100 to 50,000) BCSC and non-BCSC populations. CD44 (Cluster of 
differentiation 44) is a receptor for hyaluronic acid and is involved in cell to cell and 
cell to extracellular Membrane (ECM) interactions. CD24 is a small glycoprotein 
that negatively regulates the chemokine receptor CXCR4, which has been shown 
to regulate metastasis of breast cancer cells (Schabath et al., 2006). To confirm 
that tumor cells were being selected, Lineage- (Lin-) enabled selection of neoplastic 
tumor cells from normal cell type lineage markers (CD2, 3, 10, 16, 18, 31, 64, and 
104b). Cells were also selected by epithelial specific antigen (ESA+) expression, 
or epithelial cell adhesion molecule (EpCAM), which is expressed on the surface 





mesothelial cells (Al-Hajj et al., 2003). Establishment of the CD44+/CD24-/low 
surface expression is now a common marker for epithelial BCSC as well as a poor 
prognostic factor for women with early stage breast cancer (Buess et al., 2009). 
Further research into the CD44+/CD24-/low BCSC marker found that its expression 
does not always correlate with tumorigenicity (Fillmore and Kuperwasser, 2008) 
and women with the opposite CD44-/CD24+ status had a worse breast cancer 
prognosis (Ahmed et al., 2012). 
 Infrequencies with the use of CD44+/CD24-/low as a marker of BCSCs has 
initiated the search for other BCSC markers.  BCSCs have been shown to express 
aldehyde dehydrogenase 1 (ALDH1), an enzyme that catalyzes the oxidation of 
toxic aldehydes into inert carboxylic acids. ALDH1 can be fluorescently tagged and 
used as a stem cell marker in breast cancer (Ginestier et al., 2007b). ALDH 
expression is a good marker of epithelial BCSCs as they have been shown to 
express ALDH (Liu et al., 2014). CD133 (Prominin 1) expression was found to be 
similar to CD44+/CD24-/low expression in cells derived from BRCA-1 knockout mice 
as a marker of BCSCs (Wright et al., 2008). CD44+/CD24-/low as well as increased 
vimentin (Borgna et al., 2012), and IL-1/prostaglandin E2 (Li et al., 2012) 
expression have been developed as markers of mesenchymal stem cells in breast 
cancer. BCSC markers continue to be found which include integrin markers: CD29, 
CD61 (Vaillant et al., 2008), CD49f (Cariati et al., 2008); a mucin family marker, 
MUC1 (Engelmann et al., 2008); as well as the Delta ligand from the Notch family 





found and verified both in vitro and in vivo and can vary greatly between breast 
cancer subtypes. The discovery of multiple markers of BCSCs strongly suggests 
that BCSCs are heterogeneous and their diversity may be the main reason that 
breast cancers are intrinsically heterogeneous.  None the less, the most relevant 
markers of BCSC still need to be identified for incorporation into the breast cancer 
treatment strategy.  
     Role of BCSCs in metastasis. Metastasis of breast cancer to vital organs is 
one of the major contributors to breast cancer-associated mortality. There remains 
no targeted therapeutic approach for the treatment of metastatic breast cancer 
outside of chemotherapy. Metastasis may be mediated by a small set of BCSCs 
from the primary tumor that can invade and migrate to distal vital organs to form 
secondary tumors. BCSC-mediated metastasis has been demonstrated in several 
studies. Genetic expression profiling of CD44+/CD24-/Low isolated cells from 
primary tumors was found to be similar to metastatic breast cancer cells isolated 
from the distant organs and in tumors from women with worse overall outcome (Liu 
et al., 2007). Early metastatic cancer cells found in the bone marrow of breast 
cancer patients expressed a CD44+/CD24-/Low profile (Balic et al., 2006). 
Additionally, ALDH positive cells displayed greater metastatic capacity compared 
to ALDH negative cells in a xenograft mouse model (Charafe-Jauffret et al., 2009). 
Combined, these studies underline the importance of BCSCs in promoting 





     The role of BCSCs in EMT / MET. Epithelial to mesenchymal as well as 
mesenchymal to epithelial transition are fundamental processes in early 
embryogenic morphogenesis and are proposed to be critical regulators of tumor 
metastasis. Epithelial cells convert to mesenchymal cells (EMT) and mesenchymal 
cells re-convert to epithelial cells (MET) to promote secondary tumor growth at 
distal sites away from the primary tumor. EMT occurs by epithelial cells losing their 
epithelial characteristics: cell to cell adhesion and apical-basolateral polarity, to 
take on mesenchymal cell characteristics: spindle shape and motility (Mani et al., 
2008; Morel et al., 2008). Cells undergoing EMT downregulate epithelial cell 
markers such as E-cadherin and lose occludins, adherins, and/or tight junctions. 
During EMT, the epithelial cell upregulates mesenchymal cell markers: N-
Cadherin, vimentin, and fibronectin, as well as transcription factors: SNAIL, SLUG, 
ZEB1, ZEB2, TWIST 1 and TWIST2 (Reviewed in Thiery et al., 2002). The 
transcription factors inhibit E-Cadherin, specifically claudins, and Zonula 
Occludens 1 [(ZO1) a tight junction protein], Platelet-Derived Growth Factor 
(PDGF), Hepatocyte Growth Factor (HGF), Transforming Growth Factor β (TGF-
β), or matrix metalloproteinase expression. EMT can be induced in vitro by over 
expressing TWIST or SNAIL, or exposing the cells to growth factors such as EGF 
or TGF-β (Morel et al., 2008). 
 Continued research on BCSCs makes it clear that this small subset of cells 
can be generated through EMT to promote cancer progression. It is hypothesized 





CD44+/CD24- cells have an increase in EMT markers and the potential to invade 
and migrate to distal organs. The constitutively active protein, AXL, in BCSCs 
induces EMT by inhibiting E-Cadherin while upregulating N-Cadherin, Snail, Slug, 
Zeb1, and fibronectin expression (Asiedu et al., 2013). AXL has also been shown 
to regulate a number of pathways including STAT, Akt, NF-κB, and MAPK, which 
may be pertinent to EMT. EMT can be induced in vitro by the increased activation 
of the transcription factor, FOXC2, which has been shown to promote a more 
aggressive cancer phenotype (Mani et al., 2007). EMT can be activated through 
metadherin (MTDH)-mediated activation of Twist to induce the BCSC phenotype 
(Liang et al., 2015). The more aggressive breast cancer subtypes (TNBC and 
HER2+) have increased markers for BCSCs and EMT compared to less 
aggressive subtypes (Luminal A) (Park et al., 2010b).  
 The two types of BCSCs, epithelial and mesenchymal, can be further 
characterized by their expression of mesenchymal or epithelial cell markers (Liu et 
al., 2014). Mesenchymal-like BCSCs are identified as having low E-cadherin and 
high vimentin at the invasive edge of a tumor. The mesenchymal BCSCs are ready 
to enter the blood or lymphatic circulation to form new, small tumors 
(micrometastasis) at distant organ sites. The invasive mesenchymal BCSCs can 
transition to more proliferative epithelial BCSCs (METs) to generate a secondary 
tumor. The more proliferative epithelial BCSCs express high levels of E-cadherin 
and low vimentin in the center of the tumor. The central epithelial BCSCs can 





promote metastatic formation of secondary tumors. The two BCSC states can 
switch between invasive mesenchymal and proliferative epithelial to promote 
tumor spread and growth, respectively. The transition between these two states 
may be regulated by chemokine and cytokine signaling as the plasticity of the 
BCSCs enables them to readily metastasize or adapt to changing 
microenvironment conditions.   
     BCSC maintenance and non-coding RNAs. BCSCs are able to transition 
between stem-like and non-stem-like states. BCSC plasticity indicates that there 
are regulatory mechanisms that are able to induce or maintain the stemness of 
BCSCs. Stemness of BCSCs can be regulated through interactions with non-
coding RNAs (ncRNAs), the tumor microenvironment, or fluctuations in cell 
signaling pathways within the cell.  
 There are many types of ncRNAs including: long non-coding RNAs (lnc 
RNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), and miRNAs that are 
not translated into a protein. ncRNAs have a wide variety of functions but here we 
will focus on a set of ncRNAs associated with BCSC plasticity (Reviewed in Liu et 
al., 2013). Expression of miRNAs are altered in BCSCs compared to bulk tumor 
cells. Some miRNAs altered in BCSCs are the: miR-183 cluster, miR-200 cluster, 
miR-221-222 cluster, miR-142, miR-214, and let-7. These miRNAs may target a 
variety of pathways that are responsible for maintaining the stemness of BCSCs. 
Assessment of the BCSC population can be tested in vitro by using mammosphere 





primary and secondary mammosphere formation, respectively. It has been shown 
that let-7a reduces both cell proliferation and mammosphere formation in a k-Ras-
dependent manner both in vitro and in vivo (Ma et al., 2015). The lncRNA, 
Linc00617, induces stem cell properties in breast cancer cells by upregulating the 
stem cell marker, Sox2 (Li et al., 2017). BCSC properties may be inhibited by 
targeting ncRNAs as a possible therapeutic strategy.   
     Role of BCSCs in the tumor microenvironment. The tumor 
microenvironment creates a “niche” that supports and maintains survival and self-
renewal capacity of CSCs. CSCs interact with a variety of cells in the tumor 
microenvironment such as: Tumor-associated Macrophages (TAMs), 
Mesenchymal Stem Cells (MSCs), Cancer-Associated Fibroblasts (CAFs), 
Extracellular Matrix (ECM), endothelial cells (ECs), and immune cells. CSC 
interaction with other cells in the tumor microenvironment occurs through a 
complex network of cytokine and growth factor expression. These ligands 
stimulate CSC self-renewal, angiogenesis, as well as stromal and immune cell 
recruitment into the CSC niche to perpetuate the production of additional factors 
in order to promote tumor cell invasion and migration.   
 Hypoxic conditions can induce the CSC phenotype as well as enrich the 
CSC population in various types of cancer. The BCSC population of TNBC cells, 
MDA-MB-231, is enriched by hypoxia (Xie et al., 2016). Hypoxia has been shown 
to enrich the BCSC population in primary epithelial and tumor cells (Iriondo et al., 





1 alpha (HIF1α).  Downregulation of prolyl hydroxylase 3 (PHD3) mimics hypoxic 
conditions and was found to increase the CD44+/CD24-/low population of BCSCs.   
Hypoxic activation of HIF1α has been shown to upregulate embryonic stem cell 
markers OCT4, SOX2, KLF4, NANOG, c-MYC, and microRNA-302 resulting in 
expansion of the BCSC population (Mathieu et al., 2011). Hypoxia-mediated 
enrichment of the BCSC population has been shown to be dependent on HIF1α-
mediated expression of AlkB Homolog 5 (ALKBH5) which stabilizes NANOG 
mRNA thereby increasing NANOG protein expression (Zhang et al., 2016). The 
hypoxic environment and hypoxia-induced pathways may be potential therapeutic 
targets to prevent BCSC expansion.  
 Tumor cells can increase cytokine and growth factor production which has 
been shown to stimulate CSC proliferation and survival as well as promote 
recruitment of stromal and immune cells into the CSC niche. Enrichment of stromal 
and immune cells into the CSC niche results in the secretion of additional growth 
factors creating a positive feedback loop. This positive feedback loop between 
CSCs and immune/stromal cells has been shown to increase tumor cell 
metastasis. Autocrine or paracrine signals between BCSCs and stromal cells can 
regulate BCSC phenotypes. In HER2-negative MCF-7 breast cancer cells, human 
umbilical cord-derived MSCs stimulate Interleukin-6 (IL-6) and IL-8 autocrine 
signaling which promotes the CD44+/CD24- BCSC population to migrate in vitro 
and metastasize in vivo (Ma et al., 2015). TNBC cell lines, MDA-MB-231 and MDA-





STAT3 signal transduction pathway in non-CSCs (Kim et al., 2013). The OCT4 
transcription factor has been shown to promote dedifferentiation of non-CSCs into 
CSCs. Primary breast CAFs and fibroblasts produce high levels of the chemokine 
(C-C motif) ligand 2 (CCL2) to induce CSC self-renewal through upregulation of 
Notch-1 (Tsuyada et al., 2012). BCSCs can be regulated though interactions 
between endothelial cells and CD44+/CD24- cells. Tumor-endothelial cell 
interactions can regulate BCSCs by establishing a feedback loop in which tumor 
cells secrete endothelial stimulatory signals such as FGF12, VEGF, NF1, and PTN 
causing endothelial cells to secrete PDGFB to promote cancer cell proliferation 
(Buess et al., 2009). Cytokines and growth factors are critical to maintaining the 
CSC population and require careful consideration when assessing the BCSC 
environment. 
 A major cellular component of the breast tumor microenvironment is Tumor 
Associated Macrophages (TAMs) which have been hypothesized to originate from 
resident tissue macrophages or circulating monocytes to establish leukocyte 
accumulation within the stroma of a tumor. The function of TAMs is debatable as 
evidence has shown their involvement in tumor growth and metastasis by 
stimulating angiogenesis as well as tumorostatic or tumoricidal processes (Bingle 
et al., 2002). TAMs have been shown to promote a CSC-like phenotype through 
paracrine EGFR/Stat3/Sox-2 signaling in murine breast cancer cells (Yang et al., 
2013). TAMs may play a critical role in BCSC maintenance as previous work has 





growth compared to the injection of CSCs cell alone. Increased TAM infiltration 
around breast tumors correlates with increased tumor vascularization and a worse 
overall prognosis for women with breast cancer (Leek et al., 1996). The 
accumulation of CAFs, TAMs, stromal cells, and freshly produced blood vessels 
at the tumor invasive front allow CAFs to secrete macrophage colony stimulating 
factor (M-CSF) to activate TAM’s pro-angiogenic switch. The cellular milieu of the 
CSC niche plays an important role in supporting the BCSC population. 
 T-cells can promote breast cancer when recruited into the tumor 
microenvironment. TAMs and CD4+ T helper cells are able to secrete TNFα in 
order to upregulate NF-κB signaling. This increase in NF-κB signaling stimulates 
transcription of Snail, Slug, and Twist as well as increased crosstalk with the TGF-
β pathway resulting in CSC maintenance and self-renewal (Reviewed in Smith et 
al., 2012). Infiltration of FOXP3+ regulatory T cells and CD8+ cytotoxic T cells was 
associated with high histological grade and steroid receptor negative status (Liu et 
al., 2011). Elevated levels of CD4+ and CD8+ T cell infiltration are closely 
correlated with EMT and the BCSC phenotype.  Interestingly, infiltration of both T 
cell types was also associated with the absence of residual invasive disease in the 
breast or lymph nodes upon completion of neoadjuvant treatment (Seo et al., 
2013). Therefore, the presence of T cells in the tumor could be an early response 
to therapy where the non-CSCs are targeted by the immune system but not 





 The ECM is critical in the niche of both normal and cancer stem cells as it 
plays a multitude of roles in maintaining normal cell and stem cell properties. ECM 
anchorage retains stem cells in the niche allowing them to be available to receive 
critical paracrine signals necessary for maintaining stem cell properties. Cellular 
differentiation processes can be obstructed by irregular changes in the ECM 
resulting in enrichment of the stem cell population and a reduction in cell 
differentiation (Reviewed in Lu et al., 2012). ECM stiffness in breast cancer can 
promote transcriptional coactivator with PDZ-binding motif (TAZ) activity, resulting 
in an increase in the BCSC population (Cordenonsi et al., 2011; Dupont et al., 
2011). These data suggest a possible role for the ECM in promoting BCSC self-
renewal resulting in breast cancer disease progression.  
    Role of BCSCs in HER2+ breast cancer. Treatment of HER2+ breast cancer 
by biologics such as trastuzumab has greatly improved the clinical outcome of 
women with tumors overexpressing the HER2 protein. Evidence has been 
presented that shows a positive correlation between HER2 amplification and 
BCSC frequency as assessed by ALDH1 expression (Korkaya et al., 2008) (Figure 
5). Although the precise mechanism of trastuzumab’s actions remain unknown, 
trastuzumab has been shown to reduce BCSC enrichment in trastuzumab 
sensitive cells but not trastuzumab resistant cells in vitro (Magnifico et al., 2009). 
Previous work has demonstrated that HER2 cooperates with c-Myc to promote a 
stem-like phenotype and BCSC self-renewal (Nair et al., 2013a). The BCSC 





trastuzumab. The Akt pathway has been shown to be required for this enrichment 
(Korkaya et al., 2008). Several markers for BCSCs have been found in HER2+ 
breast cancer cell lines and patient samples including: MUC1+ (Engelmann et al., 
2008), Vimentin+, CK18+, and GATA3+ (Park et al., 2010b) combined with CD24+ 
or CD44+ expression. It has been shown that inhibition of CXCR1 and 2 
(CXCR1/2), which are regulated by IL-8, significantly reduces BCSC activity in 
patient-derived HER2+ breast cancers (Singh et al., 2013). Trastuzumab may not 
be inhibiting the BCSC population specifically but acting on the emerging TAC 
population. Trastuzumab-mediated TAC inhibition may occur in resistant cells in 
which trastuzumab inhibits CSC differentiation into TACs thereby increasing the 
BCSC population. Another possibility is the occurrence of a mutation in the TAC 
population promoted by prolonged trastuzumab treatment that results in TAC 
dedifferentiation into BCSCs.  
     Role of BCSCs in treatment resistance. BCSCs have been shown to play a 
role in drug resistance both in vitro and in vivo. TNBC BCSCs are enriched by 
chemotherapy such as paclitaxel and thus are inherently resistant to this type of 
therapy (Samanta et al., 2014). Therapy was shown to increase the BCSC 
population in HER2+ breast cancer from patient biopsies post chemotherapy 
and/or lapatinib treatment (Li et al., 2008). A number of BCSCs from different 
breast cancer cell lines demonstrated resistance to radiotherapy (Phillips et al., 
2006). Additionally, the Wnt pathway has been shown to drive SOX2 gene 





(Piva et al., 2013). Similarly, either letrozole or docetaxel treatment has been 
shown to increase the BCSC population in patient tumor samples post therapy 
(Creighton et al., 2009). Together, these data suggest that BCSCs have an intrinsic 
resistance to some breast cancer treatments or their ability to be quiescence 
enables the BCSC population to evade chemotherapy and/or radiotherapy. 
Therefore, investigating novel therapies to target the BCSC population may prove 
to be an effective strategy for the treatment of breast cancer. 
The Notch Pathway. 
 The Notch receptor is a type 1, single pass, transmembrane protein (Kopan, 
2009). The NOTCH1 gene is transcribed by the E26 transformation-specific (ETS) 
family member, polymavirus enhancer activator 3 (PEA3) (Clementz et al., 2011) 
in TNBC or by p53 in keratinocytes and epithelial cells (Lefort et al., 2007). 
Furthermore, E2A (E-proteins E12 and E47) in conjunction with Notch-1 induce 
NOTCH1 gene expression in the early stages of T cell development (Yashiro-
Ohtani et al., 2009), indicating that Notch-1 can regulate its own expression during 
T cell maturation. Additionally, during T cell selection, the basic helix-loop-helix 
(bHLH) transcription factor, Id3, is upregulated by the MAPK pathway to inhibit 
Notch-1 transcription.  
 The mature Notch receptor (272,505 Da.) is constructed as a heterodimer 
comprised of two domains bound by a non-covalent bond that is typically mediated 
by a calcium (Ca2+) ion (Figure 6). During maturation, the nascent, full length Notch 





1) site by a furin-like convertase, furin / proprotein convertase 5 / 6 (PC5/6), into 
two domains: the Notch extracellular domain (NECD) and the Notch 
transmembrane / intracellular domain (NTMICD). The extracellular domain of the 
Notch receptor contains a series of EGF-like repeats that arbitrate ligand 
interactions which are facilitated by Notch ligand expression on the surface of a 
neighboring cell. The EGF repeats are preceded by the Negative Regulatory 
Region (NRR) that inhibits Notch receptor activation in the absence of a Notch 
ligand. In humans, there are five known Notch ligands: Jagged-1, -2 (Jag-1, -2), 
Delta-Like-1, -3, and -4 (DLL-1, -3, -4) that are able to bind to and activate the 
Notch receptor when expressed on the surface of a cell in close proximity to the 
Notch receptor of a neighboring cell (Figure 7). The affinity of a Notch ligand to a 
Notch receptor can be attenuated by the addition of sugar moieties to the Notch 
receptor which is facilitated by Fringe glycosyltransferases (Lunatic, Manic, or 
Radical). Fringe glycosyltransferases add N-acetylglucosamine moieties to the 









Figure 6: The Notch Receptor. 
The Notch receptor is composed of several domains that can be divided by the 
extracellular domain (NECD) and the transmembrane and intracellular domain 
(NTMICD). The NECD starts at the N-terminal (NH3) end and contains ligand 
binding epidermal growth factor-like (EGF) repeats as well as the negative 
regulatory region (NRR). Fringe proteins are able to target the EGF repeats for 
glycosylation, which can change their ligand binding ability to the Notch receptor. 
The NRR is composed of Lin12-Notch repeats (L) and the heterodimerization 
domain (HD). The NTMICD contains: the transmembrane domain (T, TMB), the 
RBP-Jκ associating module (R) or RAM domain, one of two nuclear localization 
signals (N), the ankyrin domain, a second nuclear localization signal, the cysteine 
response region (NCR), the transactivating domain (TAD), and a proline/glutamic 
acid/serine/threonine-rich motif (PEST) at the C-terminal (COOH) end of the Notch 
receptor. Ligand bound Notch is cleaved at a series of scissile sites (S1, 2, 3, 4) 
represented just outside of S1 and inside the transmembrane domain [S2, 3, 4 
(TMB enlargement)]. Furin-like convertase cleaves immature Notch at S1 to create 
the mature, heterodimeric Notch receptor, which is stabilized by a non-covalently 
bound calcium ion (Ca+2). The RAM domain facilitates core binding factor-1 (CBF-
1) binding. NICD binding to CBF-1 allows binding of mammal-like mastermind-1 
(MAML-1) to the Ankyrin domain to form a ternary complex. The histone 
acetyltransferase, p300, is recruited to NICD bound CBF-1 to form the Notch 
transcriptional complex. The PEST domain is responsible for protein stability of the 


















Figure 7: The Notch Pathway. 
The Notch pathway is activated by a Notch ligand (Jagged-1, -2, DLL-1, -3, -4) on 
the surface of a signal sending cell (top) binding to a Notch receptor (Notch-1, -2, 
-3, -4) on the surface of a signal receiving cell (bottom). The ligand bound Notch 
receptor undergoes a series of cleavages. ADAM/TACE-mediated cleavage at S2 
generates the NEXT fragment then γ-secretase-mediated cleavage at S3/4 
generates NICD. NICD is translocated to the nucleus to bind to CBF-1 allowing the 
release of negative co-regulators (NCoR) and the recruitment of co-activators 
(CoA) such as MAML-1 and p300 to form the Notch transcriptional complex (NTC). 
Proper NTC formation allows NICD to act as a transcriptional activator of Notch 






 The intracellular domain of the Notch receptor is comprised of the active 
portion of the Notch receptor, the Notch Intracellular domain [NICD (110 kDa.)]. 
NICD is comprised of the: Recombining Binding Protein-Jκ (RBP-Jκ) associating 
molecule (RAM) domain, Ankyrin domain, cysteine response region (NCR), 
transactivation domain (TAD), proline/glutamic acid/serine/threonine-rich motifs 
(PEST domain), and a pair of nuclear localization sequences (NLS) flanking the 
Ankyrin domain. The NLSs direct the cleaved NICD to enter the nucleus where it 
facilitates transcriptional activation of Notch target genes.  
 Activation of the Notch pathway requires a series of events beginning with 
the expression of the Notch receptor on the surface of the signal receiving cell 
binding to a Notch ligand on the neighboring signal sending cell. Subsequently, 
ligation of the Notch ligand to the Notch receptor is necessary for removal of 
inhibitory NECD from the NTMICD portion of the Notch receptor which results in 
two subsequent cleavage events: S2 and S3 cleavage. S2 cleavage is mediated 
by a disintigrin and matrix metalloproteinase 10 or 17 (ADAM10/17) which results 
in the Notch Extracellular Truncated (NEXT) Fragment.  The S3 cleavage is 
mediated by the γ-secretase complex. Cleavage by γ-secretase results in the 
release of the NICD portion of the Notch receptor (Figure 7). NICD is translocated 
to the nucleus where it binds the constitutive repressor, RBP-Jκ/Core Binding 
Factor-1 (RBP-Jκ/CBF-1) poised on promoter regions of Notch target genes. In the 
absence of NICD, CBF-1 is bound to co-repressor proteins such as SMRT/HDAC-





(Oswald et al., 2005). This CBF-1-co-repressor complex represses gene 
transcription until NICD is available. Upon the binding of NICD to CBF-1, co-
repressors are replaced by co-activator proteins. NICD binding to CBF-1 results in 
the recruitment of transcriptional co-activators beginning with Mammal 
Mastermind-like-1 (MAML-1) followed by the Histone Acetyltransferase (HAT), 
p300.  Recruitment of the transcriptional co-activators to NICD1 results in 
unwinding of chromatin and exposing the promoter region of the target gene 
thereby initiating transcription. The binding of NICD to CBF-1 and the recruitment 
of transcriptional co-activators forms the Notch transcriptional complex. Canonical 
Notch target genes are predominantly helix-loop-helix transcriptional repressors 
including: Hairy/Enhancer of Split (HES-1-5) and Hairy/Enhancer of split with a 
unique YRPW motif (HEY-1, HEY-L). In mammals, there are four Notch paralogs, 
Notch-1, -2, -3, and -4. Each Notch paralog has unique structures that may 
facilitate synergistic and/or counteracting functions depending on the context of 






Figure 8: Notch Receptor Paralogs. 
The Notch receptor paralogs (Notch-1-4) have a similar overall composition but 
slight differences in their structure to facilitate diversification of their attributes. 
Differences amongst the Notch paralogs include changes in the number of EGF-
like repeats or the subtraction or addition of domains such as the PDZ domain or 
cysteine response region. 
 The Notch pathway is most frequently associated with lateral inhibition in 
which the Notch ligand, Delta, if expressed in one cell is capable of inhibiting Delta 
expression on a neighboring cell. In a cluster of undifferentiated cells, when one 
cell begins to differentiate into an epithelial cell, it signals the surrounding cells to 
also differentiate into epithelial cells. Originally, an undifferentiated cell can 
express both the Notch receptor and the Delta ligand. Stimulation of the Notch 
receptor will inhibit Delta production in the same cell. Through juxtacrine signaling, 
adjacent cells compete to produce Delta, causing a feedback loop that drives the 
two neighboring cells to assume dissimilar cell fates established by the number of 





to institute a border between two different populations of cells such as progenitor 
and stromal cells. Boundary development by oscillating Notch activity is most 
prominent in somite formation in which the continuous inactivation and activation 
of Notch-mediated transcriptional activity results in the segmented formation of 
somites in vertebrates (Pasinia et al., 2001; Palmeirim et al., 1997). Notch is able 
to direct cell lineage via asymmetrical inheritance of Notch regulators between two 
dividing, daughter cells, and is most apparent during neurogenesis (Lowell et al., 
2006).  
 The Numb drosophila homolog (Numb) is encoded by the NUMB gene and 
acts as an inhibitor/negative regulator of Notch activity. Asymmetric distribution of 
Numb and Notch between two dividing cells determines if one daughter cell is a 
signal receiving cell and if the other is a signal sending cell. This uneven 
distribution of Notch and Numb is inherited through multiple cell divisions to sustain 
stem cell populations as well as influence cell lineage decisions (Reviewed in 
Chiba, 2006). The culmination of the Notch pathway outlines its capacity to act as 
a method of short range communication between cells. Notch juxtacrine signaling 
has been found to be involved in a variety of processes, most notably in stem cell 
differentiation, self-renewal, and cell fate determination as well as cell growth, 
proliferation, and survival (Reviewed in Artavanis-Tsakonas, 1999).  
 Notch targeted treatments include the use of γ-secretase inhibitors (GSIs). 
GSIs inhibit the critical S3 cleavage mediated by the γ-secretase complex 





activation. First generation GSIs were chemically designed to mimic the transition 
state of the γ-secretase substrate bound to the catalytic subunit, presenilin-1, such 
as Notch or the amyloid precursor protein (APP) (Figure 7). Second generation 
GSIs were designed as non-transition state analogs. These small molecule 
inhibitors bind allosterically to γ-secretase and attenuate γ-secretase enzymatic 
activity that is independent of direct competitive binding. Both types of GSIs 
ultimately interfere with the ability of γ-secretase to cleave and activate the Notch 
receptor (Clarke et al., 2006). There are several distinct GSIs including MRK-003, 
DAPT, and Compound E as well as γ-secretase modulators (PF-03084014), which 
are designed to specifically inhibit specific Notch paralogs (Zhang et al., 2012). 
     Role of Notch in breast cancer. There is a growing body of evidence 
indicating that an increase in Notch expression or mutation results in a series of 
events that enable breast cancer cells to: undergo EMT, become resistant to 
targeted treatments, metastasize, and promote BCSC survival and self-renewal 
(Reviewed in Nickoloff et al., 2003). Initial discovery of a role for Notch in breast 
cancer was made by an observation from studies using the mouse mammary 
tumor virus (MMTV) model of breast cancer. It was found that MMTV was inserted 
in the in the Int3/Notch-4 locus of murine mammary tumors (Gallahan and 
Callahan, 1987). The insertion of MMTV into the Notch-4 locus resulted in a Notch-
4 mutation that made it constitutively active. Further investigations revealed that 
MMTV-driven NICD1 or NICD4 expression in the mammary gland induced 





of the Notch pathway has been shown to transform normal breast epithelial cells 
into cancerous cells which can be inhibited by targeting Notch-1 (Stylianou et al., 
2006). Additionally, the expression of Numb is frequently lost in breast tumors 
(Pece et al., 2004). Increased co-expression of Jagged-1 and Notch-1 in breast 
tumors has been associated with worse overall survival in women with breast 
cancer (Reedijk et al., 2005). Increased Notch-1 expression has been shown to 
occur early in the development of HER2+ breast cancer (Zardawi et al., 2010) and 
both Notch-1 and Notch-4 have been identified as prognostic markers for breast 
cancer (Yao et al., 2012). Notch signaling has been shown to inhibit apoptosis by 
activation of the Akt pathway via an autocrine loop in breast cancer cells (Meurette 
et al., 2009). Notch-1, -3, and -4 are bonafide oncogenes in T-cell acute 
lymphoblastic leukemia (T-ALL) (Ellisen et al., 1991), cervical (Zagouras et al., 
1995), B-cell lymphoma (Fabbri et al., 2011), lung (Konishi et al., 2007), colon 
(Akiyoshi et al., 2008), and ovarian (Rose et al., 2010) cancers. In contrast, Notch-
2 has tumor suppressive activity in some breast cancer subtypes (O'Neill et al., 
2007; Parr et al., 2004; Shimizu et al., 2002). Notch-3 has been shown to facilitate 
proliferation and survival of HER2 negative tumors (Yamaguchi et al., 2008) as 
well as promotion of BCSC survival and self-renewal in a hypoxic environment 
(Sansone et al., 2007) (Figure 8). There are a number of studies suggesting that 
Notch functions as a tumor suppressor in myeloid malignancies (Klinakis et al., 
2011) and skin cancer (Lefort et al., 2007). Research in melanoma indicates that 





been shown to activate both Akt and MAPK pathways as well to induce expression 
of the EMT marker, N-Cadherin, both in vitro and in primary melanoma tumors (Liu 
et al., 2006). These data indicate that Notch acts as an oncogene or a tumor 
suppressor in a cell and/or tissue-dependent context.  
 The Notch pathway has been referred to as the Notch-survival pathway due 
to its ability to stimulate cell proliferation and growth. One of the Notch target genes 
responsible for regulation of cell longevity is called survivin. Survivin is an inhibitor 
of apoptotic protein (IAP) and functions to downregulate caspase 3, 7, and 9-
mediated apoptotic activities. Survivin has also been shown to regulate the cell 
cycle by interacting with spindle microtubules during mitosis (Li et al., 1998).  
Cyclin dependent kinase 1 (CDK1) phosphorylates the threonine 34 residue of 
survivin to increase its protein stability (O'Connor et al., 2000) enabling survivin to 
evade degradation arbitrated by the X-linked IAP-X-linked association factor-1 
complex (XIAP-XAF1).  The XIAP-XAF1 complex induces E3 ligase activity that 
targets survivin for ubiquitinylation and subsequent proteasome-mediated 
degradation. Prolonged survivin expression has been associated with breast 
cancer survival through PI3K/Akt and MAPK/ERK pathway activities (Siddiqa et 
al., 2008). There is a clear association between Notch-1 and survivin as women 
with ER+ breast tumors that overexpress both Notch-1 and survivin have poorer 
survival outcomes than women whose tumors do not co-express both transcripts 





      Role of Notch in BCSCs. Notch plays a critical role in determining cell fate of 
both normal SCs and cancer SCs. It was found that Notch-4 plays a critical role in 
proper mammopoiesis suggesting that it directs normal breast SC and BCSC fate. 
It has been demonstrated that Notch, particularly Notch-4, plays a prominent role 
in BCSC self-renewal, survival, and cell fate, or differentiation (Dontu et al., 2004). 
In particular, Notch-4 was found to promote BCSC self-renewal and promote side 
branching of breast cells in vitro. Additionally, breast stem cells are hypothesized 
to be at the tips of extending branches in the developing mammary gland. 
Conversely, specific inhibition of Notch-4, or Notch-1, reduced BCSC enrichment 
as well as tumor initiation in vitro and in vivo yet inhibition of Notch-4 had a greater 
effect than inhibition of Notch-1 (Harrison et al., 2010) (Figure 5).  
 It has been shown that Notch-1 promotes HER2+ tumor recurrence post 
trastuzumab treatment in dormant residual tumor cells (Abravanel et al., 2015) 
suggesting that these dormant cells were BCSCs. It has been shown that Notch-1 
expression in BCSCs is low compared to differentiated progenitor cells yet 
particular expression of the Notch paralogues appears to vary by breast cancer 
subtype (Grudzien et al., 2010). Inhibition of Notch signaling by a GSI, or a Notch 
decoy, reduces BCSC mammosphere formation in vitro suggesting that blockade 
of Notch signaling is a viable treatment option to eliminate BCSCs. One way Notch 
may promote BCSC survival is by regulating the differentiation of mammary 
progenitor cells to either myoepithelial cells or epithelial cells (Reviewed in Dontu 





cell fate and inhibited side branching of the developing breast tissue in a 
doxycycline regulated Notch-1 mammary tumor model in mice (Simmons et al., 
2012). In this model, inhibition of Notch-1 promoted tumor regression and 
prevented tumor metastasis. Notch-1 was found to regulate the embryonic stem 
cell marker Nanog which is suggested to be the mechanism by which Notch-1 
regulates the BCSC population in vivo.  An increase in Notch-1 was shown to 
increase BCSC markers, ALDH1 and ABC transporters, which have been show to 
facilitate excretion of chemotherapeutic drugs from the cancer cell. Notch-1 was 
shown to facilitate the transcription of the embroyonic stem cell marker Sox2, 
which establishes a Notch-1/Sox2 signaling axis that is critical for ovarian CSC 
activity. Similar work has been done in TNBC BCSCs, demonstrating the ability of 
Notch-1 to activate transcription of Sox2 resulting in post trastuzumab treatment 
enrichment of the BCSC population (Azzam et al., 2013). 
 In an interesting study, Notch was shown to regulate HER2 expression 
thereby possibly regulating the survival and differentiation of BCSCs (Chen et al., 
1997). Work in a HER2+ DCIS model showed that Notch inhibition reduced 
mammosphere formation and acini size yet had no effect on the HER2- DCIS 
model (Burchell et al., 2013). Conversely, gefitinib or lapatinib reduced 
mammosphere formation and acini size in HER2- DCIS with no effect on the 
HER2+ DCIS cell model. Notch-EGFR crosstalk has been implicated as a 
paracrine mediator of estrogen action to increase ER-/ER low BCSC survival as 





2013). Estrogen has been shown to increase expression of FGFR, EGFR, and 
Notch ligands in ER+ bulk breast cancer cells to act in a paracrine manner to 
regulate expression via FGF/FGFR/Tbx3, EGFR/MAPK/ERK, and DLL-
Jag/Notch/Pea3 pathways in the ER-/ER low BCSC population. Estrogen-
mediated BCSC regulation can be attenuated by blocking estrogen with tamoxifen, 
EGFR with gefitinib, or Notch with a GSI to inhibit BCSC survival and early 
progenitor cell differentiation, and possibly dedifferentiation, respectively. 
Crosstalk between FGFR, EGFR, and Notch pathways are responsible for 
estrogen induced changes to ER-/ER low BCSC population and may play a part in 
endocrine resistance as well as offer possible therapeutic targets for the treatment 
of ER+ breast tumors. 
     Notch-1-HER2 crosstalk in trastuzumab resistance.  Notch-HER2 crosstalk 
was initially observed in HER2+ breast cancer cells treated with trastuzumab which 
resulted in an increase in Notch-1 expression and activation (Osipo et al., 2008). 
Similarly, chronic trastuzumab treatment of HER2+ breast cancer cells to induce 
trastuzumab resistance resulted in an increase in Notch-1 as well as upregulation 
of genes transcribed by Notch-1. Targeted inhibition of Notch-1, or pan-inhibition 
of Notch by a GSI, enhanced trastuzumab sensitivity and reversed trastuzumab 
resistance in vitro. Combinatorial targeting of HER2 by trastuzumab and Notch by 
a GSI inhibited trastuzumab resistant HER2+ tumor growth as well as tumor 





relationship between Notch-1 and HER2 in breast cancer in which inhibition of 
HER2 upregulates Notch-1 expression.  
 Interestingly, there is evidence that Notch-HER2 crosstalk can be 
stimulatory rather than inhibitory. The HER2 promoter contains a CBF-1 binding 
site and overexpression of NICD1 was shown to induce transcription of the HER2 
gene indicating that Notch-1 positively regulates HER2 expression (Chen et al., 
1997). HER2 overexpression in DCIS increased Notch-3-mediated transcription of 
Notch target genes (Pradeep et al., 2011). In the HER2+ DCIS model, effectors of 
the Notch pathway: ADAM17, Jag-1, DLL-1, presenilin-1, and Notch-1 were 
increased upon Notch-3 nuclear localization. Notch-3 inhibition resulted in reduced 
spheroid formation, cell proliferation, and luminal spheroid filling indicating that 
HER2-mediated upregulation of Notch-3 promotes HER2+ DCIS survival and cell 
proliferation. In addition to these studies, others have demonstrated that HER2 
may enable increased expression of effectors of the Notch pathway such as Notch 
activating matrix metalloproteinases (presinilin-1, ADAM) or Notch ligands (DLL-1, 
Jag-1, -2).  
         Notch-1-HER2 crosstalk through the MAPK pathway. HER2 is a potent 
activator of the Ras-MAPK pathway and communication between the Notch and 
MAPK pathway has been investigated. TNBC cell lines use the MAPK/ERK 
pathway to promote upregulation of Jagged-1 to activate Notch. TGFα-mediated 
EGFR activation of the MAPK pathway has been shown to enhance Jagged-1 





2011). The pseudokinase Tribble-3 (TRB3) was identified to activate both TGF-β 
and MAPK/ERK pathways (Izrailit et al., 2013). Inhibition of TRB3 reduced TNBC 
(MDA-MB-231) cell proliferation while Jagged-1 overexpression in TRB3-silenced 
cells rescued cell proliferation. TRB3 knockdown was found to reduce tumor 
growth in TNBC tumor xenografts in mice in vivo. These results indicate that TRB3 
elevates Jagged-1 expression through the MAPK/ERK pathway and is critical for 
TNBC cell proliferation and tumorigenesis. 
         Notch-1-HER2 crosstalk through the Akt pathway. It is well established 
that HER2 activates a multitude of signal transduction pathways including 
PI3K/Akt/mTOR signaling. This is critically important as most of the work to date 
has focused on mechanisms of crosstalk between the PI3K/Akt pathway and 
Notch. Hyperactivation of mTOR signaling has been associated with elevated 
Notch signaling in poorly differentiated breast cancers as well as a poor clinical 
outcome for women with mTOR/Notch overexpressing tumors (Ma et al., 2010). 
The correlation between hyperactivation of mTOR and Notch pathways revealed 
that RTK activation of PI3K/mTOR pathway promoted upregulation of several 
mTOR targets: p63 (a member of the p53 family), signal transducer and activator 
or transcription 3 (STAT3), Notch, Jagged-1, and HES-1. Aberrant 
RTK/PI3K/Akt/mTORC1 signaling was found to increase Stat3 expression and 
activation resulting in an increase in p63 transcription. This increase in p63 
expression was found to induce Jagged-1-mediated Notch activation and 





which the upregulation of the RTK/PI3K/Akt/mTOR signaling axis activates the 
STAT3/Jag-1/Notch signaling cascade to promote breast tumorigenesis. 
Conversely, Notch can activate the PI3K/Akt/mTOR pathway in T-ALL (Calzavara 
et al., 2008; Palomero et al., 2007), indicating that Notch and mTOR may 
cooperate in a positive regulatory loop to promote cancer cell proliferation or 
differentiation.  
 Investigators have elucidated crosstalk between the PI3K/Akt/mTOR and 
Notch pathways in several different cancer cell lines including a chemoresistant 
ER+/HER2-, MCF-7 cell line, which displayed elevated Notch-1 expression and 
activity (Mungamuri, 2006). Notch-1 activation inhibited p53 nuclear localization 
and prevented phosphorylation of p53 at Ser15, Ser20, and Ser392 residues. This 
Notch-1-mediated blockade of p53 activity was found to be dependent on the 
mTOR/eIF4E signaling axis as the mTOR inhibitor, rapamyacin, reversed 
chemoresistance in these cells and restored p53 activity. These studies reveal an 
important role for the PI3K/mTOR pathway on Notch-1-mediated regulation of drug 
resistance and p53-dependent apoptosis.  
PTEN. 
     Role of PTEN in breast development and tumorigenesis. The PTEN gene 
is located on chromosome 10 in the 10q23 region. PTEN expression is frequently 
lost in a variety of cancers including breast cancer. To better understand the role 
of PTEN in mammary gland development, mice with a conditional PTEN knockout 





tumors (Li et al., 2001). PTEN null mice displayed hyperplastic mammary gland 
ducts, an increase in side branching, and amplified lobulo-aveolar budding 
compared to the mammary tissue of control mice. Such developmental changes 
were also observed at puberty and during pregnancy as the PTEN deficient mice 
also had defective mammary gland involution after pregnancy. In addition to 
defects in mammary gland development, the PTEN knockout mice developed 
cancer earlier as well as benign lesions compared to control mice. Interestingly, 
the PTEN null mice displayed increased staining for cytokeratins 5 and 6 (Li et al., 
2002), markers for the basal subtype of breast cancer (Sørlie et al., 2001). 
Furthermore, mammary tumors from the PTEN null mice showed similar 
characteristics to breast cancers containing BRCA-1 mutations (Saal et al., 2008). 
Loss of PTEN is associated with Cowden syndrome which is an uncommon 
autosomal dominant, inherited disorder and is categorized by the growth of non-
cancerous hamartomas. Cowden syndrome is associated with PTEN mutations 
which results in an increase in mTOR activity and a predisposition to cancers, 
including breast cancer. These data present the role for PTEN in proper mammary 
gland development as well as the development of breast cancer when PTEN 
expression is lost.  
     Role of PTEN in HER2+ breast cancer and trastuzumab resistance. Loss 
of PTEN has been associated with worse overall outcome for women with HER2+ 
breast cancer (Stern et al., 2015). Loss of PTEN occurs in approximately 12% to 





occurs in only 3.5% of breast cancers (Rexer et al., 2013; TCGA, 2012). Detection 
of PTEN mutations in breast cancers had little overlap with HER2 amplification 
indicating that a majority of the PTEN mutations do not occur in the HER2+ 
subtype. Transcription of the PTEN gene is regulated by a number of different 
mechanisms and pathways, particularly during development and tumorigenesis. 
PTEN transcription is regulated by p53, SMADs, and NFκB for proper 
organogenesis and immune function (Knobbe et al., 2008; Luyendyk et al., 2008). 
Loss of PTEN expression can occur a number of ways besides loss-of-function 
mutations such as: loss of heterozygosity, RNA degradation, miRNA-mediated 
transcriptional inhibition, epigenetic modification, or post translational modification 
of PTEN.  Additionally, transcriptional repression of PTEN could be due to the loss 
of other tumor suppressors critical to breast cancer located in the vicinity of the 
PTEN locus (Feilotter et al., 1999).  
  Trastuzumab treatment has been shown to increase expression of the 
tumor suppressor, PTEN. PTEN loss and the resulting increase in PI3K/Akt activity 
is a fairly good predictor of trastuzumab resistance and is improved when 
combined with PIK3CA activating mutation status in women with HER2+ breast 
cancer (Berns et al., 2007; Loibl et al., 2016). Women with tumors expressing low 
PTEN were less likely to achieve pCR when treated with trastuzumab compared 
to women with tumors expressing elevated PTEN (Dave et al., 2010). There are 
many reports showing that loss of PTEN’s tumor suppressive activity results in 





overall survival in women with HER2+ breast cancer (Fujita et al., 2006; Nagata et 
al., 2004). 
     Trastuzumab-mediated activation of PTEN. Trastuzumab can increase 
PTEN activity by disrupting the association between HER2 and Src (Nagata et al., 
2004). Trastuzumab treatment of HER2+ breast cancer cells, such as BT474 and 
SkBr3, resulted in activation of PTEN. Trastuzumab was shown to inhibit 
phosphorylation of tyrosine residues (Y240 and Y315) on the C2 domain of PTEN 
(Figure 9). This blockade of tyrosine phosphorylation resulted in PTEN 
translocating to the cell membrane where it is positioned to dephosphorylate PIP3 
to PIP2. The non-receptor tyrosine kinase Src has been shown to bind to and 
activate HER2 (Belsches-Jablonski et al., 2001) as well as increase tyrosine 
phosphorylation of PTEN (Lu et al., 2003) in HER2+ breast cancer cells. 
Trastuzumab-mediated inhibition of Src kinase activity resulted in reduced 
phosphorylation of PTEN as well as decreased phosphorylation of Akt. Inhibition 
of Src kinase activity was found to be a major contributor to the anti-proliferative 
effect of trastuzumab in HER2+ breast cancer in vitro as well as reducing tumor 
growth in vivo. Importantly, reduced PTEN expression in HER2+ tumors, by PTEN 
siRNA, promoted HER2+ cell proliferation in vitro as well as tumor growth in vivo, 
regardless of trastuzumab or paclitaxel treatment. HER2+ cell proliferation and 
tumor growth can be inhibited by a PI3K inhibitor, LY294002, thereby re-sensitizing 
PTEN deficient tumors to trastuzumab treatment. PTEN deficient tumors from 





trastuzumab treatment compared to PTEN expressing tumors, making PTEN 
deficiency a potential predictor of trastuzumab resistance.  
 
Figure 9: PTEN. 
The PTEN protein is composed of two domains, the phosphatase and C2 (C-
terminal) domains. The N-terminus contains a PIP3 binding domain followed by a 
nuclear localization signal (NLS1), a cytoplasmic localization sequence (CLS), and 
a second nuclear localization signal (NLS2). The phosphatase domain is 
responsible for lipid and protein phosphatase activity. The catalytic core binds PIP3 
to facilitate its dephosphorylation. The C2 domain binds to lipids and contains 
NLS3 and 4, two proline/glutamic acid/serine/threonine-rich motifs (PEST), and the 
PDZ domain. Monoubiquitylation can occur at residue K289 as well as residues 
S370-S385. Phosphorylation can occur at residues Y240 and Y315. 
     Mechanisms of Notch-1-mediated inhibition of PTEN. Notch-1 has 
demonstrated the ability to regulate the PI3K/Akt pathway through repression of 
PTEN in several different cancers. Aberrant activation of Notch-1 is common in T-
ALL (Reviewed in Grabher et al., 2006). Thus, GSI treatment was proposed as a 
possible therapeutic for T-ALL, but half of T-ALL cells failed to respond to GSI 
treatment (Palomero et al., 2007). Interestingly, GSI effectively reduced NICD1 
levels and Notch target gene expression suggesting that compensatory signaling 
pathways may be responsible for continued T-ALL cell growth. Palomero et al. 
analyzed GSI sensitive and resistant T-ALL cell lines to find decreased expression 
of PTEN in both cell types. GSI resistant cells were found to have a loss-of-function 





Notch-1 activity in GSI sensitive cells was found to indirectly represses PTEN. In 
the GSI sensitive cells, constitutive activation of Notch-1 increased transcription of 
the transcriptional repressor, and Notch-1 target gene, HES-1. HES-1 is directly 
recruited to the PTEN promoter where it is able to inhibit transcription of PTEN. 
These data demonstrate a parallel relationship between the Notch-1 and PI3K/Akt 
pathway in which they both promote T-ALL cell growth. Accordingly, the inverse 
relationship of Notch-1 and PTEN in T-ALL predicts a worse overall outcome for 
T-ALL patients.  
 Repression of PTEN by Notch-1 has been shown to occur in melanoma cell 
lines. Pan Notch inhibition by GSI (RO4929097) resulted in elevated PTEN 
expression, reduced Akt pathway activity, and an increase in senescence and 
apoptosis in PTEN wild type expressing melanoma cancer cells (Nair et al., 
2013b). PTEN null or mutant melanoma cell lines did not enter apoptosis or 
senesce when treated with GSI suggesting that PTEN status dictates sensitivity to 
GSI. As such, wild type PTEN is inhibited by Notch-1 and is sensitive to GSI 
treatment but neither mutant nor PTEN null cells are dependent on Notch-1-
mediated repression of PTEN and are therefore, resistant to GSI. Additionally, in 
wild-type PTEN expressing melanoma cells, GSI treatment improved the effect of 
chemotherapeutic temozolomide treatment both in vitro and in vivo. These studies 
highlight the importance of Akt pathway activity in dictating melanoma tumor 





 Notch-1-mediated repression of PTEN can occur through post translational 
modification of PTEN. In gastric cancer, Notch-1 inhibition results in increased 
PTEN activity, cell cycle arrest at the G2/M checkpoint, and reduced tumor growth 
in vivo (Kim et al., 2015). Notch-1 was shown to induce phosphorylation of the 
PTEN C-terminus to promote accumulation of PTEN in the nucleus. Nuclear PTEN 
accumulation resulted in cell apoptosis through interaction with the cyclin-1/CDK1 
complex. Increased Akt activation through PTEN inhibition was also found to be 
important in other cancer models such as mesothelioma, in which Notch-1 and 
Notch-2 were found to have contrasting effects (Graziani et al., 2008). 
Interestingly, Notch-1 was required for PTEN downregulation, Akt activation, and 
DNA synthesis in mesothelioma cell models. However, Notch-2 had the opposite 
effect by increasing PTEN expression, Akt inhibition, reduced DNA synthesis, and 
cell death. Interestingly, Notch-1 was found to directly bind to CBF-1 at the PTEN 
promoter thereby directly inhibiting PTEN transcription in mesothelioma cells. 
Together, these data suggest several mechanisms in which Notch can inhibit 
PTEN activity to regulate cancer cell growth and survival as well as tumorigenesis 
in vivo.  
     Role of PTEN in BCSCs. Given the frequency of PTEN loss or downregulation 
in breast cancer, it is probable that changes in PTEN activity can affect the BCSC 
population. PTEN has been shown to regulate self-renewal of neuronal and 
hematopoietic stem cells (Figure 5). Case in point, PTEN is an acute regulator of 





survival (Sengupta et al., 2011). Inhibition of PTEN in malignant and normal 
BCSCs from HER2 negative / ER+ cell lines activates the Akt pathway and 
phosphorylation of GSK-β resulting in activation of the Wnt/β-catenin pathway 
(Jordan et al., 2009). The PTEN/Akt/GSK-β/Wnt/β-catenin signaling pathway is 
involved in enrichment of the mammary stem/progenitor cell population. Targeted 
inhibition of Akt activity, by perifosine and not the mTOR inhibitor rapamycin, 
reduces the BCSC population in vitro as well as tumor growth and recurrence in 
vivo.  
 MicroRNAs have been shown to play a role in regulating PTEN expression 
and consequently effecting enrichment of the BCSC population. Elevated miR-205 
expression increased the mouse mammary epithelial progenitor cell population 
and the CSC population through regulation of Zeb-1, -2, and PTEN expression 
(Greene et al., 2010). Interestingly, it has been shown that overexpression of 
HER2 attenuates miR-205 and may be essential for HER2-driven tumorigenesis 
(Adachi et al., 2011). miR-10b is capable of increasing BCSC stemness, self-
renewal, and EMT markers by sustaining Akt pathway activation through PTEN 
inhibition in MCF-7 cells (Bahena‐Ocampo et al., 2016). The BCSC population and 
EMT have been shown to be dependent on miR-21 activity as inhibition of miR-21 
reverses EMT. This reversal of EMT was shown to require both the PI3K/Akt and 
MAPK/ERK pathway inactivation through upregulation of PTEN (Han et al., 2012). 
Together these data indicate that PTEN attenuates both the Akt and MAPK 





     Subcellular location of PTEN determines its phosphatase activity. Lipid or 
protein phosphatase activity of PTEN depends on its location within the cell. 
Canonically, PTEN acts as a lipid phosphatase by dephosphorylating the D3 
position of PIP3 reversing PIP3 to PIP2. PTEN attenuation of PI3K signaling 
occurs in the cytoplasm. Noncanonically, PTEN has been shown to act as a protein 
phosphatase in the nucleus by regulating MAPK activity through 
dephosphorylation of ERK1/2. In MCF-7 cells, expression of a mutant PTEN that 
is localized in the nucleus resulted in cell cycle arrest in the G0/G1 phase through 
downregulation of cyclin D1 (Chung et al., 2005b). Whereas, expression of a wild 
type PTEN, that localized in the cytoplasm, resulted in a higher G1/S ratio of cells 
compared to nuclear PTEN expressing cells (Figure 10). Cytoplasmic PTEN was 
found to be pro-apoptotic while nuclear PTEN promoted cell cycle arrest. The 
diversity of PTEN phosphatase activity makes it an attractive target for suppression 












Figure 10: Subcellular Phosphatase activity of PTEN. 
The phosphatase functionality of PTEN can change by its location within the cell. 
Cytoplasmic PTEN dephosphorylates Akt resulting in upregulation of p27Kip1 and 
apoptosis of the cell. Nuclear PTEN dephosphorylates ERK1/2 resulting in 
downregulation of cyclin D1. Reduced cyclin D1 results in arrest of the cell cycle 
at the G0-G1 phase and the cell to enter quiescence.  
  Nuclear PTEN acts as a protein phosphatase in which it regulates ERK1/2 
phosphorylation and cyclin D1 expression (Weng et al., 2001). Ras mutations are 
infrequent in breast cancer but increased Ras activation can occur through 
overexpression of EGFR or HER2 amplification in HER2+ breast cancer (von Lintig 
et al., 2000). Hyper-activation of the MAPK pathway through Ras correlates with 
increased cancer stem cell enrichment and poor patient survival in TNBC (Mittal 





cancer promotes dependency on the MAPK pathway through elevated MEK/ERK 
activity (Ebbesen et al., 2016). 
 The mechanism of PTEN entry into the nucleus remains controversial. 
There are examples of PTEN entering the nucleus by simple transport (Li et al., 
2005). However, PTEN binding to a major vault protein (MVP) has been shown to 
transport PTEN from the cytoplasm into the nucleus in MCF-7 cells (Chung et al., 
2005a). Further assessment of PTEN nuclear translocation revealed 4 putative 
nuclear localization signal (NLS)-like sequences (NLS-1, -2, -3, -4) (Figure 9). 
PTEN localization was not affected by the mutation of one of these sequences but 
mutation of a pair of the NLS sequences (NLS-2 and -3; NLS-3 and -4) inhibited 
binding to MVP as well as entry into the nucleus. Calcium ions were found to 
positively regulate MVP binding to PTEN (Minaguchi et al., 2006). PTEN entry into 
the nucleus may also be regulated by the E3 ligase, Neural precursor cell 
Expressed Developmentally Downregulated 4 -1 protein (NEDD4-1). 
Monoubiquitinylation prevents PTEN nuclear entry whereas polyubiquitinylation by 
NEDD4-1 results in PTEN degradation and loss of its tumor suppressive activity 
(Wang et al., 2007). Together these data present the hypothesis that PTEN 
functionality changes based on its location within the cell and that nuclear PTEN 
may play a role in breast cancer. 
The MAPK Pathway. 
     Role of the MAPK pathway in breast development. The MAPK pathway 





effectors of the MAPK pathway have been implicated in mammary gland 
development, specifically ERK1/2, c-Jun N-terminal kinase (JNK), and p38 
(Reviewed in Whyte et al., 2009). As described above, the phosphorylation 
cascade of Raf/MEK/ERK results in translocation of ERK1/2 into the nucleus to 
phosphorylate a number of targets including hormone receptors as well as 
regulators of apoptosis and transcription. Biologically, ERK1/2 phosphorylation of 
target substrates encourages cell proliferation, survival, differentiation (Reviewed 
in Pearson et al., 2001), angiogenesis (Zeng et al., 2005), invasion, and motility 
(Joslin et al., 2007). MAPK/ERK1/2 is involved in a number of cellular functions 
important to organogenesis making activation of the MAPK pathway necessary for 
proper mammary gland development as well as induction of breast cancer if 
dysregulated. For example, normal mammary epithelial cells form spherical acini 
that organize into branching alveolus structures when supported by a healthy 
ECM. Alveolar structuring by breast epithelial cells can be recapitulated in vitro by 
three dimensional culturing techniques (Blatchford et al., 1999). ERK1/2 signaling 
is necessary for bidirectional crosstalk between β1-integrins and EGFR for the 
proper polarization and placement of mammary epithelial cells in acinar formation 
(Wang et al., 1998). Conversely, previous work has shown that HER2, and not 
EGFR, plays an important role in acinar development in the early stages of breast 
cancer disease progression (Muthuswamy et al., 2001). Inhibition of ERK1/2, 
EGFR, or β1-integrins resulted in malformation of spherical acini as well as 





important roles in the proper mammary gland formation. Together these data 
present the importance of the MAPK/ERK1/2 pathway in proper mammary gland 
development and tumorigenesis. 
     Role of the MAPK pathway in HER2+ breast cancer. Increased HER2 activity 
in HER2+ breast cancer cells upregulate both downstream PI3K/Akt and MAPK 
pathways. Downstream effects of trastuzumab treatment on MAPK pathway 
activity have been controversial. One study shows that trastuzumab treatment 
does not affect downstream MAPK activity in HER2-positive SKBr3 and MDA-MB-
453 cell lines (Cuello et al., 2001). The trastuzumab treatment concentration for 
this study, 1 μM, and length of treatment, 4 days, was very low. In vitro trastuzumab 
treatment is typically between 10 and 20 μM in order to mimic physiological 
treatment conditions. Conversely, a three-day course of 10 μM trastuzumab 
treatment resulted in inhibition of MAPK phosphorylation and activation in BT474 
and SkBr3 cells (Yakes et al., 2002) as well as in metastatic breast cancer patient 
samples (Gori et al., 2009). These data suggest that trastuzumab affects 
downstream MAPK pathway activity when given at the proper dose. 
 MAPK pathway activation has been shown to be the central node in a 
variety of breast cancer subsets under varying treatment conditions. For instance, 
alcoholism has been shown to increase the risk of breast cancer. Alcohol exposure 
was shown to increase HER2+ cell migration and invasion (Xu et al., 2016). 
Increased aggressiveness of HER2+ cells exposed to alcohol occurred through 





DNA damage and cell stress. Activation of p38 interacted with downstream 
synapse associated protein 97 (SAP97) to promote cell migration and invasion as 
well as enrichment of the BCSC population in a HER2+ MMTV mouse model. 
Similarly, in a TNBC cell and mouse xenograft model, p38γ-MAPK inhibition was 
found to reduce the BCSC population as well as downregulate Nanog, Sox2, and 
Oct 3/4 cancer stem cell drivers (Qi et al., 2015). MAPK phosphatases 
(DUSP/MKP1) are overexpressed in HER2+ breast cancers (Candas et al., 2014). 
MKP1 attenuates MAPK activity by removing phosphate groups necessary to 
progress the MAPK phosphorylation cascade. MKP1 has been shown to induce 
chemoresistance and radioresistance by preventing apoptosis in HER2+ bulk and 
cancer stem cells. These data represent how the MAPK pathway can contribute to 
expansion of the BCSC population, resistance, and metastasis of HER2+ breast 
cancer. 
     Notch-1- MAPK crosstalk in breast cancer. Here we assess bi-directional 
crosstalk between Notch-1 and MAPK pathways in an effort to better understand 
their involvement in mechanisms of cancer bulk and stem cell proliferation as well 
as drug resistance in breast cancer. Ras (specifically H-Ras) can activate Notch-1 
signaling in both in vitro and in vivo cancer models (Weijzen et al., 2002). Notch-1 
activation by Ras was necessary to maintain the abnormal tumor phenotype in 
Ras-transformed cells. Aberrant activation of Ras signaling through p38-MAPK 
was found to upregulate proteins involved in Notch signaling, specifically 





growth of Ras transformed cells and tumor xenografts, respectively. Interestingly, 
in cells with null or low Ras expression (human foreskin fibroblasts and HER2-
negative MCF-7 cells) overexpression of Notch-1 was unstable and toxic to these 
cells. Additionally, NICD1 overexpression in hTERT/SV40 immortalized fibroblasts 
was found to increase cell proliferation and anchorage independent growth 
compared to the vector control but not to level of Ras transformed cells. This result 
suggesting that oncogenic Ras allows cells to tolerate elevated Notch-1 
expression. Together these data present a potential mechanism for Ras-mediated 
upregulation of Notch-1 to drive and maintain the neoplastic phenotype in breast 
cancer.   
 Immunohistological assessment of Notch in progressive stages of breast 
carcinogenesis revealed that Notch-1, and downstream Notch targets, were 
increased in approximately 75% of breast cancer tissue samples compared to 
normal breast tissue samples (Mittal et al., 2009). Furthermore, aberrant activity of 
Notch was apparent in DCIS and hyperplasia suggesting that abnormal Notch 
activity occurs early in breast cancer progression. HMLE (Human Mammary 
Epithelial cells overexpressing hTERT and SV40 large and small T antigens) cells 
have low Notch-1 and Ras expression. Transformation of HMLE cells with Notch-
1 failed to form mammospheres in vitro or tumors in vivo. Conversely, NICD1 
overexpression in Ras transformed cells (HMLER) increased mammosphere 
formation in vitro and tumor growth in a mouse xenograft model compared HMLE 





Ras/MAPK pathway by the MEK inhibitor PD 98059 reduced BCSC survival and 
self-renewal. Positive staining for both Notch and/or HES-5 as well as nuclear P-
ERK1/2 in breast tumor tissues correlated to aggressive grade III carcinomas with 
a high risk of metastasis. These results suggest an important role for the co-
expression of Notch-1 and Ras/MAPK to promote BCSC survival and self-renewal 
as well as tumor progression.  
Conclusion. 
 These data presented here begin to reveal the complexity of the Notch-
1/PTEN/MAPK signal transduction pathway. As described above there are 
numerous interactions between Notch-1 and PTEN, as well as downstream 
PI3K/Akt and MAPK/ERK1/2 pathways. Being that both Notch-1 and PTEN are 
context dependent we have limited our scope to trastuzumab resistant HER2+ 
breast cancer which may draw from more aggressive cancer models such as 
TNBC or endocrine resistant ER+ breast cancer. However, little work has been 
done on the role of Notch-1, PTEN, and the MAPK/ERK pathway in trastuzumab 
resistant breast cancer.  The results presented here may shed some light on the 
mechanics of more aggressive cancers by presenting a novel role for Notch-1 in 









MATERIALS AND METHODS 
Cell Culture. 
 BT474TS and HCC1954 breast cancer cells were purchased from 
American Type Culture Collection (ATCC). BT474TR, trastuzumab resistant, cells 
were generated in vitro by treating parental BT474TS, trastuzumab sensitive, cells 
with increasing concentrations of trastuzumab for 6 months till the cells could 
survive under constant trastuzumab treatment of 10μg/mL in PBS (Osipo et al., 
2008). Cells were cultured in Dulbecco’s minimal essential media with high glucose 
[1x DMEM (Fisher Scientific, Hampton, NH)] 10% fetal bovine serum (FBS), 
100μM L-Glutamine, and 100μM nonessential amino acid. Cells were maintained 
at 37⁰C with 5% CO2 and 95% O2. Cells were authenticated by STR allelic profiling 
(DCC Medical).  
Drugs. 
 Trastuzumab is a humanized monoclonal antibody against extracellular 
domain IV of the HER2 receptor (Carter et al., 1992). Lyophilized trastuzumab was 
resuspended in sterile PBS for a concentration of 22mg/mL. Cells in culture were 
maintained at 7 to 10μg/mL in media. Experimental trastuzumab treatments were 
20μg/mL. U0126 inhibits MAPK pathway activity by noncompetitive inhibition of the 





inhibition of MEK1/2 results in reduced phosphorylation of the MEK1/2 kinase 
substrate, ERK1/2. U0126 was resuspended in DMSO for a concentration of 
20mg/mL and used in treatments at concentration of 10μg/mL in vitro.  
Expression Vectors. 
 The pcDNA and pcDNA-NICD1 expression vectors were kindly provided by 
Dr. Lucio Miele (Department of Genetics, Louisiana State University, New Orleans, 
LA). The MEK1 S218D/S222D phosphomutant pEXP304-MEK1DD/V5, and 
control vector pEXP304-LacZ/V5, were kindly provided by Dr. Takeshi Shimamura 
(Department of Molecular Pharmacology and Therapeutics, Maywood, IL). The 
pUSEamp and N-terminal Myrstoylated-Akt1 expression vectors were purchased 
from Upstate Cell Signaling Solutions (Lake Placid, NY). 
RNA Interference and Transfection Reagents. 
 Notch-1, PTEN, and HES-1 siRNAs were purchased from Santa Cruz 
Biotechnology (Dallas, TX). Secondary Notch-1 siRNA (Notch-1i #2) was 
purchased from Thermo Fisher Scientific [Dharmacon (Waltham, MA)] and 
scrambled siRNA (SCBi) was purchased from Qiagen (Hilden, Germany). 
Transfection reagents, Lipofectamine 2000, Lipofectamine 3000, and RNAiMax 
were purchased from Invitrogen (Carlsbad, CA) as well as Polyethylenimine (PEI) 
form PolySciences (Niles, IL).   
 BT474 (3 x 105) or HCC1954 (1 x 105) cells per well were seeded into a 6 
well tissue culture treated plate. The following day, 1μg of vector DNA was mixed 





separate microcentrifuge tube, 4μL of Lipofectamine 2000 or PEI were mixed with 
250μL of Opti-MEM. The two tubes were incubated for 5 minutes at room 
temperature then mixed together and incubated for an additional 20 minutes at 
room temperature. The total volume of the transfection reaction was 500μL. The 
cells were washed with PBS. 1.5mL of media was added to the transfection 
reaction and then added to the washed cells. Similarly, transfections using 
Lipofectamine 3000 in a 6 well plate, mixed 5μg of vector DNA, 5μL of P3000, and 
250μL of Opti-MEM in one tube. 3.75μL of Lipofectamine 3000 and 250μL of Opti-
MEM were mixed in a separate tube followed by incubation and mixing in the same 
manner as Lipofectamine 2000. siRNA transfections using RNAiMax were 
performed in a similar manner. In a 6 well plate, 10μM of siRNA was added to 
250μL of Opti-MEM in a 15mL tube. 10μM of RNAiMax was added to 250μL of 
Opti-MEM in a separate tube. Both tubes were mixed, incubated, and added to the 
cells in the same manner as previous transfections. Co-transfections used halved 
ratios of siRNA and RNAiMax, 5μM and 5μL, respectively. The siRNA sequences 










siRNA Company Catalog # 
Sense Sequence 
(5’ – 3’) 
Antisense 
Sequence (5’ – 3’) 













































Qiagen 1027281 Sequence held by Qiagen 
Table 1: siRNA sequences 
Antibodies. 
  PTEN (9559S), Phosphorylated Akt1 (Ser473, 9271S and Thr308, 9275S), 
Pan Akt (4691S), Total p44/42 ERK1/2 (4695), Histone H3 (4620) and 
Phosphorylated p44/42 ERK1/2 (Tyr202/Tyr204, 4370) were purchased from Cell 
Signaling Technologies (Danavers, MA). Notch-1 (C-20, sc-6014), MEK-1 (C-18, 
sc-219), and normal rabbit IgG (sc-2027) were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA). Total HER2 [(ErbB2) MS0730-P] was 
purchased from Thermo Fisher Scientific (Waltham, MA). Phosphorylated HER2 
at tyrosine 1248 [PY1248-ErbB2 (AF1768)] was purchased from R and D Systems 
(Minneapolis, MN). β-Actin (A5441) was purchased from Sigma Aldrich (St. Louis, 





antibodies used include donkey anti-rabbit (1:1000, sc-2313) and donkey anti-
mouse (1:5000, sc-2314) purchased from Santa Cruz Biotechnologies (Santa 
Cruz, CA).  
Reverse Transcription Real-Time Polymerase Chain Reaction (RT-PCR). 
 BT474 (3 x 105) or HCC1954 (1 x 105) cells were plated in a 6-well tissue 
culture treated dish. The next day, the cells were transfected using the appropriate 
transfection reagents and incubated at 37 ⁰C with 5% CO2 and 95% O2 for 2 days. 
Similarly, co-transfections combining siRNA and expression vectors were 
staggered meaning that one transfection was done in the morning and one in the 
evening. 2 days later, the cells were harvested in TRIzol® (Thermo Fisher 
Scientific, Waltham, MA). The cells were harvest on ice, by scraping the cells into 
the TRIzol® (500μL) solution. Total RNA was extracted from the harvested cells 
using the RiboPureTM Kit (Thermo Fisher Scientific). The cells in TRIzol® were 
incubated at room temperature for 5 minutes then 50μL of 1-bromo-3-
chloropropane [(BCP) Sigma Aldrich, St. Louis, MO] was added to each sample. 
The sample was vortexed and incubated for 5 minutes at room temperature. Next, 
the samples were centrifuged at 15,000 RPM for 10 minutes at 4⁰C. On ice, the 
clear aqueous phase was transferred to a new tube to which 200μL of 100% 
ethanol was added and mixed immediately. The sample was passed through a 
filter cartridge by centrifugation at 12,000 RPM for 30 seconds at room 
temperature. Each sample was washed twice with 250μL of wash buffer and spun 





tubes were spun one more time at 12,000 RPM to discard any access 
ethanol/wash buffer. Each filter cartridge was added to a new tube and 100μL of 
elution buffer was added. The tubes were incubated in a 37 ⁰C water bath for 5 
minutes then the RNA was extracted from the filter cartridge into a new 
microcentrifuge tube via centrifugation at 12,000 RPM for 30 seconds at room 
temperature. Total RNA quality and quantity was determined by measuring the UV 
absorbance at 260 nm using the NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific).  
 The harvested total RNA was reverse transcribed (RT) into total cDNA using 
the TaqMan Reverse Transcriptase Kit (Applied Biosystems, Ford City, CA). 1μg 
of total RNA was reverse transcribed into cDNA in a total volume of 100μL 
containing: 1x RT buffer, 5.5mM MgCl2, 500μM dNTPs, 2.5μM random hexamers, 
0.4 U/μL RNase inhibitors, and 1.25 U/μL RT enzyme (MultiscribeTM Reverse 
Transcriptase Kit, Applied Biosystems). The RT reaction was incubated in a 
thermal cycler under the parameters:10 minutes at 25 ⁰C, 30 minutes at 48 ⁰C, 5 
minutes at 95 ⁰C, 60 minutes at 25 ⁰C, and held at 4 ⁰C until use.  
 Real time PCR was performed using iTaqTM SYBR® Green Supermix with 
ROX (BioRad, Hercules, CA) in a 96-optical PCR plate. A mastermix solution of 
22.5μL per sample was made of: 50μM forward and reverse primers, and 2x 
SYBER® Green Universal Master Mix. 2.5μL of cDNA was added to 22.5μL of 
mastermix in triplicate wells. Quantitative PCR was run using the StepOnePlus 





parameters: initial denature at 95 ⁰C for 10 minutes, PCR cycling for 10 seconds 
at 95 ⁰C for 40 cycles, and annealing for 45 seconds at 60 ⁰C. Upon completion of 
the PCR cycling, melt curves were recorded and analyzed to determine the 
average cycle threshold (Ct) value. The Ct value is the number of cycles necessary 
for the fluorescent signal to overcome the background level, or threshold, of 
fluorescent signal. Ct values were normalized to the housekeeping gene 
hypoxanthine-guanine phosphoribosyltransferase (HPRT), an endogenous 
control, to discern ΔCt. ΔΔCt was calculated by normalizing the ΔCt values to a 
control sample, such as the scrambled control siRNA treated cells. Relative 
quantification (Rq) was calculated using the 2- ΔΔCt method to determine relative 
fold increases or decreases in transcript compared to the control sample (Rao et 
al., 2013). The PCR primers used for the detection of specific transcripts are shown 












Real Time PCR Primers 
cDNA Primers Forward Primer 5'-3' Reverse Primer 5’-3’ 
Notch-1 ATCAACGCCGTAGATGACC TTGTTAGCCCCGTTCTTCAG 
PTEN ACCAGGACCAGAGGAAACCT GCTAGCCTCTGGATTTGACG 
HEY-1 TCATTTGGAGTGTTGGTGGA CTCGCACACCATGATCACTT 
HPRT ATGAACCAGGTTATGACCTTGAT CCTGTTGACTGGTCATTACAATA 
ChIP Primers 
PTEN TTCTCCTGAAAGGGAAGGTG GGAGGCAGTAGAAGGGGAGAG 
HEY-1 AGCGTGGGAAAGGATGGTTG CTCGCTTCATGCTGGCTCCC 
 Table 2: PCR Primer sequences 
Western Blot Analysis. 
 BT474 or HCC1954 were plated in 10 cm2 (3 x 106 or 1 x 106) tissue culture 
treated dish. The following day, the cells were transfected with plasmid DNA or 
siRNA, treated with 20μg/mL trastuzumab or 10μg/mL U0126 and incubated at 37 
⁰C with 5% O2 and 95% CO2 for 48 hours. After transfection, the plates were put 
on ice, media was aspirated, and the cells were washed with cold PBS. Cells were 
lysed by adding 300μL per 10 cm2 dish of Triton X-100 lysis buffer or 
Radioimmunoprecipitation Assay (RIPA) buffer, scraped, and collected in 
appropriately labeled microcentrifuge tubes. Triton X-100 buffer consists of: 50mM 
HEPES (pH to 7.4), 1% Triton X-100, 150mM NaCl, 5mM EDTA, 1mM Na3VO4, 
10mM NaF, 1mM PMSF, 1 protease inhibitor cocktail tablet. RIPA buffer consists 
of: [0.1 % SDS, 50mM Tris-HCl, 1% NP-40, (pH to 7.0)] 0.5% Na deoxycholate, 





difference was observed between using Triton X-100 and RIPA buffer but both 
were used. The harvested samples were vortexed for 5 seconds at a setting of 10 
followed by incubation on ice for 20 minutes. After incubation, the samples were 
sonicated two times for 10 seconds at 20% amplitude using the Sonic 
Dismembrator (Thermo Fisher Scientific, Waltham, MA). 10μL of each sample 
were plated into a 96-well plate, along with 0, 0.5, 1, 2, 4, 6, 8, and 10mM BSA 
protein standards, to determine protein concentration by BCA protein assay [50:1 
Reagent A:Reagent B (Thermo Fisher Scientific)]. The plate was incubated at 37 
⁰C for 30 minutes then read on a 96-well plate fluorescent plate reader. Protein 
concentrations were calculated [regression line from protein standard curve 
(y=mx+b) used to calculate Average protein concentration – b / m)] and made into 
10 – 20 μg aliquots in beta-mercaptoethanol (Fisher, Waltham, MA) and 2x lamelli 
buffer (BioRad, Hercules, CA). Samples were heated for 5 minutes at 95 ⁰C.  
 Proteins were detected by Western blot using a 7% Tris-Acetate or 4-12% 
Bis-Tris pre-cast gel (Invitrogen, Carlsbad, CA) as the proteins are detectable in 
either gel. 10 to 40μg of prepared protein lysate as well as a pre-stained protein 
ladder (SeeBlue® Plus 2, Thermo Fisher Scientific) were loaded into separate 
lanes of an SDS-PAGE gel in 1x Tris-Acetate SDS running buffer (Invitrogen). The 
7% Tris acetate gel was run at 150V for 1 hour or the 4-12% Bis-Tris gel was run 
at 200V for 50 minutes using the XCell SureLock © MiniCell apparatus (Thermo 
Fisher Scientific). The gel was transferred to a polyvinylidene fluoride (PVDF) 





(Invitrogen), 200 mL methanol, 750 mL water] at 40 volts for 2 hours using the 
XCell IITM Blot Module (Thermo Fisher Scientific). After completion of the gel 
transfer, the PVDF membrane was hydrated in methanol for 30 seconds then 
rinsed in deionized water. The membrane was blocked in 5% non-fat milk (Bio-
Rad) or Roche blocking solution [Roche buffer (Roche, Basel, Switzerland)] in 1x 
Tris Buffered Saline with Tween 20 (TBST) [(10x TBST (12.1 g Tris Base, 87 g 
sodium chloride, ph to 8.0 in 1 L) 0.2% Nonidet P-40, 0.05% Tween-20] or 1x Tris 
Buffered Saline [(TBS) no Tween-20 added], respectively, for 1 hour at room 
temperature under constant agitation. The membrane was incubated with a 
primary antibody at 4⁰C overnight under constant agitation. The following day, the 
membrane was washed 3 times in 1x TBST solution for 10 minutes while under 
constant agitation at room temperature then the appropriate secondary antibody 
conjugated to horseradish peroxidase was added. The secondary antibody was 
diluted in the appropriate blocking solution for 1 hour at room temperature under 
agitation. Membranes were washed 3 times in 1x TBST for 10 minutes. Proteins 
were detected by adding Enhanced Chemiluminesence (Thermo Fisher Scientific) 
or SuperSignal West Extended Duration substrate (Thermo Fisher Scientific) in a 
1:1 volume, incubated for 1 or 5 minutes, respectively, at room temperature. 
Stained bands were visualized by exposing the membrane to radiography film 
(MedSci) in the dark room.  
 Membranes were regularly stripped and re-probed to detect additional 





Fisher Scientific) was added to cover the membrane and incubated for 30 minutes 
at room temperature under constant agitation. After 30 minutes, the membrane 
was hydrated in methanol for 30 seconds then rinsed in deionized water. The 
membrane was washed 3 times for 10 minutes in 1x TBST then blocked in 5% 
non-fat milk for 1 hour at room temperature. The appropriate primary antibody was 
added and the procedure was continued as described previously.  
 Densitometry of Wester blots was done using ImageJ software to quantitate 
protein amounts in three separate experiments (Rasband, 1997). Notch-1 and 
PTEN proteins were normalized to the loading control, β-actin. Phosphorylation of 
Akt at Serine473 was normalized to total Akt.   
Chromatin Immunoprecipitation (ChIP). 
 Chromatin Immunoprecipitation (ChIP) assays were performed using the 
SimpleChIP© Plus kit (Cell Signaling Technology, Danvers, MA). Specifications 
for some of the components used in this kit would not be disclosed by Cell 
Signaling Technology. BT474 (5 x 106) were seeded in 3x 15 cm2 tissue culture 
treated dishes. The following day, BT474TS cells were transfected with NICD1 
(7.5μg) or pcDNA3 using PEI (30μL) for 48 hours. After 2 days, the cells were 
washed in cold PBS, trypsinized (2x trypsin), and the 3 plates were harvested into 
one appropriately labeled 50mL canonical tube on ice. Cells were counted using 
the Countess Automated Cell Counter (Life Technologies, Carlsbad, CA) by 
Trypan Blue staining and 25 x 106 live cells were used for one ChIP sample. The 





for 30 minutes at room temperature under constant agitation. After 30 minutes, the 
cross-linking reaction was quenched with 1.25M glycine, swirled, and incubated 
for 5 minutes at room temperature. The cross-linked cells were centrifuged at 1500 
RPM for 5 minutes at 4⁰C then washed twice with ice cold PBS. The cells were 
pelleted by centrifuged at 1500 RPM for 5 minutes at 4⁰C. Untransfected BT474TS 
and BT474TR cells were seeded and harvested in the same manner. 
 The cells were resuspended in 1mL of ice cold Buffer A (750μL deionized 
water, 250μL 4x Buffer A, 0.5μL (1M) DTT, 5μL (200x) PIC) for each 
immunoprecipitation (IP) and incubated on ice for 10 minutes. The cells were 
mixed by inversion and lightly vortexed every 3 minutes during the 10-minute 
incubation period. The nuclei were pelleted by centrifugation at 3000 RPM for 5 
minutes at 4⁰C. The supernatant was aspirated from the pelleted nuclei and 
resuspended in 1mL of ice cold Buffer B (825μL deionized water, 275μL 4x buffer 
B, 0.55μL (1M) DTT). Centrifugation was repeated at 3000 RPM for 5 minutes at 
4⁰C, supernatant was aspirated, and 100μL of buffer B was added. 1μL of 
micrococcal nuclease (4000 gel units/μL) was added to the nuclei for chromatin 
digestion and incubated at 37 ⁰C for 20 minutes with intermittent mixing by 
inversion every 3 to 5 minutes. After 20 minutes, the digestion was stopped by the 
addition of 10μL of 0.5M Ethylenediaminetetraacetic acid (EDTA). The nuclei were 
pelleted by centrifugation at 13,000 RPM for 1 minute at 4 ⁰C. The supernatant 
was aspirated and the pellet was resuspended in 100μL of 1x ChIP Buffer (90μL 





10 minutes. After 10 minutes, the sample was sonicated 3 times for 20 seconds 
(pulse 20 seconds on, 30 seconds off) at 20% amplitude. The chromatin was 
centrifuged for 10 minutes at 10,000 RPM at 4 ⁰C and transferred to a fresh 
microcentrifuge tube. 10μL of digested chromatin was put aside at -20 ⁰C to be 
used as a 2% input control. This method of digestion should yield chromatin 
fragments of 150 – 900 base pairs (bp). 3 antibodies were used for chromatin 
immunoprecipitation: C-terminal Notch-1 (C-20), normal rabbit IgG, and Histone 
H3 meaning that the prepared chromatin is immunoprecipitated by 3 different 
antibodies in 3 separate microcentrifuge tubes. 100μL of chromatin was diluted in 
400μL of 1x ChIP buffer for each ChIP. 10μL of Notch-1 (200 g/mL), 1μL of 
normal rabbit IgG (200 g/0.5 μL), or 10μL of Histone H3 antibody was added to 
the diluted chromatin. The antibody:chromatin mixture was rotated overnight at 4 
⁰C to facilitate chromatin immunoprecipitation.  
 The next day, condensation in the ChIP sample was lightly spun down to 
get all of the antibody:chomatin mixture to the bottom of the microcentrifuge tube. 
The ChIP sample was placed in a magnetic rack. The tube was left in the rack for 
1 to 2 minutes until the beads visibly gathered on one side of the tube allowing 
aspiration of the supernatant from the tube. The ChIP sample was washed with 
low salt buffer (1x ChIP Buffer) 3 times then high salt buffer [(1x ChIP Buffer and 
5M NaCl] one time. 150μL of ChIP elution buffer (2x ChIP Buffer) was added to 
the ChIP sample in a fresh screw top microcentrifuge tube and put in a shaker at 





sample and placed in the magnetic rack. The supernatant contains the 
immunoprecipitated DNA which is placed in a new screw top microcentrifuge tube. 
150μL of ChIP elution buffer was added to the 2% Input samples. 6μL of 5M NaCl2 
and 2μL of proteinase K (20 mg/mL) was added to both the ChIP and 2% input 
samples followed by incubation at 65 ⁰C for 2 hours.  
 After the 2 hour incubation, 600μL of DNA binding reagent A was added at 
a 4:1 ratio to each sample. The mixture was transferred to a DNA purification 
column in a microcentrifuge tube and centrifuged for 30 seconds at 14,000 RPM. 
The supernatant was discarded and the DNA in the purification column was 
washed twice with 700μL of wash reagent B. The spin column was put in a new, 
properly labeled microcentrifuge tube. 50μL of DNA elution reagent C was added 
to the DNA and spun down again for 30 seconds at 14,000 RPM. The DNA was 
diluted in deionized water at a 1:5 ratio. Quantitative PCR was performed as 
described in section 6, Reverse Transcription Real-Time Polymerase Chain 
Reaction (RT-PCR), using HEY-1 and PTEN ChIP primers that were designed to 
flank CBF-1 binding elements (Persson et al., 2010) (Table 2) to quantitate NICD1 
enrichment of the PTEN and HEY-1 promoters. 
Mammosphere Assay. 
 BT474 or HCC1954 were plated in a 6-well (3 x 105 or 1 x 105) tissue culture 
treated dish. The following day, the cells were transfected with plasmid DNA or 
siRNA and incubated at 37 ⁰C with 5% O2 and 95% CO2 for 48 hours. After 2 days, 





Countess Automated Cell Counter (Life Technologies, Carlsbad, CA) by Trypan 
Blue staining. 1.0 x 106 cells were suspended in 1 ml of PBS. 1.0 x 105 BT474 or 
5.0 x 104 HCC1954 cells were seeded in mammosphere forming media [(196mL 
DMEM/F12 (Life Technologies), 4g methyl cellulose (Sigma Aldrich, St. Louis, 
MO), 10mL B27 (Life Technologies), 1μL recombinant EGF (Sigma Aldrich)] on 
low attachment 6 well plates (Dot Scientific, Burton, MI). Mammosphere media 
was pretreated with PBS, trastuzumab (20μg/mL in PBS), dimethylsulfoxide 
(DMSO), or U0126 (10µg/mL in DMSO) per well. Mammosphere media was added 
to the well followed by the cells on top of the media then vigorously swirled to 
assure cell individualization in the mammosphere media. The BT474 
mammospheres were incubated at 37 ⁰C with 5% O2 and 95% CO2 for 10 days 
and the HCC1954 mammospheres for 7 days.  
 After incubation, pictures of the mammospheres were taken at 20x 
magnification using a Nikon Diaphot TMD Fluorescence Phase Contrast Inverted 
microscope (Nikon, Tokyo, Japan). 2mL of PBS were added to the well and 
incubated at 37 ⁰C for 30 minutes to dissolve the mammosphere media. After 30 
minutes, the PBS:mammosphere solution was put in a properly labeled 50mL tube. 
Care was taken not to disrupt the mammospheres during collection. Addition of 
PBS to the mammospheres was repeated a total of three times to completely 
remove all mammospheres from the well. The harvested mammospheres were 
centrifuged at 1200 RPM for 2 minutes at 4 ⁰C. Care was taken to only aspirate off 





bottom of the 50mL tube. BT474TS mammospheres were resuspended in 3mL of 
PBS and BT474TR or HCC1954 in 5 mL of PBS. 50μL of the mammosphere:PBS 
mixture was plated in a flat bottom, 96 well plate. 4 to 5 pictures at 4x magnification 
were taken of the of the mammospheres. These pictures were used to count the 
number of mammospheres/50μL. Mammospheres larger than 50 μmicrons were 
counted as such. Percent mammosphere forming efficiency (%MFE) was 
calculated as follows: number of mammospheres counted/number of cells seeded 
x 100.  
 After the pictures were taken, 300μL of trypsin was added to the primary 
mammospheres. The mammospheres were incubated at 37 ⁰C for 5 minutes then 
disaggregated by vigorous pipetting. Once the mammospheres were 
disaggregated into single cells, media was added to deactivate the trypsin and the 
cells were washed twice in PBS. 1.0 x 106 live cells from primary mammospheres 
were resuspended in 1mL of PBS. The live cells were plated in mammosphere 
media and incubated to form secondary mammospheres. The secondary 
mammospheres were harvested, counted, and secondary %MFE was calculated 
in the same manner as primary mammospheres.  
Trastuzumab Resistant BCSC Tumor Xenograft Growth. 
 3 x 106 BT474TR cells were seeded in a 10 cm2 tissue culture treated dish. 
The following day, the cells were transfected with scrambled control, Notch-1, 
PTEN, or Notch-1 and PTEN siRNA for 2 days. After transfection, the cells were 





mammosphere media as described in section 9, mammosphere assay. After a 10 
day incubation period, the mammospheres were harvested and disaggregated. 1 
x 104 live cells in 50μL of PBS were mixed in 50μL of Matrigel (Corning, Corning, 
NY). The Matrigel:PBS suspension of cells was injected bilaterally into the 
mammary fats pads of 5 to 6 week old, ovariectomized, FoxN1nu/nu athymic, nude 
female mice (Charles River, Chicago, IL) along with implantation of a 17β-
estradiol-containing silastic release capsule of 0.3cm in length for a constant 
release of 83-100pg/mL as previously described (O’Regan et al., 1998). Each 
mouse was tagged with an ear tag to identify their treatment group (SCBi, N-1i, 
PTENi, N1i + PTENi) as well as record their tumor take and growth. Tumor growth 
was measured weekly as area (length x width) using Vernier calipers. Some 
tumors reached the maximum cross sectional area [(l x w)π/4)] allowed (0.5cm2) 
by week 12. On week 12, mice were sacrificed, tumors were harvested, and frozen 
at -80 ⁰C. Percent tumor take as well as tumor growth was calculated and graphed. 
All animal study protocols were approved by Loyola University’s Institutional 
Animal Care and Use Committee. 
Statistical Analysis. 
 Statistical analysis of at least 3 independent experiments was performed. 
Means plus or minus standard deviations were calculated using Excel software 
(Microsoft). A two-sided student’s t-test was used to compare 2 groups. A one-way 
ANOVA with Tukey’s range test was used to compare multiple groups. Asterisk (*) 





(**) represents statistical significance between Notch-1 inhibition compared to 
other treatment groups. We performed power analysis to determine the 
appropriate number of mice needed per treatment group for the in vivo study. 
Based on previous experience, we determined the number of mice required for 
each treatment group was 6. A Kaplan-Meier curve for tumor formation was 
generated by Prism Version 6 (GraphPad Software). P-values <0.05 were 
considered statistically significant.  
     Meta-Analysis of microarray cohorts. The Hatzis, Bonnefoi, and Curtis 
breast cancer microarray cohorts were acquired from oncomine (oncomine.org). 
Dr. Jun Li from the University of Notre Dame analyzed the cohorts with a log rank 













HYPOTHESIS AND SPECIFIC AIMS 
 Resistance to anti-ErbB-2 (HER2)-targeted therapy remains a clinical 
problem for women with HER2+ breast cancer. Resistance has been shown to 
lead to enrichment of cancer stem cells, tumor recurrence, disease progression, 
and ultimately death. There is an immediate need to elucidate mechanisms 
responsible for drug resistance and breast cancer stem survival and self-renewal. 
Discerning these mechanisms will identify actionable targets to combat breast 
cancer progression. Several markers of trastuzumab resistance are known 
including downregulation of the tumor suppressor, PTEN. Canonically, PTEN acts 
as a lipid phosphatase to reduce the PI3K/Akt pathway and non-canonically as a 
protein phosphatase to dephosphorylate nuclear ERK1/2 resulting in diminished 
MAPK signaling. Women with HER2+ breast tumors expressing less PTEN and 
increased PI3K/Akt or MAPK activity have worse overall outcome. Our lab has 
previously shown that trastuzumab resistant cells have increased expression of 
Notch-1 which drives cell proliferation in vitro as well as tumor recurrence in vivo. 
Yet, we do not know the mechanism by which Notch-1 represses PTEN to increase 
downstream signaling and trastuzumab resistance. Initial characterization of 
trastuzumab resistant cells (BT474TR) display an increase in Notch-1 and a 





pathway activity as measured by phosphorylation of Akt (Ser473-Akt1 and Thr308-
Akt1) and ERK1/2 compared to trastuzumab sensitive cells (BT474TS) (Figure 
11A). Preliminary results demonstrate an increase in PTEN protein (Figure 11B) 
and transcript (Figure 11C) expression upon Notch-1 knockdown. Additionally, 
Notch-1 knockdown results in downregulation of ERK1/2 phosphorylation (Figure 
11B) indicating reduced MAPK pathway activity. Taken together, these results 




















Figure 11: Characterization of the trastuzumab resistant (BT474TR) cell 
line. 
A. Total protein lysates from BT474TS [Trastuzumab Sensitive (Sen.)] and 
BT474TR [Acquired Trastuzumab Resistant (Res.)] cells underwent Western blot 
analysis to detect HER2, HER2 phosphorylation (PY-HER2), Akt phosphorylation 
(PSer473-Akt1, PThr308-Akt1), Notch-1, PTEN, and β-Actin protein expression. 
B. BT474TR cells were transfected with scrambled control (SCBi) or Notch-1 
siRNA (N-1i) for 48 hours. Post transfection, total cellular Notch-1, PTEN, and β-






Figure 12: Notch-1 mediated inhibition of PTEN in trastuzumab resistant 
cells promotes activation of the MAPK/ERK1/2 pathway. 
 The role of Notch-1-mediated repression of PTEN in HER2+ 
 trastuzumab resistant breast cancer   
We will address this hypothesis with the following specific aims: 
 Specific Aim 1: Determine if Notch-1 directly binds to the PTEN 
 promoter in trastuzumab resistant cells. 
 Specific Aim 2: Determine the biological significance of Notch-1-
 mediated downregulation of PTEN in trastuzumab resistant cells. 
 Specific Aim 3: Determine if Notch-1-mediated repression of PTEN is 





Our studies will elucidate the mechanism by which Notch-1 inhibits PTEN in 
HER2+ breast cancer cells. Upregulation of Notch-1 in trastuzumab treated, as 
well as trastuzumab resistant, cells through inhibition of HER2 has been 
established. However, the role of Notch-1 in driving trastuzumab resistance 
remains unknown. PTEN is a well-established suppressor of the PI3K/Akt pathway 
which has been associated with drug resistance and a more aggressive breast 
cancer phenotype. A majority of work focuses on PTEN-mediated downregulation 
of the Akt pathway but PTEN-mediated inhibition of the MAPK pathway has not 
been well characterized in trastuzumab resistant HER2+ breast cancer. Here, for 
the first time, we demonstrate the ability of Notch-1 to mediate PTEN inhibition 
which results in increased MAPK activity in HER2+ trastuzumab resistant cells. 
Furthermore, Notch-1-mediated inhibition of PTEN promotes trastuzumab 
resistant cell proliferation as well as breast cancer stem cell survival and self-
renewal in vitro. Additionally, Notch-1 repression of PTEN promotes tumorigenesis 
in a trastuzumab resistant tumor xenograft model. Together, these results 
demonstrate the functional relevance of Notch-1 regulation of PTEN in HER2+ 
breast cancer. These studies present a mechanism by which Notch-1 regulation 
of the PTEN-ERK1/2 signal transduction pathway promotes resistance to 
trastuzumab treatment. Furthermore, these studies establish combined low PTEN 
and high Notch-1 activity as good prognostic indicators of trastuzumab resistance 
in HER2+ breast cancer patients. This data presents a new perspective on the role 





as a therapeutic target for women who confront resistance to first line anti-HER2 














Specific Aim 1. Determine if Notch-1 Directly Binds to the PTEN Promoter 
in Trastuzumab Resistant Cells. 
The goal of specific aim 1 is to test the following hypotheses: 
 Aim 1A: Discern if Notch-1 is necessary to inhibit PTEN expression in 
trastuzumab resistant cells. 
 Aim 1B: Determine if Notch-1 is sufficient to repress PTEN expression in 
trastuzumab sensitive cells. 
 Aim 1C: Ascertain if Notch-1 is directly recruited to the PTEN Promoter. 
Aim 1A: Discern if Notch-1 is Necessary to Inhibit PTEN Expression in 
Trastuzumab Resistant Cells.  
     Rationale. We wanted to determine the mechanism by which Notch-1 
maintains trastuzumab resistance in HER2+ breast cancer cells, specifically 
through the PI3K/Akt pathway. Previous work by our laboratory has demonstrated 
that resistant cells depend on the Notch pathway to promote HER2+ breast cancer 






Pandya et al., 2011). Additionally, our preliminary data shows that trastuzumab 
resistant cells have an increase in Notch-1 protein expression and Akt-1 
phosphorylation as well as a decrease in PTEN protein expression when 
compared to trastuzumab sensitive cells (Figure 11A). Moreover, both sensitive 
and resistant cells have similar levels of tyrosine phosphorylated HER2 (PY-
HER2), suggesting that continued proliferation of trastuzumab resistant cells is 
likely independent of HER2 activity. Importantly, upon Notch-1 knockdown, we 
observed an increase in PTEN protein expression as detected by Western blotting 
(Figure 11B). Together, these preliminary data suggest that Notch-1 is necessary 
for inhibition of PTEN expression in trastuzumab resistant cells. However, the 
exact mechanism by which Notch-1 represses PTEN in HER2+ breast cancer is 
unknown. The goal of aim 1A is to determine if Notch-1 is necessary to repress 
PTEN expression at the mRNA level.  
     Notch-1 inhibition increases PTEN RNA transcript and protein 
expression. Initial investigation into the mechanism of trastuzumab-mediated 
inhibition of HER2+ breast cancer demonstrated an upregulation of PTEN protein 
expression upon trastuzumab treatment. Trastuzumab-mediated upregulation of 
PTEN is hypothesized to decrease downstream PI3K/Akt pathway activation 
resulting in reduced HER2+ tumor growth. Our model of acquired resistance to 
trastuzumab include cell lines (BT474TR) that display both a decrease in PTEN 
protein and an increase in downstream Akt activity as measured by increased 





trastuzumab sensitive cell line (BT474TS). These results are consistent with 
findings from other laboratories demonstrating similar characteristics in resistant 
cells as those previously described (Figure 11A) (Chan et al., 2005). Moreover, we 
discovered that our BT474TR cells also have an increase in Notch-1 protein 
expression and activity compared to trastuzumab sensitive cells (Figure 11A) 
(Osipo et al., 2008).  
 Our preliminary data demonstrated that inhibition of Notch-1 promoted 
PTEN protein expression (Figure 11B). In order to determine if this effect occurs 
at the transcript level, we asked the question: does Notch-1 inhibit PTEN RNA 
expression? To answer this question, we measured Notch-1 and PTEN transcript 
levels using real-time PCR in acquired resistant cells (BT474TR) upon Notch-1 
knockdown compared to control. The results showed that inhibition of Notch-1 
resulted in an increase in PTEN RNA transcripts (Figure 13A). This result suggests 
that Notch-1 is required for PTEN expression at the RNA transcript level. To 
determine if Notch-1 repression of PTEN was reproducible in other cell lines, 
protein and transcript levels of PTEN were measured post Notch-1 knockdown in 
inherently resistant HCC1954 cells by Western blot and real time PCR analysis, 
respectively. In agreement with results from acquired resistant BT474 cells, Notch-
1 knockdown also resulted in an increase in PTEN RNA transcript (Figure 13B) 







Figure 13: Notch-1 represses PTEN expression in trastuzumab resistant 
cells.  
A. BT474TR cells were transfected with scrambled control (SCBi) or Notch-1 
siRNA (N-1i) for 48 hours. Post transfection, relative expression of Notch-1 (top) 
or PTEN (bottom) was measured by RT-PCR. B. Similarly, intrinsically resistant 
HCC1954 were transfected with SCBi or Notch-1i and relative expression of Notch-
1 (top) or PTEN (bottom) was measured by RT-PCR. C. Post transfection of 
HCC1954 cells, total cellular Notch-1, PTEN, and β-Actin protein expression was 
analyzed by Western blot. D. BT474TR cells were transfected with SCBi, N-1i, and 
a second Notch-1 siRNA (N-1i#2) for 48 hours. Post transfection, total cellular 
Notch-1, PTEN, and β-Actin protein expression was analyzed by Western blot. 
Asterisk (*) represents statistical significance compared to SCBi from three 
independent experiments using a Student’s t-test. 
 Taken together, these results indicate that Notch-1 is necessary for PTEN 





     Notch-1-mediated inhibition of PTEN is not due to an off target effect by 
Notch-1 siRNA. It has become a common practice to validate effects of siRNAs 
using a second, distinct siRNA targeting the same transcript. This is now standard 
due to siRNAs having off target effects (Jackson et al., 2010). To ensure that 
knockdown of Notch-1 by the first siRNA resulting in an increase in PTEN 
expression was not due to an off target effect, we repeated the previous studies 
using a distinct Notch-1 siRNA (#2).  The results using the second Notch-1 siRNA 
(#2) were similar to findings using the first Notch-1 siRNA (#1).  Knockdown of 
Notch-1 using either siRNA (#1 or #2) resulted in upregulation of PTEN protein 
expression (Figure 13D). Notch-1 siRNA #1 is used throughout this manuscript 
unless otherwise noted. This result confirms that Notch-1 is necessary for inhibition 
of PTEN in our trastuzumab resistant cell models.   
Aim 1B: Determine if Notch-1 is Sufficient to Repress PTEN Expression in 
Trastuzumab Sensitive Cells. 
 Aberrant expression of Notch-1 has been shown to regulate PTEN in T-ALL 
(Palomero et al., 2007) and gastric cancers (Kim et al., 2015). Similarly, 
trastuzumab resistant cells display an increase in Notch-1 and a decrease in PTEN 
expression compared to trastuzumab sensitive cells. Thus far, our results 
demonstrate that Notch-1 is required for PTEN inhibition in both acquired and 
inherently resistant HER2+ breast cancer cells. However, Notch-1 is elevated in 
trastuzumab resistant cells compared to trastuzumab sensitive cells (Figure 11A) 





transcription. Under this assumption, an inverse relationship exists between 
Notch-1 and PTEN in which high Notch-1 expression results in PTEN inhibition 
and low Notch-1 expression allows increased PTEN expression. Thus, the goal for 
aim 1B is to determine if Notch-1 is sufficient to inhibit PTEN expression in 
trastuzumab sensitive cells. 
     Overexpression of Notch-1 results in decreased PTEN expression. Given 
our initial data demonstrating that Notch-1 is required to attenuate PTEN transcript 
and protein expression in resistant cells, we asked if Notch-1 overexpression 
downregulates PTEN in trastuzumab sensitive cells. To address this question, we 
measured PTEN protein and transcript levels expression in BT474 sensitive cells 
transfected with a control plasmid (pcDNA3) or a plasmid harboring cDNA for the 
Notch-1 Intracellular Domain 1 (pcDNA3-NICD1) by Western blot and real time 
PCR analysis. The results showed that NICD1 overexpression in trastuzumab 
sensitive, BT474 cells resulted in a significant decrease in PTEN transcript (Figure 









Figure 14: Notch-1 overexpression represses PTEN in trastuzumab 
sensitive cells. 
A. BT474TS cells were transfected with a vector control (pcDNA3) or NICD1 
expression vector (NICD1) for 48 hours. Post transfection, Notch-1 (left) or PTEN 
(right) mRNA expression was measure by RT-PCR. B. Total cellular Notch-1, 
PTEN, and β-Actin protein expression was analyzed by Western blot post 
transfection. Asterisk (*) represents statistical significance compared to pcDNA 
from three independent experiments using Student’s t-test. 
 Taken together, these data suggest that Notch-1 is sufficient to regulate 
PTEN expression at the transcript and protein levels in trastuzumab sensitive, 
HER2+ breast cancer cells.  
Aim 1C: Ascertain if Notch-1 is Directly Recruited to the PTEN Promoter. 
 Recruitment of Notch-1 to a CBF-1 element on a gene promoter 
canonically activates transcription of the target gene. Previous work reported that 
Notch-1 activated PTEN transcription in an embryonic kidney cell model (293T) 
(Whelan et al., 2007). In contrast, Notch-1 was shown to repress PTEN 
expression in T-ALL (Palomero et al., 2007). Canonically, Notch-1 is a 
transcriptional activator of CBF-1-driven gene targets. In T-ALL, Palomero et al. 





transcriptional repressor HES-1, which is recruited to the PTEN promoter to 
repress transcription of PTEN. Thus far, our results show that Notch-1 is both 
necessary and sufficient to downregulate PTEN at the transcript level. To 
determine if Notch-1 enrichment at the PTEN promoter correlates with reduced 
PTEN transcript RNA expression, we performed a series of chromatin 
immunoprecipitation (ChIP) assays to measure direct recruitment of NICD1 to a 
CBF-1 site on the PTEN promoter. The goal of aim 1C is to determine if aberrant 
Notch-1 expression results in an increase in NICD1 recruitment to the PTEN 
promoter in HER2+ breast cancer cells.                             
     Trastuzumab resistant cells have increased recruitment of Notch-1 at 
the PTEN promoter. The canonical role of Notch-1 is to activate transcription, 
leading us to ask the question: Is there an increase in NICD1 recruitment at the 
PTEN promoter in resistant cells compared to sensitive cells? We measured 
endogenous NICD1 enrichment at CBF-1 sites on HEY-1 and PTEN promoters in 
both trastuzumab sensitive and resistant cells through a series of ChIP assays. 
Enrichment of NICD1 on the HEY-1 promoter was performed as a positive 
control as HEY-1 is a canonical Notch-1 target gene (Katoh and Katoh, 2007). 
NICD1 enrichment at the HEY-1 promoter was measured by ChIP followed by 
quantitative PCR (qPCR). The DNA fragment from the HEY-1 promoter region -
243 bps upstream of the transcriptional start site (maps above bar graphs, Figure 
16A) was amplified using a pair of primers flanking this region. Similarly, primers 





gene amplified a DNA fragment enriched by NICD1. The primer pairs used in this 
study were shown to flank a canonical CBF-1 binding sequence (CTGGGAA) 
(Persson and Wilson, 2010), in the PTEN promoter as previously described by 
Graziani et al. (Graziani et al., 2008). Analysis of the PTEN and HEY-1 
promoters revealed 5 to 6 putative CBF-1 sites and we found that putative site #4 
(CTGGGAA) was the most highly enriched for NICD1 in our HER2+ breast 
cancer cell model (Figure 15). We detected more than a 3-fold increase in 
endogenous NICD1 enrichment at both the HEY-1 and PTEN promoters in 



















Figure 15: PTEN promoter region. 
The PTEN promoter region includes the transcription initiation site [ATG(+1)], 
forward (-585 to -610) and reverse (-389 to -410) ChIP pimers, CBF-1 (olive green) 
#4 (-425 and -1160), #5 (-1930), #1 (-2210), #10 (-2566), c-Ets (pink), GATA-1 
(agua blue), c-Fos (blue-green), AP-1 (Yellow), RUNX-1 (blue with white letters), 
NF-κB (purple), c-Myc (red), Oct-1 (blue), GATA-1/Oct-1 (Maroon with white 






Figure 16: Notch-1 is directly recruited to the PTEN promoter. 
A. HEY-1 (left) and PTEN (right) promoter maps showing CBF-1 binding sites 
flanked by specific primer amplification sites. These primers were used to quantify 
NICD1 enrichment of the HEY-1 or PTEN promoter by qPCR. B. BT474TR and 
BT474TS cells were fixed, fragmented, and chromatin was immunoprecipitated by 
a C-terminal Notch-1 (Santa Cruz Notch-1 Ab) or control IgG antibody. Purified 
DNA from Notch-1 or IgG immunoprecipitated chromatin was used to quantify 
NICD1 enrichment of HEY-1 or PTEN promoters by qPCR using the primers 
shown in A. C. BT474TS cells were transfected with NICD1 or pcDNA3 expression 
vectors for 48 hours. Post transfection, cells were harvested, fixed, fragmented, 
immunoprecipitated by Notch-1 or IgG antibodies, and NICD1 enrichment of HEY-
1 or PTEN promoters was quantified by qPCR using the same HEY-1 or PTEN 
primers as in B. Asterisk (*) represents statistical significance compared to 
sensitive (B) or pcDNA3 (C) mean NICD1 enrichment from three independent 
experiments using Student’s t-test. 
 These results are contrary to the canonical role of Notch-1 as a 
transcriptional activator as we observe a decrease in PTEN transcripts in resistant 
compared to sensitive cells.  Yet, there is an increase in NICD1 enrichment at the 





Notch-1 is potentially acting as a direct inhibitor of PTEN transcript RNA 
expression in trastuzumab resistant, HER2+ breast cancer cells. 
     Overexpression of Notch-1 increases Notch-1 enrichment at the PTEN 
promoter in trastuzumab sensitive cells. Previous results indicated that Notch-
1 is sufficient to repress PTEN transcripts in trastuzumab sensitive cells (Figure 
14). Given this result, and the enrichment of NICD1 at the PTEN promoter in 
resistant cells, lead us to ask the question: is NICD1 directly recruited to the PTEN 
promoter in trastuzumab sensitive cells? We addressed this question by 
performing the same ChIP assays used to determine endogenous enrichment of 
NICD1 at the PTEN promoter in resistant and sensitive cells. Similar to the 
previous results, we observed a 3-fold increase in NICD1 enrichment at CBF-1 
sites on the HEY-1 and PTEN promoters in sensitive cells-overexpressing NICD1 
as compared to the vector control (pcDNA3)-transfected cells (Figure 16C).  
 Taken together, these data presented in aim 1C suggests that Notch-1 is 










Specific aim 2. Determine the Biological Significance of Notch-1-Mediated 
Downregulation of PTEN in Trastuzumab Resistant Cells. 
The goal of specific aim 2 is to test the following hypotheses: 
 Aim 2A: Determine if Notch-1-mediated repression of PTEN promotes cell 
proliferation of trastuzumab resistant cells.  
 Aim 2B: Determine the role of the MAPK pathway in Notch-1-mediated 
repression of PTEN in trastuzumab resistant cells. 
 Aim 2C: Deduce if Notch-1-mediated repression of PTEN promotes 
trastuzumab resistant breast cancer stem cell survival and self-renewal. 
Aim 2A: Determine if Notch-1-Mediated Repression of PTEN Promotes 
Proliferation of Trastuzumab Resistant Cells.  
     Rationale. Notch-1 has been shown to promote tumorigenesis in a number of 
different cancers. Additionally, PTEN is a well-known inhibitor of the PI3K/Akt 
pathway which has presented itself as a central node in drug resistant, HER2+ 
breast cancer (Berns et al., 2007). Thus far, we have shown that Notch-1 is 
required for the inhibition of PTEN expression potentially through direct recruitment 
of NICD1 to the PTEN promoter. Moreover, we have shown that there is an 
increase in Akt activation in resistant compared to sensitive cells. Thus, we wanted 
to determine the biological significance of Notch-1-mediated repression of PTEN 
on cell growth and the PI3K/Akt pathway in trastuzumab resistant cells. The goal 
of aim 2A is to determine if Notch-1-mediated repression of PTEN is responsible 





     Trastuzumab reduces trastuzumab sensitive cell proliferation yet has no 
effect on resistant cell proliferation. First, we wanted to ensure that our 
trastuzumab resistant cells were resistant to trastuzumab treatment and that our 
trastuzumab sensitive cells remained sensitive to trastuzumab treatment. To 
assess trastuzumab sensitivity, we measure cell proliferation of resistant and 
sensitive cells treated with 0, 2.5, 5, 10, 20, or 40 μg/ml of trastuzumab for 10 days. 
The results demonstrate that our resistant cells are able to proliferate under high 
doses of trastuzumab treatment while our sensitive cells are unable proliferate 
when exposed to low doses of trastuzumab (Figure 17). These data show that our 
sensitive cells are indeed sensitive to trastuzumab treatment while our resistant 
















Figure 17: Trastuzumab reduces trastuzumab sensitive cell proliferation 
but has no effect on resistant cell proliferation. 
100,000 BT474S and BT474TR cells / well were seeded in 6 well plates and 
treated daily with 0, 2.5, 5, 10, 20, 30, or 40 μg/mL of trastuzumab for 10 days. 
Mean cell proliferation was calculated as the number of live cells / number of cells 
seeded from triplicate wells. 
     Notch-1-mediated inhibition of PTEN promotes trastuzumab resistant cell 
proliferation regardless of trastuzumab treatment. Previous work showed that 
Notch-1 was required for cell proliferation of trastuzumab resistant breast cancer 
cells (Osipo et al., 2008). Thus far, we have shown that Notch-1 is directly recruited 
to the PTEN promoter which associates with reduced PTEN transcript RNA 
expression in the same trastuzumab resistance cells. Additionally, we have shown 
that low PTEN expression in trastuzumab resistance cells correlated with 
hyperactivation of Akt. What is not known is if Notch-1-mediated repression of 
PTEN is responsible for cell proliferation and the increase in hyper-phosphorylation 





we measured cell proliferation in resistant cells transfected with a scrambled 
control, Notch-1, and/or PTEN siRNA treated with PBS or trastuzumab (20 μg/ml) 
for 10 days. In the acquired resistant model (BT474TR), knockdown of Notch-1 
reduced cell proliferation by more than 4 fold compared to the scrambled control 
(Figure 18A and B). Additionally, simultaneous knockdown of Notch-1 and PTEN 
rescued cell proliferation by 2-fold compared to Notch-1 knockdown alone. 
Furthermore, these proliferations results were similar either in the absence or 
presence of trastuzumab treatment. We repeated this assay using another 
trastuzumab resistant, HER2+ breast cancer line, HCC1954, and observed similar 
results (Fig 18C and D). It is important to note that combined knockdown of Notch-
1 and PTEN in HCC1954 cells completely rescued cell proliferation compared to 







Figure 18: Notch-1-mediated inhibition of PTEN promotes trastuzumab 
resistant cell proliferation. 
A-B. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours. 
Post transfection, the cells were harvested and seeded at 100,000 cells/ well in a 
6 well plate and treated daily with 20 μg/mL of PBS (A) or trastuzumab (B) for 10 
days. After treatment, the cells were harvested and counted. Mean proliferation 
was calculated as the number of live cells harvested / number of live cells seeded. 
C-D. HCC1954 cells were transfected with SCBi, N-1i, and/or PTENi and treated 
with PBS (C) or trastuzumab (D) in the same manner as A-B. Asterisk (*) denotes 
statistical significance compared to SCBi or (**) Notch-1i mean proliferation as 
calculated using a one-way ANOVA with an overall statistical significance of p < 
0.0001 from three independent experiments. 
 Taken together, these results demonstrate that Notch-1-mediated 





     Notch-1-mediated repression of PTEN is not responsible for hyper-
activation of Akt. The results from the cell proliferation assays encouraged us to 
assess downstream PI3K/Akt pathway activity to determine if Notch-1-mediated 
inhibition of PTEN resulted in increased Akt activation. Western blotting was 
performed to assess the efficiency of Notch-1 and PTEN protein knockdown as 
well as to detect the activation of Akt as measured by phosphorylation of Akt at 
serine 473 and threonine 308. Additionally, densitometric analysis using ImageJ 
was used to quantitate Notch-1 and PTEN protein expression normalized to the 
loading control, β-actin (Rasband, 1997). This was repeated for protein levels of 
phosphorylated serine473 on Akt normalized to overall Akt expression (Figure 19A 
below blot). The results show that we were consistently able to knockdown both 
Notch-1 and PTEN in both the acquired [(BT474TR) left] and inherently 
[(HCC1954) right] resistant breast cancer cell models. Additionally, Notch-1 
knockdown consistently resulted in an increase in PTEN protein expression. 
Interestingly, the increase in PTEN expression in response to Notch-1 knockdown 
either slightly increased or had little effect on the phosphorylation status of Akt. 
This result is contrary to our initial hypothesis as we anticipated that inhibition of 
Notch-1 would increase PTEN which in turn would inhibit PI3K kinase activity 
resulting in decreased phosphorylation of Akt. Moreover, trastuzumab treatment 
of acquired resistant cells (BT474TR) reduced phosphorylation of Akt yet 
trastuzumab had little to no effect on proliferation (Figure 19A). Similar results were 





increased PTEN expression, yet slightly increased phosphorylation of Akt. This 
result was again independent of trastuzumab treatment (Figure 19B).   
 
Figure 19: Notch-1 mediated inhibition of PTEN has little to no effect on 
phosphorylation of Akt. 
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours. 
Post transfection, total cellular Notch-1, PTEN, Akt, β-Actin, phosphorylation of 
Akt-1 at threonine308 (PThr308-Akt1) and serine473 (PSer473-Akt1) protein 
expression from the transfected cells post 48 hour PBS (left) or trastuzumab (right) 
treatment was analyzed by Western blot. Mean values from densitometric analysis 
of Notch-1, PTEN, and PSer473-Akt1 normalized to β-Actin or Akt, respectively, 
are displayed below their respective blots, and quantitated from three independent 
experiments. B. HCC1954 cells were transfected, treated, and analyzed by 
Western blot in a similar manner as in A. 
 Taken together, these data indicate that Notch-1-mediated repression of 
PTEN is not promoting trastuzumab resistance due to activation of Akt. Contrary, 
Notch-1-mediated repression of PTEN could be promoting cell proliferation by 





     PTEN siRNA B inhibits trastuzumab resistant cell proliferation. We wanted 
to validate the results of our cell proliferation assays by using the three individual 
siRNAs that comprise the PTEN SmartPool siRNA. The results of our cell 
proliferation assays displayed a decrease in resistant cell proliferation when 
transfected with the PTEN SmartPool siRNA (Figure 18A and B). Therefore, we 
asked the question: Is one of the individual siRNA oligonucleotides in the PTEN 
SmartPool having an anti-proliferative effect on trastuzumab resistant cells? To 
address this question, we measured cell proliferation of acquired resistant cells 
(BT474TR) transfected with the three separate oligonucleotides (A, B, C) 
compared to a control siRNA and the PTEN SmartPool siRNA.  The cell 
proliferation studies revealed that PTEN siRNA B reduced resistant cell 
proliferation (Figure 20A). Additionally, whole cell lysates from the cell proliferation 
study were used to measure PTEN protein expression by Western blotting. The 
three PTEN siRNAs were able to downregulate PTEN protein expression (Figure 
20B). These results explain the decrease in resistant cell proliferation when 








Figure 20: Distinct Notch1 and PTEN siRNAs Produce Similar Effects. 
A. BT474TR cells were transfected with SCBi, PTENi-A, PTENi-B, PTENi-C, or 
the PTENi SmartPool for 48 hours. Post transfection, the cells were harvested and 
100,000 live cells / well were plated into a 6 well plate and grown for 10 days. On 
day 10, the cells were harvested and counted. Mean cell proliferation was 
calculated as the number of live cells / number of cells seeded from triplicate wells. 
B. Total cellular PTEN and β-Actin protein expression from samples in A was 
analyzed by Western blot. C. BT474TR cells transfected with SCBi, Notch-1i #2 
and/or PTENi-A for 48 hours. Post transfection, the cells were harvested and 
100,000 live cells / well were seeded into 6 well plates and grown for 10 days. 
Mean cell proliferation was calculated from triplicate wells in the same manner as 
A.  D. Total cellular Notch-1, PTEN, and β-Actin protein expression from samples 





     Distinct Notch-1 and PTEN siRNAs have similar effects on the 
proliferation of trastuzumab resistant cells. Given the off-target effects of one 
of the PTEN SmartPool siRNAs, we wanted to validate the results of the Notch-1 
siRNA in our cell proliferation studies. Thus, we asked the question: does a second 
Notch-1 siRNA yield similar results when combined with an individual PTEN 
siRNA? We addressed this question by performing the same cell proliferation 
studies in which we transfected acquired resistant cells (BT474TR) with a 
scrambled control, a second Notch-1 siRNA (#2), and/or a single PTEN siRNA A. 
The cell proliferation study yielded similar results to the initial studies in which 
combined knockdown of Notch-1 and PTEN partially rescued cell proliferation 
compared to Notch-1 knockdown alone (Figure 20C). Western blotting confirmed 
that the second, distinct siRNAs against Notch-1 and PTEN were efficient in 
decreasing protein levels (Figure 20D). These results confirm that Notch-1 is 
required to repress PTEN expression and this mechanism is responsible for 
proliferation of trastuzumab resistant, HER2+ breast cancer cells.                                                    
     Notch-1 is not sufficient to induce trastuzumab resistance. Thus far, we 
have demonstrated that proliferation of trastuzumab resistant cells is dependent 
on Notch-1-mediated repression of PTEN. Previous results have shown that 
Notch-1 is sufficient to repress PTEN in sensitive cells. Thus, the critical aim now 
is to determine if Notch-1 is sufficient to induce resistance in cells that are initially 
sensitive to trastuzumab. To address this aim, we performed a series of cell 





(pcDNA3) in trastuzumab sensitive cells and treated them with PBS or 
trastuzumab (20 μg/ml) for 10 days. NICD1 overexpression modestly increased 
cell proliferation of sensitive cells in response to trastuzumab treatment. Taken 
together, these results suggest that Notch-1 overexpression alone is not sufficient 
to promote trastuzumab resistance (Figure 21A and B). These results indicate that 
prolonged exposure to trastuzumab treatment is necessary for upregulation of 
Notch-1 and the development of resistance. 
 
 
Figure 21: Notch-1 overexpression in trastuzumab sensitive cells modestly 
increases proliferation in response to trastuzumab treatment. 
A. BT474TS cells transfected with NICD1 or pcDNA3 expression vectors for 48 
hours. Post transfection, the cells were harvested and 100,000 cells were seeded 
/ well in a 6 well plate. Cells were treated daily with 20 µg/mL trastuzumab or PBS 
for 10 days. On day 10, the cells were harvested and live cells were counted. B. 
Cell proliferation of BT474TS cells transfected with pcDNA or NICD1 and treated 
with trastuzumab from A. Mean cell proliferation rate was calculated by the number 
of live cells / number of cells seeded. Asterisk (*) denotes statistical significance 
between mean cell proliferation of PBS and trastuzumab treated cells (A) or 
pcDNA3 and NICD1 transfected cells under trastuzumab treatment (B) from three 





Aim 2B: Determine the Role of the MAPK Pathway in Notch-1-Mediated 
Repression of PTEN in Trastuzumab Resistant Cells. 
 Our results demonstrate that Notch-1 inhibition resulted in little to no effect 
on the activation status of Akt in the resistant cell models. Previous work has 
demonstrated that PTEN is able to attenuate phosphorylation of ERK1/2 in a 
HER2-negative breast cancer cell model, MCF-7 (Chung et al., 2005b). 
Additionally, MAPK pathway activity is inhibited by trastuzumab and has been 
found to be upregulated in models of acquired resistance to trastuzumab (Chan et 
al., 2005). The MAPK pathway is known for controlling cell death and proliferation 
which leads us to hypothesize that Notch-1-mediated repression of PTEN is 
promoting the activation of ERK1/2 to increase cell proliferation.  
     Trastuzumab resistant cells have increased ERK1/2 activity compared to 
sensitive cells. If the ERK1/2 pathway is critical to promoting proliferation of 
resistant cells, then these cells should have higher expression of phosphorylated 
ERK1/2 than sensitive cells. To address this aim, we measured the 
phosphorylation status of ERK1/2 in both sensitive and resistant whole cell lysates. 
The results indicate that resistant cells have increased ERK1/2 phosphorylation 
compared to sensitive cells (Figure 22A) (Rogowski, 2011). This result suggests 










Figure 22: Trastuzumab resistant cells have increased phosphorylation of 
ERK1/2 mediated by Notch-1. 
A. Total protein lysates from BT474TS (Sen.) and BT474TR (Res.) underwent 
Western blot analysis to detect P-ERK1/2, ERK1/2, and β-Actin protein 
expression. B. BT474TR cells were transfected with SCBi or N-1i for 48 hours. 
Post transfection, total cellular P-ERK1/2, ERK1/2, and β-Actin protein expression 
was analyzed by Western blot. 
     Notch-1 is required for ERK1/2 phosphorylation in trastuzumab resistant 
cells. Our data demonstrate that the ERK1/2 pathway is upregulated in 
trastuzumab resistant cells compared to sensitive cells, yet the role of Notch-1 in 
regulating the ERK1/2 pathway has yet to be assessed. Therefore, we asked the 
question: is expression of Notch-1 required for the increased phosphorylation of 
ERK1/2 in trastuzumab resistant cells? To address this question, we measured 
ERK1/2 phosphorylation in lysates from scrambled control or Notch-1 siRNA 





phosphorylation decreases upon Notch-1 knockdown compared to the scrambled 
control (Figure 22B).  
 These data suggest that Notch-1 is necessary to activate or at least 
maintain ERK1/2 activity in trastuzumab resistant cells.  
     Inhibition of the MAPK pathway reduces proliferation of trastuzumab 
resistant cells. Proliferation of trastuzumab resistant cells depends on Notch-1. 
This dependence may be due, in part, to the ability of Notch-1 to activate or 
maintain the ERK1/2 pathway. To determine if proliferation of resistant cells is 
dependent on the MEK1/2-ERK1/2 pathway, we used a MEK1/2 inhibitor, U0126, 
in a series of cell proliferation assays. We transfected resistant cells with a 
scrambled control, Notch-1, and/or PTEN siRNA and treated them with the vehicle, 
dimethylsulfoxide (DMSO) or U0126 for 10 days. We found that treatment of 
resistant cells with U0126 dramatically reduced proliferation of resistant cells 
(Figure 23A). Importantly, Western blot analysis of cell lysates showed that the 
decrease of ERK1/2 phosphorylation in response to Notch-1 knockdown was 
rescued by knockdown of PTEN. The U0126 treatment almost completely 









Figure 23: Notch-1 mediated repression of PTEN activates ERK1/2 which is 
necessary for resistant cell proliferation. 
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi-A for 48 hours. 
Post transfection, 100,000 cells/well were plated in a 6 well plate and treated daily 
with 10 µg/mL U0126 (left) or DMSO (right) for 10 days. Post treatment, the cells 
were harvested and counted. Mean cell proliferation was calculated as the number 
of live cells harvested / number of cells seeded from triplicate wells. C. Total 
cellular Notch-1, PTEN, P-ERK1/2, ERK1/2 and β-Actin protein expression from 
the cells in A post 48 hours of DMSO (left) or U0126 (right) was analyzed by 
Western blot. 
  Taken together, these results suggest that Notch-1-mediated repression of 
PTEN maintains or activates ERK1/2 phosphorylation via MEK1/2 activity to drive 





     Constitutive MEK1/2 activation rescues trastuzumab resistant cell 
proliferation from Notch-1 inhibition. Thus far, we have shown that MEK1/2 
activity is required for proliferation of resistant cells.  What is not known is whether 
constitutive activation of MEK1/2-ERK1/2 activity can rescue the decrease in 
resistant cell proliferation upon Notch-1 knockdown.  To test this, we measured 
proliferation of resistant cells transfected with a scrambled control or a Notch-1 
siRNA in combination with a vector control (pEXP) or a constitutively active mutant 
of MEK1/2 (pEXP-MEK1DD) (www.addgene.org/31202/). MEK1DD has been 
reported to maintain phosphorylation of ERK1/2 (Yang et al., 2011). Protein 
expression from cell lysates were measured by Western blotting. The results show 
that constitutive ERK1/2 phosphorylation by MEK1DD partially rescued the growth 
inhibitory effects mediated by Notch-1 knockdown by nearly 4-fold compared to 
Notch-1 knockdown alone (Figure 24A). Importantly, the decrease in ERK1/2 
phosphorylation by Notch-1 knockdown was prevented when MEK1DD was 












Figure 24: Notch-1 promotes ERK1/2 phosphorylation which is sufficient 
for resistant cell proliferation. 
A. BT474TR cells were transfected with SCBi or Notch-1i and MEK1DD or pEXP 
expression vectors for 48 hours. Post transfection, cells were harvested and 
seeded at 100,000 cells / well of a six well plate. After 10 days, the cells were 
harvested and counted. Mean cell proliferation was calculated as number of live 
cells harvested / number of cells seeded from triplicate wells. B. Total cellular 
Notch-1, MEK1, P-ERK1/2, ERK1/2 and β-Actin protein expression from the cells 
in A post transfection was analyzed by Western blot. 
 Together, these results indicate a novel mechanism in which Notch-1 
maintains proliferation of trastuzumab resistant, HER2+ breast cancer cells by 
repressing PTEN expression to increase the activity of the MEK1/2-ERK1/2 
pathway.   
Aim 2C: Deduce if Notch-1-Mediated Repression of PTEN Promotes 
Trastuzumab Resistant, Breast Cancer Stem Cell Survival and Self-Renewal. 
 The discovery of the cancer stem cell population has garnered much 
attention as it is hypothesized to promote cancer metastasis, recurrence, and drug 





2014) and Notch-1 (Harrison et al., 2010) promote expansion and survival of the 
BCSC population. Additionally, PTEN has been shown to increase BCSC 
differentiation through inhibition of both PI3K/Akt and MAPK pathways (Jordan et 
al., 2009; Han et al., 2012). Moreover, trastuzumab resistant breast cancer cells 
have displayed an increase in BCSC enrichment through increased Akt pathway 
activity (Korkaya et al., 2008). With data presented so far, we found it important to 
determine the role of the Notch-1-PTEN-ERK1/2 signaling axis in survival and self-
renewal of our trastuzumab resistant cells. The goal of aim 2C is to determine the 
effect of Notch-1-mediated activation of the downstream MAPK pathway through 
PTEN inhibition on the survival and self-renewal of the trastuzumab resistant 
BCSC population. 
     Trastuzumab resistant cells are enriched for BCSCs. Trastuzumab has 
been shown to reduce the BCSC population in trastuzumab sensitive cells 
(Magnifico et al., 2009). These data led us to assess the effect of trastuzumab on 
the BT474 sensitive BCSC population. We assessed BCSC survival of BT474 
sensitive cells by using an in vitro mammosphere forming assay (Shaw et al., 
2012) in response to a vehicle control (PBS) or trastuzumab (20 μg/ml) treatment.  
We found that trastuzumab treatment significantly reduced the primary percent 
mammosphere forming efficiency (%MFE) of the BT474 sensitive cells (Figure 
25A). Moreover, we observed that the size of mammospheres from BT474 
sensitive cells were smaller (<50m) in response to trastuzumab treatment (Figure 





trastuzumab inhibited the survival of the HER2- dependent BCSC population as 
previously demonstrated by Magnifico et al.  
 
Figure 25: Breast Cancer Stem survival effects in trastuzumab sensitive 
and resistant cells. 
A. 100,000 BT474TS cells were plated into PBS or trastuzumab (20 μg/mL) 
inoculated mammosphere media. Mammospheres were grown for 10 days. On 
day 10, mammospheres were harvested and counted to determine mean percent 
mammosphere forming efficiency (%MFE) which is calculated as [(number of 
mammospheres counted / number of cells seeded) X 100]. B. Representative 
photographs of BT474TS mammospheres from A at 20x magnification before 
harvest. C. 100,000 BT474TS or BT474TR cells were plated into mammosphere 
media and incubated for 10 days. On day 10, mammospheres were harvest and 
counted from three independent experiments in the same manner as A. D. 
Representative photographs of BT474TS and BT474TR mammospheres from C 
at 20x magnification before harvest. Scale bare = 50m. Asterisk (*) denotes 
statistical significance between mean %MFE of PBS and trastuzumab treated cells 
(A) or BT474TS and BT474TR mammospheres (C) from three independent 






 Previously, trastuzumab resistant cells have been shown to be enriched for 
BCSCs compared to sensitive cells (Korkaya et al., 2008). Given this information, 
we wanted to assess the mammosphere forming potential of our resistant cells 
compared to sensitive cells to characterize the BCSC population in our cell models. 
We assessed %MFE of both BT474 sensitive and resistant cells and determined 
that %MFE of trastuzumab resistant cells was significantly higher than %MFE of 
trastuzumab sensitive cells by almost 8 fold (Figure 25C). It is important to note 
that mammospheres from resistant cells were nearly twice the size of 
mammospheres from sensitive cells (100m versus 50m) (Figure 25D).  
 Together, these data confirm findings from previous work and suggest that 
long term treatment with trastuzumab enriches for BCSCs.  
     Notch-1-mediated repression of PTEN is necessary for breast cancer 
stem cell survival and self-renewal. Notch has been shown to be a primary 
driver of BCSC survival and self-renewal from studies performed on breast cancer 
cells lines as well as patient tumor samples (Grudzien et al., 2010; Harrison et al., 
2010). Yet, the mechanism by which Notch-1 promotes BCSC survival and self-
renewal remains, for the most part, unknown. In order to investigate the role of 
Notch-1-mediated repression of PTEN in the BCSC population in vitro, we 
performed both primary and secondary mammosphere forming assays from 
trastuzumab resistant cells transfected with a scrambled control, Notch-1, and/or 
PTEN siRNAs in response to PBS or trastuzumab. Measurement of primary %MFE 





renewal capacity of the BCSC (Shaw et al., 2012). The results showed that 
knockdown of Notch-1 significantly reduced both primary and secondary %MFE 
by nearly 5-fold compared to the scrambled control (Figure 26). Knockdown of 
PTEN had little effect on primary or secondary %MFE compared to the control 
(Figure 26). Importantly, knockdown of PTEN partially rescued the effects of 
Notch-1 knockdown by more than 2-fold compared to Notch-1 knockdown alone. 
These results were similar regardless of trastuzumab treatment (Figure 26, 
compare right panels to left panels). Mammospheres were photographed at 20x 
magnification with a 100m scale bar (Figure 26A and C). Similar results were 
observed with the inherently resistant HCC1954 cell line. Simultaneous 
knockdown of Notch-1 and PTEN almost completely recovered both primary and 













Figure 26: Notch-1-mediated inhibition of PTEN promotes trastuzumab 
resistant breast cancer stem cell (BCSC) survival and self-renewal of 
BT474TR cells. 
A and C. BT474TR cells were transfected with SCBi, Notch-1i, and/or PTENi for 
48 hours. Post transfection, the cells were harvested and 100,000 cells/well were 
seeded into PBS (A) or trastuzumab (20 μg/mL) (C) inoculated mammosphere 
media in a 6 well plate. The mammospheres were incubated for 10 days to form 
primary (1⁰) mammospheres then harvested, disaggregated, and 100,000 live cells 
from the primary mammospheres were seeded into PBS or trastuzumab inoculated 
mammosphere media. The cells were incubated for 10 days to form secondary (2⁰) 
mammospheres. Before harvesting, representative photographs of primary (top) 
and secondary (bottom) mammosphere were taken on day 10 at 20x 
magnification. B and D. Mammospheres were harvested in PBS and 
mammospheres over 50 μm were counted as such. Primary percent 
mammosphere forming efficiency (%MFE) (black bars) was calculated as: 
[(number of mammospheres counted / well) / number of cell seeded X 100]. 
Secondary %MFE (white bars) was calculated in the same manner as primary 
%MFE. Asterisk (*) denotes statistical significance compared to SCBi or (**) Notch-
1i mean %MFE as calculated using a one-way ANOVA with an overall statistical 








Figure 27: Notch-1-mediated inhibition of PTEN promotes trastuzumab 
resistant breast cancer stem cell (BCSC) survival and self-renewal of 
HCC1954 cells. 
A and C. HCC1954 cells were transfected with SCBi, Notch-1i, and/or PTENi for 
48 hours. Post transfection, the cells were harvested and 50,000 cells/well were 
seeded into PBS (A) or trastuzumab (20 μg/mL) (C) inoculated mammosphere 
media in a 6 well plate. The mammospheres were incubated for 7 days to form 
primary (1⁰) mammospheres then harvested, disaggregated, and 50,000 live cells 
from the primary mammospheres were seeded into PBS or trastuzumab inoculated 
mammosphere media. The cells were incubated for 7 days to form secondary (2⁰) 
mammospheres. Representative photographs of primary (top) and secondary 
(bottom) mammosphere were taken on day 7 before harvest at 20x magnification. 
B and D. Mammospheres were harvested in PBS and mammospheres over 50 
μm were counted as such. Primary percent mammosphere forming efficiency 
(%MFE) (black bars) was calculated as: [(number of mammospheres counted / 
well) / number of cell seeded X 100]. Secondary %MFE (white bars) was calculated 
in the same manner as primary %MFE. Asterisk (*) denotes statistical significance 
compared to SCBi or (**) Notch-1i mean %MFE as calculated using a one-way 
ANOVA with an overall statistical significance of p < 0.01 from three independent 







 Taken together, these results indicate that Notch-1 is necessary for the 
survival and self-renewal of trastuzumab resistant BCSCs at least partially through 
repression of PTEN.  
     Inhibition of MEK1/2 (MAPKK) activity reduces trastuzumab resistant 
BCSC survival. We showed that activation of MEK1/2-ERK1/2 signaling rescued 
proliferation of bulk, trastuzumab resistant cells from knockdown of Notch-1. If the 
bulk, resistant cell population is dependent on MEK1/2-ERK1/2 activity for 
proliferation, then this pathway may be required for BCSC survival. To test this, 
%MFE was measured from trastuzumab resistant cells transfected with a 
scrambled control, Notch-1, and/or PTEN, siRNAs in response to a vehicle 
(DMSO) or the MEK1/2 inhibitor (10M U0126). The results showed that %MFE of 
control siRNA transfected, resistant cells was decreased by nearly 3 fold in 
response to U0126 (Figure 28). Knockdown of Notch-1 almost completely inhibited 
%MFE regardless of U0126 treatment. Importantly, %MFE of cells transfected with 
the PTEN siRNA alone or PTEN plus Notch-1 siRNAs was inhibited to the same 
degree as cells transfected with the Notch-1 siRNA alone when treated with U0126 
(Figure 28). These data suggest that survival of BCSCs from the trastuzumab 
resistant cell population are dependent on Notch-1-mediated activation of MEK1/2-






Figure 28: MEK1/2 inhibition reduces trastuzumab resistant BCSC survival. 
A. BT474TR cells were transfected with SCBi, Notch-1i, and/or PTENi-A for 48 
hours. Post transfection, cells were harvested and 100,000 live cells / well were 
seeded into 10 μg/mL DMSO (left) or U0126 (right) inoculated mammosphere 
media in a 6 well plate and incubated for 10 days. On day 10, mammospheres 
were harvested in PBS and counted. Mean percent mammosphere forming 
efficiency (%MFE) which was calculated as [(number of mammospheres counted 
/ number of cells seeded) X 100] from triplicate wells. B. Representative 
photographs of BT474TR mammospheres from A at 20x magnification before 
harvest. Scale bare = 50m. 
     Constitutive MEK1/2 activity and ERK1/2 phosphorylation does not 
rescue BCSC survival of trastuzumab resistant cells from Notch-1 inhibition. 
Since the survival of BCSCs from the resistant cell population is dependent on 
MEK1/2-ERK1/2 activity, we tested whether constitutive MEK1/2-ERK1/2 activity 
is sufficient to rescue %MFE in response to Notch-1 knockdown. We assessed 
%MFE of resistant cells transfected with a scrambled control or a Notch-1 siRNA 
plus a vector control (pEXP) or the MEK1DD mutant. The results showed that 





rescue BCSCs from these inhibitory effects (Figure 29). Surprisingly, expression 
of MEK1DD with the control siRNA inhibited %MFE similarly to Notch-1 
knockdown. One main problem with this assay could have been that expression of 
MEK1DD and increased ERK1/2 phosphorylation was not maintained in the 
mammosphere culture up to 10 days. Alternatively, hyper-activation of ERK1/2 
could potentially be detrimental to the survival of BCSCs. These studies need to 








Figure 29: Constitutive activation of ERK1/2 does not promote resistant 
BCSC survival.  
A. BT474TR cells were transfected with SCBi or Notch-1i and MEK1DD or pEXP 
expression vectors for 48 hours. Post transfection, cells were harvested and 
100,000 live cells / well were seeded into mammosphere media in a 6 well plate 
and incubated for 10 days. On day 10, mammospheres were harvested in PBS 
and counted. Mean percent mammosphere forming efficiency (%MFE) which was 
calculated as [(number of mammospheres counted / number of cells seeded) X 
100] from triplicate wells. B. Representative photographs of BT474TR 
mammospheres from A at 20x magnification before harvest. Scale bare = 50m. 
     Notch-1 and PTEN siRNAs do not have off target effects on trastuzumab 
resistant BCSCs. Previous work in the resistant bulk cell population demonstrated 
than PTEN siRNA B has an off target effect on resistant cell proliferation. We 





not due to off target effects. To address this issue, we transfected resistant cells 
with a scrambled control, secondary Notch-1 (#2), and/or PTEN-A siRNAs and 
performed mammosphere forming assay to assess %MFE (Figure 30A and B). 
The %MFE results were similar to the previous results using distinct siRNAs 
(Figure 30). These data confirm that Notch-1- mediated inhibition of PTEN is 
necessary to promote survival and self-renewal of BCSCs from trastuzumab 








Figure 30: Distinct Notch1 and PTEN siRNAs Produce Similar Effects in 
BCSCs.  
A. BT474TR cells were transfected with SCBi, secondary Notch-1 siRNA (Notch-
1 #2) and/or PTENi-A for 48 hours. Post transfection, 100,000 live cells were 
seeded / well into mammosphere media and incubated for 10 days. % MFE was 
calculated as [(number of mammospheres counted / number of cells seeded) X 
100] from triplicate wells. B. Representative photographs of BT474TR 








Specific Aim 3. Determine if Notch-1-mediated repression of PTEN is 
necessary for trastuzumab resistant tumor initiating potential in vivo. 
The goal of specific aim 3 is to test the following hypotheses: 
 Aim 3A: Determine if Notch-1-mediated inhibition of PTEN is necessary for 
tumor initiation.   
 Aim 3B: Discern the co-expression profile of Notch-1 and PTEN and if this 
co-expression predicts outcome in patients with breast cancer. 
Aim 3A: Determine if Notch-1-Mediated Inhibition of PTEN is Necessary For 
Tumor Initiation.   
     Rationale. The data from the mammosphere assays demonstrate that the 
survival and self-renewal of resistant BCSCs are dependent on Notch-1-mediated 
repression of PTEN. These results encouraged us to determine if Notch-1-
mediated inhibition of PTEN was necessary for tumor formation in a mouse tumor 
xenograft model. Due to a lack of pharmacological means to specifically inhibit 
Notch-1 and PTEN, we inhibited Notch-1 and PTEN using siRNAs as in our in vitro 
studies which have demonstrated the ability to persistently inhibit target gene 
expression for an extended period of time. Pandya et al. showed that GSI can 
reduce BT474TR tumor xenograft growth and recurrence (Pandya et al., 2011). 
However, GSI is a pan Notch inhibitor, and bulk BT474TR cells were used to create 
resistant tumor xenografts in a nude mouse model. However, the specific role and 
contribution of Notch-1 on trastuzumab resistant BCSC tumor xenografts remained 





reduce BCSC tumor xenograft formation and if this inhibition can be recovered by 
combined knockdown of Notch-1 and PTEN in vivo.  
     Notch-1-mediated inhibition of PTEN promotes trastuzumab resistant 
breast cancer stem cell tumor formation in vivo. Breast tumor xenografts were 
generated from resistant BCSCs. BT474TR cells were transfected with a 
scrambled control, Notch-1, and/or PTEN siRNAs and incubated in mammosphere 
media for 10 days. The primary mammospheres were harvested and 
disaggregated into single cells. 10,000 live, primary mammosphere-derived cells 
in PBS were mixed at a 1:1 ratio with matrigel and subcutaneously injected into 
the mammary fat pads of FOXN1-null, athymic, nude mice. Injection of the cells 
was followed by implantation of an estrogen capsule to provide a constant release 
of estrogen as BT474 cells express moderate levels of ER and require estrogen 
for optimal growth. Tumors were allowed to grow for 12 weeks at which time some 
tumors had reached the maximum cross sectional area (0.5cm2) allowed and all of 
the tumors were harvested. The results demonstrate that Notch-1 knockdown 
prevented tumor formation while the combined Notch-1 and PTEN knockdown 
rescued tumor formation compared to Notch-1 or PTEN siRNA (Figure 31A – C). 
Additionally, tumor growth rates and volumes were similar in the control, PTEN, 







Figure 31: Notch-1 mediated inhibition of PTEN promotes trastuzumab 
resistant breast cancer stem cell xenograft tumor formation in vivo. 
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours. 
Post transfection, the cells were harvested and seeded in mammosphere media 
at 100,000 cells/ well in a 6 well plate for 10 days. After 10 days, the primary 
mammospheres were harvested and trypsinized into single cells. 10,000 live cells 
in 50 μl of PBS were mixed with 50 μl of Matrigel and subcutaneously injected 
bilaterally into the mammary fat pads of athymic nude mice along with a 17β-
estradiol capsule. Mice were monitored for tumors weekly for 12 weeks. The 
Kaplan-Meier curves and log rank test (<0.0001) displays percent tumor free mice 
in SCBi, Notch-1i, PTENi, and Notch-1i combined with PTENi tumor-bearing mice. 
B. Photographs of SCBi, Notch-1i and/or PTENi treated BCSC tumor formation 
(red circles) in nude mice. C. SCBi, Notch-1i and/or PTENi treated BCSC tumors 










Figure 32: Notch-1 is required for Trastuzumab resistant breast cancer 
stem cell xenograft tumor growth in vivo. 
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours. 
Post transfection, the cells were harvested and seeded in mammosphere media 
at 100,000 cells/ well in a 6 well plate for 10 days. After 10 days, the primary 
mammospheres were harvested and trypsinized into single cells. 10,000 live cells 
in 50 μl of PBS were mixed with 50 μl of Matrigel and subcutaneously injected 
bilaterally into the mammary fat pads of athymic nude mice along with a 17β-
estradiol capsule. Tumors in mice were measured (l X w) weekly for 12 weeks to 
determine average tumor volume for each treatment group weekly.  B. Final tumor 
sizes at week 12 for each treatment group. Asterisk (*) denotes statistical 
significance compared to SCBi mean tumor volume as calculated using a one-way 
ANOVA with an overall statistical significance of p < 0.06.   
 Taken together, these results demonstrate that Notch-1 is required for 
trastuzumab resistant tumor initiation and BCSC self-renewal in vivo. Furthermore, 
Notch-1-mediated repression of PTEN is necessary for self-renewal of 
trastuzumab resistant BCSCs.  
Aim 3B: Discern the Co-Expression Profile of Notch-1 and PTEN and if this 
Co-Expression Predicts Outcome in Women With Breast Cancer. 
 The data thus far suggest that an inverse relationship between Notch-1 and 
PTEN expression may increase trastuzumab resistance as well as promote a 
worse outcome for women with HER2+ breast cancer. We used the Oncomine 





assessed Notch-1 and PTEN RNA transcript expression in human breast tumor 
samples (Curtis et al., 2012; Bonnefoi et al., 2007; Hatzis et al., 2011). Analysis of 
Notch-1 and PTEN co-expression as well as their effect on patient survival time 
was performed by Dr. Jun Li from the University of Notre Dame. The goal of aim 
3B is to determine if an inverse relationship between Notch-1 and PTEN 
expression exists in breast tumors and if this relationship has an effect on overall 
survival outcome in patients with breast cancer.  
     There is a potential inverse relationship between Notch-1 and PTEN co-
expression in breast cancer patient tumors. RNA can be extracted from core 
biopsies of breast cancer patient tumors and analyzed by microarray screening. 
Analysis of microarray data can determine variations in gene expression between 
patient samples. This high-throughput screening technology can determine 
differences in gene expression between multiple patient samples. For instance, 
gene expression profiling by microarray screening can determine gene alterations 
in patients responding to a treatment compared to patients that aren’t responding 
to a treatment. These data can determine if particular genes are up or 
downregulated to induce resistance to a particular cancer treatment regimen. 
Here, we identified three cohorts of microarray data sets (Curtis, Bonnefoi, and 
Hatzis) that expressed Notch-1 and PTEN (Curtis et al., 2012; Bonnefoi et al., 
2007; Hatzis et al., 2011). First, Dr. Li used Spearman’s correlation coefficient to 
assess if there is a relationship between Notch-1 and PTEN expression in each 





and PTEN exists in the Bonnefoi cohort (Table 3, top). Conversely, there appears 
to be no relationship between Notch-1 and PTEN in the Curtis or Hatzis cohorts as 
this analysis did not reach statistical significance. It is important to note that these 
cohorts contain both HER2-positive and HER2-negative patient samples. The 
HER2+ patient samples were analyzed in the largest cohort (Curtis) but the 
number of HER2+ tumors was very small and did not produce statistically 
significant results. 
 
Table 3: Inverse expression of Notch-1 and PTEN in breast cancer patient 
tumors is associated with poorer outcome. 
Top, correlation of Notch-1 and PTEN co-expression in each of the three breast 
microarray datasets as calculated by Spearman’s correlation coefficient. Bottom, 
co-expression of high Notch-1 and low PTEN correlates with an overall increase 
in patient survival time in the Curtis Breast dataset as determined by the Cox 
proportional hazards model. The log-rank test p-value = 0.001262. 
     Co-expression of high Notch-1 and low PTEN predicts poorer breast 
cancer patient survival outcome. If there is an inverse relationship between 
Notch-1 and PTEN occurring one cohort of breast tumors, then this inverse 
relationship may negatively affect patient survival time. To this end, the effect of 
Notch-1 and PTEN expression on patient survival time was assessed using a Cox 
Co-Expression Correlations of Notch-1 and PTEN 
  Rank Correlation p-value 
Curtis 0.0141 0.515 
Bonnefoi -0.1537 0.052 
Hatzis -0.03651 0.412 
Cox Proportional Hazards Model 
  Hazard Function Estimate p-value 
Notch-1 Coeffecient 1.112 0.0636 





proportional hazards model in the largest cohort, the Curtis dataset. To this end, 
we found that co-expression of high Notch-1 and low PTEN in patient tumors 
significantly reduced survival time (p-value = 0.001262 by a log-rank test) (Table 
3, bottom).  
 Overall, these data indicate that an inverse relationship between Notch-1 
and PTEN occurs in 1 out of 3 microarray data cohorts. The inverse relationship 
between Notch-1 and PTEN may be associated with decreased overall patient 
survival time but we cannot say for sure as we would need further statistical 
analysis of microarray cohorts. Further analysis may need to include another 







 Trastuzumab has improved the treatment of HER2+ breast cancer by 
specifically blocking HER2 receptor activity. Trastuzumab combined with 
chemotherapy has been shown to reduce HER2-driven tumor growth. 
Unfortunately, resistance to trastuzumab treatment remains a major clinical 
problem. Determining the mechanism of trastuzumab resistance could improve 
trastuzumab-based therapies, avoid development of resistance, and may shed 
some light on mechanisms of resistance in other cancers. Here, we have shown a 
novel mechanism for Notch-1 as it is directly recruited to the PTEN promoter which 
correlates with reduced PTEN expression at the transcriptional level. Notch-1-
mediated inhibition of PTEN reduces dephosphorylation of ERK1/2 resulting in 
increase MAPK pathway activity in resistant cells. The Notch-1-PTEN-ERK1/2 
signaling axis promotes bulk cell proliferation as well as BCSC survival and self-
renewal. Notch-1-mediated inhibition of PTEN was shown to promote tumor 
initiation of resistant BCSCs while inhibition of Notch-1 alone blocked tumor 
formation in a mouse tumor xenograft model. Together these data present a new 
role for Notch-1 in which Notch-1 directly binds to the PTEN promoter potentially 
to inhibit PTEN transcript expression and promote trastuzumab resistant, HER2+ 






 The transcription of Notch target genes is facilitated by the formation of a 
Notch transcriptional complex (NTC). CBF-1 is a critical repressor of Notch target 
genes when NICD is not present. CBF-1 binds to a number of CBF-1 binding sites 
in the promoter of Notch target genes. Promoter bound CBF-1 recruits negative 
co-regulators such as SHARP and CtBP to block gene transcription in the absence 
of NICD (Oswald et al., 2005). Binding of NICD to CBF-1 allows the release of the 
negative co-regulators and the recruitment of co-activators to form the NTC. 
Proper NTC formation begins transcription of the Notch target gene. Our data 
shows that Notch-1 is both necessary and sufficient to inhibit PTEN transcript RNA 
levels possibly by directly binding to regions containing CBF-1 elements near the 
PTEN promoter. Notch-1 enrichment on the PTEN promoter may inhibit 
transcription in a number of ways. For instance, formation of the NTC may be 
incomplete at the PTEN promoter. As such, the CBF-1:NICD1 complex may fail to 
completely release all negative co-regulators or recruit all co-activators to initiate 
transcription. NTC formation begins with MAML-1 which is the lynch pin to 
formation of the NTC (Reviewed in Gordon et al., 2008). Previous work has shown 
that recruitment of MAML-1 alone to the CBF-1:NICD1 complex is a potent inhibitor 
of gene transcription in T-ALL (Weng et al., 2003). Additionally, failure to recruit 
the histone acetyltransferase, p300, would result in nearby histones remaining in 
a closed conformation with DNA, thereby blocking access of RNA polymerase II to 
the initiation start site. Moreover, competition between transcription factors for co-





in the nucleus. Previous work has shown that MAML-1 is necessary for the proper 
formation of several transcription complexes such as p53 (Zhao et al., 2007) and 
β-catenin (Alves-Guerra et al., 2007). These data allow us to form several 
hypotheses as to how NICD1 could be involved in the inhibition of PTEN 
transcription, all of which would require further investigation. 
 Notch-1-mediated inhibition of PTEN may be caused by interactions with 
transcription factors that regulate transcription of PTEN. For instance, previous 
work has shown that p53 can bind to MAML-1 in the NTC (Yun et al., 2015) 
resulting in inhibition of Notch transcriptional activity in an in vitro breast cancer 
model. By this rationale, an increase in p53 expression may increase recruitment 
of p53 to the NTC thereby inhibiting NICD1 from activating transcription of PTEN. 
In agreement with this scenario, it was shown that co-expression of HER2 and p53 
correlated with higher rates of cancer recurrence and poorer overall survival 
(Yamashita et al., 2003). Additionally, the cell models used here, BT474 and 
HCC1954 have Y163C and E285K missense mutations, respectively, that have 
been shown to increase the stability of p53 resulting in accumulation of a putative 
active form of p53 in the nucleus (www.atcc.org).  
 Notch paralogues may compete to form NTCs and this competition could 
regulate PTEN transcription. Our lab has observed that both Notch-3 and Notch-4 
expression are increased in resistant cells upon HER2 blockade using 
trastuzumab (Data generated by Dr. Kinnari Pandya). Presumably, the four Notch 





recruitment of the co-activators needed for proper NTC formation. Competition for 
p300 has been seen among different Notch paralogues and mutant forms of the 
Notch receptor (Oswald et al., 2001) as well as between NFκB and estrogen 
receptors in heart smooth muscle cells (Speir et al., 2000). Additionally, previous 
research has demonstrated transcriptional inhibition among Notch paralogues 
through cooperative binding between two CBF-1-NICD-MAML1 complexes. The 
orientation of CBF-1-NICD-MAML complexes on the promoter determines their 
ability to initiate transcription (Nam et al., 2007). But, inhibition of PTEN 
transcription by Notch-1 has been previously described by Graziani et al. in which 
NICD1 is directly recruited to the PTEN promoter to inhibit its transcription in a 
NSCLC model (Graziani et al., 2008). Together these data indicate that NICD1 
may inhibit transcription of PTEN through multiple possible mechanisms. 
 NICD1 overexpression in trastuzumab sensitive cells results in minimal 
reduction of PTEN transcript expression indicating that the transcription of PTEN 
in sensitive cells differs from transcription of PTEN in resistant cells. As the 
sensitive cells are treated with trastuzumab over an extended period of time, we 
presume they acquire changes in their genomic landscape that may alter how 
PTEN transcription is activated or repressed. By this hypothesis, the promoter of 
PTEN may be crowded with transcriptional activators that keep PTEN expression 
high in sensitive cells. In sensitive cells, Tremendous over expression of Notch-1 
may be able to interact with PTEN transcription factors on the PTEN promoter by 





promoter in the resistant cell may lack some of the transcriptional activators at the 
PTEN promoter compared to the sensitive cell or may have room for Notch-1 to 
bind to and counteract these activators or actively repress PTEN transcript 
expression in resistant cells. Regardless, thorough analysis or both sensitive and 
resistant PTEN promoters and the effects of NICD1 on PTEN transcriptional 
activity should be done to address these hypotheses.  
 Indirect inhibition of PTEN by Notch-1 has been shown to occur in several 
types of cancer. PTEN inhibition by Notch-1 has been shown to occur through 
Notch-1-mediated upregulation of the transcriptional repressor, HES-1 (Palomero 
et al., 2007). Aberrant Notch-1 activity in T-ALL cells, due to mutations, results in 
increased expression of HES-1, a direct Notch target gene. HES-1 is directly 
recruited to the PTEN promoter to inhibit transcription of PTEN. Such is not the 
case in trastuzumab resistant cells, as knockdown of HES-1 had no effect on 
PTEN RNA transcript levels (Figure 33). Indirect inhibition of PTEN by Notch-1 has 
been shown to occur through regulation of the NFκB pathway. Work by Du et al. 
has shown that the p65 (RelA), a subunit of NFKB, increases PTEN transcription 
in trastuzumab resistant cells (Du et al., 2014). In this work, Notch-1 was shown to 
sequester p65 in the cytoplasm thereby inhibiting its ability to enter the nucleus 
and initiate transcription of PTEN. Moreover, Notch-1 has been shown to 
upregulate the NFkB pathway in TNBC (Li et al., 2016) and in HER2-negative 
BCSCs (Mao et al., 2013) suggesting a possible feedback mechanism between 





these data do not speak to direct inhibition of PTEN by Notch-1, indirect inhibition 







Figure 33: HES-1 has no effect on PTEN RNA transcript expression. 
BT474TR cells were transfected with SCBi or HES-1i for 48 hours. Post 
transfection, relative expression of HES-1 (left) and PTEN (right) was measured 
by RT-PCR. 
 Other than direct transcriptional repression of PTEN, inhibition of PTEN can 
be facilitated by modification of the PTEN protein to block its phosphatase activity. 
Post-translational modification of PTEN activity is exemplified by its acetylation. 
Acetylation of PTEN promotes binding to PCAF which facilitates its entry into the 
nucleus, loss of PI3K regulation, and an increase in cell cycling (Okumura et al., 
2006). Silent mating type information regulation 2 homolog 1 (SIRT1) has been 
shown to facilitate inhibition of PTEN nuclear translocation by deacetylation of the 
PTEN PDZ domain (Ikenoue et al., 2008) (Figure 9). Deacetylation of PTEN by 
SIRT1 inhibits its nuclear activity such as dephosphorylation of MAPK effectors. 





survival and DFS in breast cancer patients (Cao et al., 2014). These results 
suggest that crosstalk between Notch-1 and SIRT1 may occur to regulate PTEN 
protein activity as well in resistant cells.  
 The role of the Akt pathway in the trastuzumab resistant model presented 
here remains controversial. Our results show that Notch-1-mediated inhibition of 
PTEN has little to no effect on the phosphorylation status of Akt. This finding was 
observed in two distinct models of trastuzumab resistant breast cancer cells, 
BT474 and HCC1954. This finding is counterintuitive to the lipid phosphatase 
activity of PTEN on PIP3. These results suggest that PTEN may have lost the ability 
to dephosphorylate PIP3, PIP3 is not responsive to PTEN phosphatase activity, or 
that Notch-1 may be regulating phosphorylation of Akt through other proteins 
capable of changing the phosphorylation status of Akt. One other possible 
explanation is that the resistant cells used in these experiments have a H1047R or 
K111N PIK3CA missense mutation (www.atcc.org) resulting in increased catalytic 
activity of the p110 subunit of PI3K that can counter act PTEN-mediated inhibition 
of PI3K activity. 
 Characterization of our acquired resistant cells shows that these cells 
express markers of trastuzumab resistance: increased IGF-1R and decreased 
p27Kip1 compared to sensitive cells (Personal Communication with Dr. Pandya). 
Additionally, the resistant cells express more Hrg-2 and less HER4 protein 
compared to sensitive cells. Hrg-2 and HER4 are two novel markers of 





work has shown that the expression of Hrg-1 is upregulated by an increase in 
ectodomain shedding of nascent Hrg-1 by ADAM10 (Ebbing et al., 2016). 
Upregulation of Hrg-1 results in increased activation of HER3 in acquired 
trastuzumab resistant esophageal cancer. Analysis of our acquired trastuzumab 
resistant HER2+ breast cancer cells showed an increase in Hrg-2 over Hrg-1 
compared to sensitive cells hence Hrg-2 may be contributing to trastuzumab 


















Figure 34: Notch-1 is a master regulator of IGF-1R, p27Kip1, HER4, PTEN, 
and Hrg-2 in trastuzumab resistant cells. 
 Notch-1 knockdown reverses the expression of proteins and RNA 
transcripts associated with trastuzumab resistance (Personal Communication with 
Dr. Pandya). This suggests that Notch-1 is potentially regulating many of the 
markers of trastuzumab resistance. Furthermore, preliminary ChIP assays of 
NICD1 enrichment at CBF-1 sites on the HER4, IGF-1R, and Hrg-2 promoters 
show an increase in endogenous NICD1 enrichment in resistant compared to 
sensitive cells as well as in sensitive cells overexpressing NICD1 compared to the 





markers by Notch-1 may affect downstream phosphorylation of Akt. One such 
Notch-1 target, HER4, is downregulated in resistant cells. Much like PTEN, 
knockdown of Notch-1 increased HER4 protein and RNA expression (Personal 
Communication with Dr. Pandya). Similarly, overexpression of NICD1 reduced 
expression of HER4 RNA transcripts (Figure 35). HER4, like HER2, can increase 
downstream phosphorylation of Akt. Notch-1-mediated inhibition of HER4 and 
PTEN could potentially have compensatory effects on the phosphorylation status 
of Akt. For example, Notch-1 knockdown would increase HER4 expression to 
sustain PI3K activation and thus maintain Akt activity regardless of upregulation of 
PTEN. As such, PTEN attenuates PI3K-mediated phosphorylation of Akt which 
can be negated by HER4-mediated PI3K activation thereby limiting the overall 
effect of Notch-1 on the phosphorylation of Akt and Akt activity. Taken together, 
these data indicate that Notch-1 may act as a master regulator of several markers 
of trastuzumab resistance. As such, Notch-1 may have little to no overall effect on 
the phosphorylation of Akt and Akt pathway activity in HER2+, trastuzumab 




















Figure 35: Notch-1 overexpression reduces HER4 transcript expression. 
BT474TS cells were transfected with NICD1 or pcDNA3 expression vectors for 48 













Figure 36: Notch-1 is directly recruited to the HER4, IGF-1R, and Hrg-2 
promoter. 
A-C. BT474TR and BT474TS cells were fixed, fragmented, and chromatin was 
immunoprecipitated by a C-terminal Notch-1 (Santa Cruz Notch-1 Ab) or control 
IgG antibody. Purified DNA from Notch-1 or IgG immunoprecipitated chromatin 
was used to quantify NICD1 enrichment of HER4 (A), IGF-1R (B), or Hrg-2 (C) 
promoters by qPCR using primers specific to a CBF-1 binding site in the HER-4, 
IGF-1R, or Hrg-2 promoter (maps above bar graphs). D-F. BT474TS cells were 
transfected with NICD1 or pcDNA3 expression vectors for 48 hours. Post 
transfection, cells were harvested, fixed, fragmented, immunoprecipitated by 
Notch-1 or IgG antibodies, and NICD1 enrichment of HER4 (D), IGF-1R (E), or 
Hrg-2 (F) promoters was quantified by qPCR using the same HER-4, IGF-1R, or 
Hrg-2 primers as in A-C. 
 Notch-1 has been shown to regulate downstream effectors of the Akt 
pathway.  Previous work has shown that Notch-1 can upregulate cyclin D1 which 
results in activation of CDK 4/6 to increase proliferation of T-ALL cells (Choi et al., 
2012). A similar increase of cyclin D1 has been observed in resistant breast 
cancer, yet the role of Notch-1-mediated upregulation of cyclin D1 has yet to be 





cells showed that expression of p27Kip1 is decreased (Nahta et al., 2004). Our 
resistant cells display a decrease in p27Kip1 protein expression compared to 
sensitive cells (Personal Communication with Dr. Pandya). More importantly, 
Notch-1 knockdown caused an increase in p27Kip1 expression in resistant cells 
suggesting that Notch-1 may regulate downstream p27Kip1 expression (Personal 
Communication with Dr. Pandya). p27Kip1 downregulation may occur through 
Notch-1-mediated upregulation of IGF-1R which has been shown to decrease 
downstream p27Kip1 expression in trastuzumab resistant, SkBr3 cells (Lu et al., 
2004). These data suggest that Notch-1 may regulate proteins downstream of the 
Akt pathway to contribute to resistant cell growth.  
 Specifically targeting Notch-1 in the resistant cell model may affect the 
expression of other proteins in an effort to adapt to the loss of Notch-1 expression. 
As seen in the development of trastuzumab resistance, HER2+ cancer cells can 
adapt to specifically targeting the HER2 receptor through upregulation of Notch-1. 
Similarly, T-ALL cells can adapt to GSI treatment by upregulating downstream Akt 
pathway activity through inhibition of PTEN. Cancer cells take advantage of the 
number of redundancies that control cell proliferation and survival in order to 
continue to survive under a multitude of treatment conditions. By this hypothesis, 
cancer cells can continue to grow and adapt to changing environmental conditions. 
As such, specifically targeting Notch-1 may alter the expression of other proteins 





 The role of the MAPK-ERK1/2 pathway in trastuzumab resistant bulk breast 
cancer cells may differ from its role in the resistant BCSCs. Our data show that 
inhibition of ERK1/2 phosphorylation by treatment with the MEK1/2 inhibitor, 
U0126 reduces both bulk (Figure 23A) and BCSC (Figure 28A and B) proliferation 
and survival, respectively. Constitutive expression of an active MEK1 (MEK1DD) 
rescues bulk resistant cell proliferation from Notch-1 inhibition (Figure 24A and B) 
but does not have the same effect on BCSC survival (Figure 29A and B). These 
data present a disconnect between MAPK activity in resistant bulk and BCSCs in 
which MAPK activity is required to promote bulk cell proliferation but not BCSC 
survival. It is important to note that the experiments using the MEK1DD expression 
vector were done in triplicate. Also, the Notch-1i/MEK1DD transfected cells used 
in the bulk cell proliferation assay were the same cells used in the mammosphere 
assay thereby reducing technical mistakes between the two experiments. None 
the less, expression of the MEK1DD plasmid may not have been able to maintain 
phosphorylation of ERK1/2 in the mammosphere culture for 10 days. Alternatively, 
hyper-activation of ERK1/2 could potentially be detrimental to the survival of 
BCSCs. These studies need to be repeated using constitutively active MEK1DD 
stable cell lines to confirm these results. 
 Differences in the effect of constitutive MEK1 activity in resistant bulk and 
BCSCs may occur for several different reasons. One reason may be that the 
mammosphere assay is unable to assess changes in the mesenchymal stem cell 





changes in the epithelial stem cell population through the formation of 
mammospheres. FACS analysis can allow us to sort and analyze specific cell 
populations such as the epithelial and mesenchymal BCSC subpopulations or the 
bulk and BCSC subpopulations. Further assessment of the resistant BCSC 
population may reveal Notch-1-mediating downstream pathways to promote 
enrichment of the BCSC population, proliferation of stem cell-like populations, or 
potentially dedifferentiating or transdifferentiating subpopulation of cells that are in 
between stem and differentiated states. Additionally, we can determine the effect 
of Notch-1 and/or PTEN knockdown on the different subpopulations within our 
resistant cell models. Assessment of the role Notch-1 plays in augmenting the 
stem-like state of resistant cells can be addressed in future studies.  
 The results presented here focus on downstream activity of the PI3K/Akt 
pathway in bulk cells but not in the BCSC population. Preliminary data 
demonstrated the ability of constitutively activated Akt (Myr-Akt) to partially rescue 
trastuzumab resistant bulk cell proliferation from Notch-1 inhibition (Figure 37A-C). 
One explanation for this effect is that any stimulation of a downstream pathway 
that promotes cell survival will be taken advantage of by the cancer cell. Another 
possible explanation is that the Akt pathway is used by the BCSCs to promote 
differentiation and bulk cell proliferation. The Akt pathway has been implicated in 
promoting enrichment of the BCSC population and drug resistance (Berns et al., 
2007). Here, resistant cells may be dependent on Akt activity in some capacity. 





BCSC population may have initially been mediated through the Akt pathway. Initial 
Akt pathway activation could be mediated through repression of PTEN, or one of 
the many other proteins regulated by Notch-1, enabling the cell to evade and 
survive under constant trastuzumab treatment.  
 
Figure 37: Constitutive activation of Akt promotes trastuzumab resistant 
cell proliferation.  
A-B. BT474TR cells were transfected with SCBi or Notch-1i and Myr-Akt1 or pUSE 
expression vectors for 48 hours. Post transfection, cells were harvested and 
seeded at 100,000 cells / well of a six well plate and treated daily with 20 μg/mL of 
PBS (A) or trastuzumab (B) for 10 days. After treatment, the cells were harvested 
and counted. Mean proliferation was calculated as the number of live cells 
harvested / number of live cells seeded. Asterisk (*) denotes statistical significance 
compared to SCBi or (**) Notch-1i mean proliferation as calculated using a one-
way ANOVA with an overall statistical significance of p < 0.0001 from three 
independent experiments. C. Total cellular Notch-1, Akt, β-Actin, phosphorylation 
of Akt-1 at threonine308 (PThr308-Akt1) and serine473 (PSer473-Akt1) protein 
expression from the transfected cells post 48 hour PBS (left) or trastuzumab (right) 





 Recent research has shown that a loss of PTEN can promote dependency 
on the MAPK pathway as inhibition of PTEN was found to be required for MEK1 
signaling in a HER2+ breast cancer model (Ebbesen et al., 2016). Initial 
dependence of the resistant cell on Notch-1 mediated activation of the Akt pathway 
through inhibition of PTEN could have switched to activation of the MAPK pathway 
to promote bulk cell proliferation but not BCSC survival. Downstream pathway 
activation may be dependent on the receptors available to dimerize with HER2. It 
has been shown that HER2 homodimers increase downstream MAPK signaling 
while HER2 heterodimers increase downstream Akt signaling (Reviewed in 
Yarden and Sliwkowski, 2001) (Chan et al., 2005). In contrast, the BCSC 
population is dependent on Akt pathway activity while the bulk cells are dependent 
on MAPK activity. Moreover, Notch-1 may increase ERK1/2 phosphorylation by 
non-canonical means as previous students in our lab have shown that membrane 
bound Notch-1 may be required for increased ERK1/2 phosphorylation and MAPK 
activation in vitro. Further assessment of the Akt and MAPK pathways during the 
development of trastuzumab resistance in vitro may shed some light onto the 
pathway used by bulk or BCSCs as resistance to trastuzumab treatment occurs. 
     Conclusion. 
 The crux of the research presented here demonstrates that trastuzumab 
resistant, HER2+ breast cancer cells have shifted their growth dependence from 
HER2 to Notch-1. Specifically targeting Notch-1 in resistant cell models inhibits 





work presented here we describe an important mechanism by which Notch-1 
promotes trastuzumab resistant, HER2+ breast cancer bulk cell proliferation and 
BCSC survival and self-renewal by repressing PTEN to maintain MAPK-ERK1/2 
activity (Summarized in Figure 12). We have set forth data that show the adverse 
effect of Notch-1 and PTEN co-expression on the survival time of breast cancer 
patients. Together, these data make the case for an investigation to determine the 
importance of Notch-1 and PTEN co-expression status as predictive markers for 
trastuzumab sensitivity in women with HER2+ breast cancer. Currently, clinical 
trials using the Notch-1 specific antibody [OMP-52M51 (Brontictuzumab)] are 
underway and should yield results soon (ACC trial, 2015). Furthermore, PTEN and 
Notch-1 expression status could deliver information for a clinical trial to validate a 
combinatorial approach using a Notch-1 biologic with a MEK-ERK inhibitor to 








 Our research demonstrates that Notch-1 represses PTEN in HER2+ breast 
cancer cells. Inhibition of PTEN results in an increase in phosphorylation of MEK1-
ERK1/2 to promote resistant cell proliferation, BCSC survival and self-renewal, as 
well as contributing to tumor initiating potential in a mouse tumor xenograft model.  
 An area of controversy in these data is that constitutive activation of MEK1 
in resistant BCSCs is not sufficient to rescue BCSC survival from inhibition of 
Notch-1. We would like to affirm these results by repeating this experiment using 
a resistant cell line with stable expression of constitutively active MEK1. 
Constitutive MEK1 activity will increase ERK1/2 phosphorylation and maintain 
MAPK pathway activity in the cell. We propose to use the MEK1 stable cell line 
with or without Notch-1 knockdown in primary, and possibly secondary, 
mammosphere assays. These assays would determine if constitutive activation of 
MEK1-ERK1/2 is sufficient to promote BCSC survival and self-renewal compared 
to Notch-1 knockdown. These mammosphere experiments could provide some 
insight into the dependency of the resistant BCSCs on Notch-1-mediated activation 





 These data presented here show that overexpression of NICD1 in sensitive 
cells was not able to induce trastuzumab resistance. These studies could be 
complimented with the creation of a stable sensitive cell line constitutively 
expressing activated MEK1. Previous work has shown that an increase in Notch-
1 and Ras-MAPK pathway activity is necessary for TNBC BCSC survival and 
possibly drug resistance. By this hypothesis, our sensitive cells may require an 
increase in both Notch-1 and MAPK pathway activity to become resistant to 
trastuzumab treatment. Under this assumption, constitutively active MEK1-
expressing sensitive cells can be transfected with NICD1 and treated with 
trastuzumab to determine if they lose sensitivity to trastuzumab treatment. 
Additionally, sensitive cells can be simultaneously transfected with NICD1 and 
PTEN siRNA in an attempt increase downstream MAPK activity and induce 
trastuzumab resistance. These experiments may determine the pathways 
necessary for sensitive cells to acquire resistance to trastuzumab treatment. 
 PTEN phosphatase activity is dependent on its location within the cell. As 
previous work has shown, cytoplasmic PTEN reverses the effects of PI3K on Akt 
activity and promotes cell death whereas nuclear PTEN attenuates ERK1/2-MAPK 
activity and promotes cell quiescence. Here, Notch-1 is shown to inhibit PTEN 
resulting in increased phosphorylation of ERK1/2 to promote resistant cell 
proliferation and possibly tumor initiating potential. This hypothesis presumes that 
PTEN is dephosphorylating ERK1/2 in the nucleus to induce resistant cell 





the resistant cells and its phosphatase activity in the nucleus or cytoplasm. To this 
end, we can determine if PTEN nuclear localization drives dephosphorylation of 
ERK1/2 in resistant cells using resistant cells that stably express NLS mutant 
PTEN constructs that inhibit PTEN nuclear localization. Similar to previous work 
done by Chung et al., resistant cells stably expressing the NLS mutant PTEN 
construct will have PTEN localized to the cytoplasm while wild-type PTEN is able 
to enter the nucleus. Additionally, the PTEN mutants are tetracycline inducible 
meaning that we can control PTEN nuclear entry with tetracycline treatment. We 
can assess the effects of cytoplasmic or nuclear PTEN by cell fractionation and 
Western blot analysis of nuclear and cytoplasmic cell fractions to determine the 
effect of PTEN on downstream Akt and ERK1/2 phosphorylation. Additionally, we 
can fluorescently label PTEN, Notch-1, Akt, and ERK1/2 to visualize where PTEN 
is localized in the cell in relation to Notch-1 and effectors of the Akt and MAPK 
pathways by fluorescent microscopy. Furthermore, we can assess the apoptotic or 
quiescent state of the resistant cells under Notch-1 and/or PTEN knockdown as 
well as cells expressing NLS mutant PTEN by propidium iodide staining for FACS 
analysis or terminal deoxynucelotide transferase dUTP nick end labeling (TUNEL) 
for fluorescent microscopy. Together, these data will determine if the location of 
PTEN effects its phosphatase activity as well as the state of resistant cells after 
Notch-1 and/or PTEN inhibition. 
 Further assessment of NICD1 enrichment at gene promoters would be 





proliferation, BCSC survival, self-renewal, and tumor initiating potential. To further 
assess the role of Notch-1 in trastuzumab resistance, we would do an unbiased 
ChIP-on-ChIP microarray, and/or ChIP sequencing, to determine where on the 
human genome, NICD1 is binding to in our resistant cells compared to our 
sensitive cells. Additionally, we can use resistant cells with Notch-1 knockdown 
and sensitive cells with NICD1 overexpression as controls in the ChIP microarrays 
for comparison purposes. We have performed extensive ChIP studies that 
demonstrate that increased Notch-1 recruitment to several different gene 
promoters correlates with inhibiton of transcript expression of these genes in our 
resistant cells. We can perform the Notch-1 ChIP-ChIP microarray with other 
members of the NTC such as CBF-1, MAML-1, p300, or RNA polymerase II to 
determine if the DNA enriched by NICD1 pull-down also contain members of the 
NTC complex. In addition, we can perform luciferase assays to determine the 
effect of Notch-1 on transcription of PTEN as well as use the Crisper-cas system 
to mutate endogenous CBF-1 binding sites to confirm the role of Notch-1 in PTEN 
transcription. 
 Additional in vivo studies would allow us to determine the effects Notch-1 
and/or ERK1/2 inhibitors on growth of resistant tumor xenografts. Using the Notch-
1 antibody, Brontictuzumab, as well as an ERK1/2 inhibitor (PD 098059 or U0126) 
in vivo could give us clinical insight into the effects of these drugs on resistant 
tumor growth and recurrence. We would use a resistant tumor xenograft model 





presented here. We would treat the mice with a Notch-1 antibody with or without a 
MEK1/2 inhibitor to determine their effects on tumor growth. Additionally, we can 
remove the treatments if complete regression is observed, to see if the tumors 
recur. If the tumors recur upon treatment removal, we can resume the treatments 
to assess their effect on reducing recurring tumors. Moreover, we can grow 
sensitive and resistant patient derived tumor xenografts (PDX) to evaluate the 
effects of Notch-1 and/or MEK-1 inhibition on patient tumors. These in vivo 
experiments will give us an idea of the efficacy of these inhibitors on reducing 
resistant tumor growth and recurrence as well as their potential for success in a 
clinical setting. 
 An interesting result in the data presented here is that resistant cells depend 
on activation of the MAPK pathway through inhibition of PTEN to promote bulk cell 
proliferation and BCSC survival. This is in contrast to a number of publications that 
show that an increase in Akt pathway activity, through the loss of PTEN, can drive 
trastuzumab resistance as well as enrichment of the BCSC population. Our results 
are more in line with current publications which state that the loss of PTEN is 
necessary for MEK1-mediated activation of the MAPK pathway in HER2+ breast 
cancer cells. The ability of PTEN to attenuate both Akt and MAPK pathways can 
have many effects on cancer development and resistance. One possibility is that 
inhibition of PTEN facilitates a shift from the Akt to the MAPK pathway as the cells 
become resistant to trastuzumab treatment. Another possibility is that different 





on either the Akt or the MAPK pathway. Further assessment of differences 
between bulk and BCSC subpopulations could determine if Notch-1-mediated 
inhibition of PTEN is driving dedifferentiation of bulk cells into BCSCs or keeping 
cells in a stem-like state to increase the BCSC population (Figure 38A).  
 
Figure 38: Sorting of BT474TR cells. 
Resistant BT474 cells can be sorted into bulk and BCSC (A) or epithelial and 
mesenchymal (B) BCSC subpopulations to discern differences in Akt and/or MAPK 
pathway activity. Inhibition of Notch-1 will allow us to determine if Notch-1 can 
regulate the number cells in each subpopulation. 
 We can further assess resistant cell subpopulations to determine if the 
BCSCs are in more epithelial or mesenchymal cell states and how this effects 
resistance and tumor growth. Previous work by Sun et al. demonstrated that 
BT474TS and BT474TR PTEN deficient cells display epithelial (ALDH+) and 
mesenchymal (CD44+/CD24-) morphology, respectively. They generated 
trastuzumab resistant cells by knockdown of PTEN combined with long term 
trastuzumab treatment (BT474-PTEN-LTT). Trastuzumab treatment combined 
with PTEN deficiency is proposed to transition epithelial stem cells into 
mesenchymal stem cells ultimately transforming the phenotype of trastuzumab 





this work by proposing that Notch-1-mediated regulation of PTEN and downstream 
activation of ERK1/2-MAPK may regulate EMT/MET in the resistant BCSC 
population and how this effects BCSC survival, self-renewal, and potentially 
tumorigenesis (Figure 38B). Sorting of resistant cells into subpopulations to 
determine how the Notch-1-PTEN-ERK1/2 signaling pathway effects their survival 
and/or proliferation would be important for future studies.  
 Development of the trastuzumab resistant model has been a source of 
intrigue as it would be interesting to see how the cells adapt to anti-HER2 treatment 
over time. Using the trastuzumab resistant cell model as an example, we would 
develop two acquired resistant cell models from BT474 and SkBr3 cell lines. In 
addition to these cell lines, we can acquire trastuzumab sensitive patient samples 
to assess changes in these cells as they are consistently exposed to anti-HER2 
treatment. We can use intrinsically resistant cell lines, such as the HCC1954 cells 
and resistant patient samples, as positive controls for resistance. The use of 
patient derived cells may give us a translational view of how cells from a patient 
can develop resistance to anti-HER2 treatments. Mimicking the development of 
the trastuzumab resistant cells, we will treat the sensitive cells with incrementally 
increasing doses of trastuzumab, pertuzumab, lapatinib, or TDM-1 over a 6-month 
period until they are resistant to high doses of the anti-HER2 treatment (Figure 39 
top). Over the course of the treatment, we will take samples from the cells on a 
monthly basis. These cells will be lysed and reverse transcribed into cDNA for 





prescribed treatment. Additionally, we will freeze down a number of cells for future 
assessment if need be. We can determine changes in Notch-1, PTEN, P-Akt, and 
P-ERK expression in the cells as they become resistant to the anti-HER2 
treatment. Moreover, we can sort the BCSC population from the bulk cell 
population to determine changes in these subpopulations over prolonged 
exposure to treatment. Together these data will determine if Notch-1 upregulation 










Figure 39: Experiment flow chart to determine efficacy of Anti-HER2 and 
Anti-Notch-1 targeted treatments 
Flow chart for the development of acquired resistant cells to anti-HER2 and anti-
Notch-1 (Brontictuzumab) targeted treatments in vitro (top). Sensitive and resistant 
cells will be injected into mice (bottom) to form tumor xenografts that are sensitive 
or resistant to their respective treatment. The tumors will be treated with the drugs 
they showed sensitivity/resistance to in vitro thereby demonstrating tumor 
sensitivity/resistance to the targeted treatment. Treatments can be stopped to 
assess recurrence and altered to determine efficacy of changing treatments to 
ablate tumor growth and/or formation. 
 Assessment of the cells as they become resistant may be better facilitated 
by microarrays to analyze changes in the whole genome, transcriptome, and 
proteome to give us an overall view of what is happening in the cell. Moreover, we 
can sort cells by high Notch-1 and low PTEN to determine when these changes 





Sequentially sampling cells as they become resistant to targeted treatment over 
time may allow us to pinpoint the time when cells acquire resistance. 
 If HER2+ cells can become resistant to targeted treatment of the HER2 
receptor, then they can also acquire resistance to targeted treatment of the Notch-
1 receptor. In accordance with this hypothesis, we would also like to look at the 
effect of persistent anti-Notch-1 (Brontictuzumab) treatment on trastuzumab 
resistant cells. If resistant cells become dependent on Notch-1 then resistant cells 
must become dependent on another receptor(s) or protein(s) when consistently 
treated with Brontictuzumab over time. Similar to the development of GSI 
resistance in T-ALL cells, we can assess our trastuzumab resistant cells for 
resistance to Brontictuzumab therapy in vitro. Additionally, the Brontictuzumab 
resistant cells may upregulate downstream Akt pathway activity to compensate for 
the loss of Notch-1 as previously seen in GSI resistant T-ALL cells. Comparable 
to the development and testing of trastuzumab resistant cell lines, we can also 
develop Brontictuzumab resistant cell lines from our trastuzumab resistant cells in 
an effort to predict how trastuzumab resistant HER2+ cancer may react to anti-
Notch-1 therapy (Figure 39 top). 
 Once we complete evaluation of acquired drug resistance to targeted 
treatments in a cell model, we can attempt to recreate resistant tumors in an in 
vivo mouse model. We will implant sensitive and resistant cells into mice to form 
tumor xenografts. The sensitive and resistant tumor xenografts can be treated to 





prescribed treatment. The treatment of resistant tumors can be stopped and 
started again to see if the treatment effects tumor recurrence. This method of 
treating resistant tumors can be done for several different treatments in an effort 
to mimic the in vitro course of acquiring resistance to targeted treatments. For 
example, we could implant several different sensitive and resistant cells into mice 
that resemble how the cells become resistant in vitro such as trastuzumab 
sensitive and resistant cells as well as Brontictuzumab sensitive and resistant cells 
(Figure 39). We would begin by treating the tumors with their respective drugs to 
show sensitivity and resistance to the initial treatments. As such, we can treat the 
trastuzumab resistant tumors with Brontictuzumab and the Brontictuzumab 
resistant tumors with the treatment found to stop their proliferation in vitro. 
Together, these data will give us insight into how resistance is developed in vitro 
in an in vivo model that we hope will translate into patients. 
 Recreating acquired resistant cells will allow us to track the changes that 
occur in cells as they become resistant to targeted treatments. Changes in protein 
and gene expression can be used to create a panel of genes that are altered to 
predict the acquisition of resistance in a patient. This panel could begin with 
changes in protein expression commonly observed at the first treatment and end 
with protein expression at the last treatment when the cells have acquired 
resistance. It can present the changes in proteins/genes over time to indicate if 
resistance is, or is not, occurring. Tendencies towards resistance or treatment 





produced to help the clinician determine if an alternative treatment is having an 
effect or not. Creating a flow chart for how to tell if a treatment is working or if 
resistance is occurring may help both the patient and the doctor react to developing 
refractory disease. 
 Development of the trastuzumab resistant model has been a source of 
intrigue as it would be interesting to see how the cells adapt to trastuzumab 
treatment over time. The continued development of treatments that specifically 
target one receptor or one protein may be promoting resistance in cancer. Cancer 
cells seem to take advantage of redundancies in the signal transduction pathways 
enabling them to grow and survive in a multitude of different treatments. By 
targeting certain proteins in cancer cells we may be motivating the cells to become 
more adaptive to targeted treatments. Like insects that are exposed to a number 
of different pesticides, or bacteria that are exposed to a number of different 
antibiotics, we may be creating cancer cells that are resistant to a number of 
different therapies. By this hypothesis, we could attempt to track the changes in 
the sensitive cell as they acquire resistance to trastuzumab, lapatinib, pertuzumab, 
TDM-1, chemotherapy, or any other therapies used to treat HER2+ breast cancer 










Abd, El-Rehim, D.M., Ball, G., Pinder, S.E., Rakha, E., Paish, C., Robertson, 
J.F., Macmillan, D., Blamey, R.W., Ellis, I.O. (2005). High-throughput 
protein expression analysis using tissue microarray technology of a large 
well-characterised series identifies biologically distinct classes of breast 
cancer confirming recent cDNA expression analyses. International Journal 
of Cancer, 116(3), 340-350. doi: 10.1002/ijc.21004. 
 
Abravanel, D.L., Belka, G.K., Pan, T-C., Pant, D.K., Collins, M.A., Sterner, 
C.J., Chodosh, L.A. (2015). Notch promotes recurrence of dormant tumor 
cells following HER2/neu-targeted therapy. The Journal of Clinical 
Investigation, 125(6), 2484-2496. doi: 10.1172/jci74883. 
 
Adachi, R., Horiuchi, S., Sakurazawa, Y., Hasegawa, T., Sato, K., Sakamaki, T. 
 (2011). ErbB2 down-regulates microRNA-205 in breast cancer. 
Biochemical and Biophysical Research Communications, 411(4), 804-808. 
doi: 10.1016/j.bbrc.2011.07.033. 
 
Adair, J.D., Harvey, K.P., Mahmood, A., Caralis, J., Gordon, W., Yanish, G. 
 (2008). Recurrent pure mucinous carcinoma of the breast with mediastinal 
great vessel invasion: HER-2/neu confers aggressiveness. The American 
Surgeon 74(2), 113-116.  
 
Adamczyk, A., Niemiec, J., Janecka, A., Harazin-Lechowska, A., Ambicka, 
A., Grela-Wojewoda, A., Domagała-Haduch, M., Cedrych, I., Majchrzyk, 
K., Kruczak, A., Ryś, J., Jakubowicz, J. (2015). Prognostic value of PIK3CA 
mutation status, PTEN and androgen receptor expression for metastasis-
free survival in HER2-positive breast cancer women treated with 
trastuzumab in adjuvant setting. Polish Journal of Pathology, 2, 133-141. 
doi: 10.5114/pjp.2015.53009. 
 
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli D, de 
Azambuja, E., Viale, G., Sotiriou, C., Piccart, M. (2014). Luminal B Breast 
Cancer: Molecular Characterization, Clinical Management, and Future 







Ahmed, M.A., Aleskandarany, M.A., Rakha, E.A, Moustafa, R.Z., Benhasouna, 
A., Nolan, C., Green, A.R., Ilyas, M., Ellis, I.O. (2012). A CD44-/CD24+ 
phenotype is a poor prognostic marker in early invasive breast 
cancer. Breat Cancer Research and Treatment, 133(3), 979-995. doi: 
10.1007/s10549-011-1865-8. 
 
Akiyoshi, T., Nakamura, M., Yanai, K., Nagai, S., Wada, J., Koga, K., Nakashima, 
H., Sato, N., Tanaka, M., Katano, M. (2008). y-Secretase Inhibitors 
Enhance Taxane-Induced Mitotic Arrest and Apoptosis in Colon Cancer 
Cells. Gastroenterology, (134)1, 131–144. doi: 
10.1053/j.gastro.2007.10.008. 
 
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F. 
(2003). Prospective identification of tumorigenic breast cancer cells. 
Proceedings of the National Academy of Sciences, 100(7), 3983-3988. doi: 
10.1073/pnas.0530291100. 
 
Al-Khouri, A.M., Ma, Y., Togo, S.H., Williams, S., Mustelin, T. (2005). Cooperative 
Phosphorylation of the Tumor Suppressor Phosphatase and Tensin 
Homologue (PTEN) by Casein Kinases and Glycogen Synthase Kinase 3β. 
Journal of Biological Chemistry, 280(42), 35195-35202. doi: 
10.1074/jbc.M503045200. 
 
Alves-Guerra, M.C., Ronchini, C., Capobianco, A.J. (2007). Mastermind-like 1 is a 
specific coactivator of beta-catenin transcription activation and is essential 
for colon carcinoma cell survival. Cancer Research, 67(18), 8690-8698. doi: 
10.1158/0008-5472.CAN-07-1720. 
 
American Cancer Society (ACS) (2015). Breast Cancer Facts and Figures 2015-
2016. Atlanta: American Cancer Society. 
 
Anastasi, S., Sala, G., Huiping, C., Caprini, E., Russo, G., Iacovelli, S., Lucini, 
F., Ingvarsson, S., Segatto, O. (2005). Loss of RALT/MIG-6 expression in 
ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency 
and favors resistance to Herceptin. Oncogene, 24(28), 4540-4548. doi: 
10.1038/sj.onc.1208658. 
 
Andrechek, E.R., White, D., Muller, W.J. (2004). Targeted disruption of ErbB2/Neu 
in the mammary epithelium results in impaired ductal outgrowth. Oncogene, 
24(5), 932-937. doi: 10.1038/sj.onc.1208230. 
 
Artavanis-Tsakonas, S. (1999). Notch Signaling: Cell Fate Control and Signal 







Arteaga, C. L., O'Neill, A., Moulder, S. L., Pins, M., Sparano, J.A., Sledge, 
G.W., Davidson, N.E. (2008). A Phase I-II Study of Combined Blockade of 
the ErbB Receptor Network with Trastuzumab and Gefitinib in Women with 
HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clinical Cancer 
Research, 14(19), 6277-6283. doi: 10.1158/1078-0432.ccr-08-0482. 
 
Asiedu, M.K., Beauchamp-Perez, F.D., Ingle, J.N., Behrens, M.D., Radisky, 
D.C., Knutson, K.L. (2013). AXL induces epithelial-to-mesenchymal 
transition and regulates the function of breast cancer stem cells. Oncogene, 
33(10), 1316-1324. doi: 10.1038/onc.2013.57. 
 
Ayyanan, A., Civenni, G., Ciarloni, L., Morel, C., Mueller, N., Lefort, K., Mandinova, 
A., Raffoul, W., Fiche, M., Dotto, G.P., Brisken, C. (2006). Increased Wnt 
signaling triggers oncogenic conversion of human breast epithelial cells by 
a Notch-dependent mechanism. Proceedings of the National Academy of 
Sciences, 103(10), 3799-3804. doi: 10.1073/pnas.0600065103. 
 
Azzam, D.J., Zhao, D., Sun, J., Minn, A.J., Ranganathan, P., Drews-Elger, 
K., Han, X., Picon-Ruiz, M., Gilbert, C.A., Wander, S.A., Capobianco, 
A.J., El-Ashry, D., Slingerland, J.M. (2013). Triple negative breast cancer 
initiating cell subsets differ in functional and molecular characteristics and 
in γ-secretase inhibitor drug responses. EMBO Molecular Medicine, 5(10), 
1502-1522. doi: 10.1002/emmm.201302558. 
 
Babiak, J., Hugh, J., Poppema, S., Significance of c-erB-2 amplification and DNA 
aneiploidy. Analysis in 78 patients with node-negative breast cancer. 
(1992).Cancer 70(4). 770-776.  
 
Bahena‐Ocampo, I., Espinosa, M., Ceballos‐Cancino, G., Lizarraga, F., Campos-
Arroyo, D., Schwarz, A., Garcia-Lopez, P., Maldonado, V., Melendez-
Zajgla, J. (2016). miR‐10b expression in breast cancer stem cells supports 
self‐renewal through negative PTEN regulation and sustained AKT 
activation. EMBO reports, 17(5), 648-658. doi: 10.15252/embr.201540678. 
 
Baker, A.T., Zlobin, A., Osipo, C. (2014). Notch-EGFR bidirectional crosstalk in 
breast cancer. Fronteirs in Oncology, 4(360), doi: 
10.3389/fonc.2014.00360. 
 
Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G., Datar, 
R.H., Cote, R.J. (2006). Most Early Disseminated Cancer Cells Detected in 
Bone Marrow of Breast Cancer Women Have a Putative Breast Cancer 







Baselga, J., Cortés, J., Im, S-A., Clark, E., Ross, G., Kiermaier, A., Swain, S.M. 
(2014). Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-
Controlled Study of Pertuzumab in Human Epidermal Growth Factor 
Receptor 2–Positive, First-Line Metastatic Breast Cancer. Journal of 
Clinical Oncology, 32(33), 3753-3761. doi: doi:10.1200/JCO.2013.54.5384. 
 
Baselga, J., Gelmon, K.A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, 
G., Cortes, J., McNally, V.A., Ross, G.A., Fumoleau, P., Gianni, L. (2010). 
Phase II Trial of Pertuzumab and Trastuzumab in Women With Human 
Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer 
That Progressed During Prior Trastuzumab Therapy. Journal of Clinical 
Oncology, 28(7), 1138-1144. doi: 10.1200/jco.2009.24.2024. 
 
Beesley, R.D., Johnson, J.V., (2008). The Breast During Pregnancy and Lactation.  
1756-2228. doi: 10.3843/GLOWM.10305. 
 
Belsches-Jablonski, A.P., Biscardi, J.S., Peavy, D.R., Tice, D.A., Romney, 
D.A., Parsons, S.J. (2001). Src family kinases and HER2 interactions in 
human breast cancer cell growth and survival. Oncogene, 20(12), 1465-
1475.  
 
Berger, M.S., Locher, G.W., Sauer, S., Gullick, W.J., Waterfield, M.D., Groner, 
B., Hynes, N.E. Correlation of c-erbB-2  Gene Amplification and Protein 
Expression in Human Breast Carcinoma with Nodal Status and Nuclear 
Grading. Cancer Research, 48(5), 1238- 1243.  
 
Berns, K., Horlings, H.M., Hennessy, B.T., Madiredjo, M., Hijmans, E.M., Beelen, 
K., Linn, S.C., Gonzalez-Angulo, A.M., Stemke-Hale, K., Hauptmann, 
M., Beijersbergen, R.L., Mills, G.B., van de Vijver, M.J., Bernards, R. 
(2007). A Functional Genetic Approach Identifies the PI3K Pathway as a 
Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer 
Cell, 12(4), 395-402. doi: 10.1016/j.ccr.2007.08.030. 
 
Bianchini, G., Gianni, L. (2014). The immune system and response to HER2-
targeted treatment in breast cancer. The Lancet Oncology, 15(2), e58-e68. 
doi: 10.1016/s1470-2045(13)70477-7. 
 
Bingle, L., Brown, N.J., Lewis, C.E. (2002). The role of tumour-associated 
macrophages in tumour progression: implications for new anticancer 







Blackwell, K.L., Burstein, H.J., Storniolo, A.M., Rugo, H.S., Sledge, G., Aktan, 
G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., Baselga, 
J., O'Shaughnessy, J. (2012). Overall Survival Benefit With Lapatinib in 
Combination With Trastuzumab for Women With Human Epidermal Growth 
Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From 
the EGF104900 Study. Journal of Clinical Oncology, 30(21), 2585-2592. 
doi: 10.1200/jco.2011.35.6725. 
 
Blatchford, D.R., Quarrie, L.H., Tonner, E., McCarthy, C., Flint, D.J., Wilde, C.J. 
(1999). Influence of microenvironment on mammary epithelial cell survival 
in primary culture. Journal of Cellular Physiology, 181, 304–331. doi: 
10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5. 
 
Bonnefoi, H., Potti, A., Delorenzi, M., Mauriac, L., Campone, M., Tubiana-Hulin, 
M., Petit, T., Rouanet, P., Jassem, J., Blot, E., Becette, V., Farmer, 
P., André, S., Acharya, C.R., Mukherjee, S., Cameron, D., Bergh, 
J., Nevins, J.R., Iggo, R.D. (2007). Validation of gene signatures that 
predict the response of breast cancer to neoadjuvant chemotherapy: a 
substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncogy, 
8(12), 1071-1078. doi: 10.1016/S1470-2045(07)70345-5. 
 
Bonnet, D., Dick, J.E. (1997). Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nature 
Medicine 3(7), 730-737. doi: 10.1038/nm0797-730. 
 
Borgna, S., Armellin, M., di Gennaro, A., Maestro, R., Santarosa, M. (2012). 
Mesenchymal traits are selected along with stem features in breast cancer 
cells grown as mammospheres. Cell Cycle, 11(22), 4242-4251. doi: 
10.4161/cc.22543. 
 
Bray, S.J. (2006). Notch signalling: a simple pathway becomes complex. Nature 
Reviews Molecular Cell Biology, 7(9), 678-689. doi: 10.1038/nrm2009. 
 
Buess, M., Rajski, M., Vogel-Durrer, B.M., Herrmann, R., Rochlitz, C. (2009). 
Tumor-Endothelial Interaction Links the CD44+/CD24- Phenotype with 
Poor Prognosis in Early-Stage Breast Cancer. Neoplasia, 11(10), 987-
1002. doi: 10.1593/neo.09670. 
 
Burchell, J.M., Farnie, G., Willan, P.M., Clarke, R.B., Bundred, N.J. (2013). 
Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets 
Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity 







Buzdar, A.U., Ibrahim, N.K., Francis, D., Booser, D.J., Thomas, E.S., Theriault, 
R.L., Pusztai, L., Green, M.C., Arun, B.K., Giordano, S.H., Cristofanilli, 
M., Frye, D.K., Smith, T.L., Hunt, K.K., Singletary, S.E., Sahin, A.A., Ewer, 
M.S., Buchholz, T.A., Berry, D., Hortobagyi, G.N. (2005). Significantly 
Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy 
With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a 
Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive 
Operable Breast Cancer. Journal of Clinical Oncology, 23(16), 3676-3685. 
doi: 10.1200/jco.2005.07.032. 
 
Calza, S., Hall, P., Auer, G., Bjöhle, J., Klaar, S., Kronenwett, U., Liu, E.T., Miller, 
 L., Ploner, A., Smeds, J., Bergh, J., Pawitan, Y. (2006). Intrinsic molecular 
 signature of breast cancer in a population-based cohort of 412 
 patients. Breast Cancer Research, 8(4), R34. doi: 10.1186/bcr1517. 
 
Calzavara, E., Chiaramonte, R., Cesana, D., Basile, A., Sherbet, G.V., Comi, P. 
(2008). Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL 
cells In Vitro. Journal of Cellular Biochemistry, 103(5), 1405-1412. doi: 
10.1002/jcb.21527. 
 
Candas, D., Lu, C.L., Fan, M., Chuang, F.Y., Sweeney, C., Borowsky, A.D., Li, J.J. 
(2014). Mitochondrial MKP1 Is a Target for Therapy-Resistant HER2-
Positive Breast Cancer Cells. Cancer Research, 74(24), 7498-7509. doi: 
10.1158/0008-5472.can-14-0844. 
 
Cao Y-W, Li W-Q, Wan G-X, Li Y-X, Du, X.M., Li, Y-C., Li, F. (2014) Correlation 
and prognostic value of SIRT1 and Notch1 signaling in breast cancer. 
Journal of Experimental and Clinical Cancer Research, 33(97), 1-11. doi: 
10.1186/s13046-014-0097-2. 
 
Cao, Y-W., Luo, J-L., Karin, M. (2007). IκB kinase α kinase activity is required for 
self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. 
Proceedings of the National Academy of Sciences, 104(40), 15852-15857. 
doi: 10.1073/pnas.0706728104. 
 
Cariati, M., Naderi, A., Brown, J.P., Smalley, M.J., Pinder, S.E., Caldas, 
C., Purushotham, A.D. (2008). Alpha-6 integrin is necessary for the 
tumourigenicity of a stem cell-like subpopulation within the MCF7 breast 
cancer cell line. International Journal of Cancer, 122(2), 298-304. doi: 
10.1002/ijc.23103. 
 
Carpenter, G. (1999). Employment of the Epidermal Growth Factor Receptor in 
Growth Factor–independent Signaling Pathways. The Journal of Cell 






Carter, P., Presta, L., Gorman, C.M., Ridgway, J.B. Henner, D., Wong, 
W.L., Rowland, A.M., Kotts, C., Carver, M.E., Shepard, H.M. (1992). 
Humanization of an anti-p185HER2 antibody for humancancer therapy. 
Proceedings of the National Academy of Sciences, 89(10), 4285-4289. 
 
Casalini, P., Botta, L., Menard, S. (2001). Role of p53 in HER2-induced 
Proliferation or Apoptosis. Journal of Biological Chemistry, 276(15), 12449-
12453. doi: 10.1074/jbc.M009732200. 
 
Castagnoli, L., Iezzi, M., Ghedini, G.C., Ciravolo, V., Marzano, G., Lamolinara, 
A., Zappasodi, R., Gasparini, P., Campiglio, M., Amici, A., Chiodoni, 
C., Palladini, A., Lollini, P.L., Triulzi, T., Menard, S., Nanni, P., Tagliabue, 
E., Pupa, S.M. (2014). Activated d16HER2 Homodimers and Src Kinase 
Mediate Optimal Efficacy for Trastuzumab. Cancer Research, 74(21), 6248-
6259. doi: 10.1158/0008-5472.can-14-0983. 
 
Chagpar, R.B., Links, P.H., Pastor, M.C., Furber, L.A., Hawrysh, 
A.D., Chamberlain, M.D., Anderson, D.H. (2010). Direct positive regulation 
of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proceedings 
of the National Academy of Sciences, 107(12), 5471-5476. doi: 
10.1073/pnas.0908899107. 
 
Chan, C.T., Metz, M.Z., Kane, S.E., (2005). Differential of trastuzumab 
(Herceptin®)-resistant human breast cancer cells to phosphoinositide-3-
kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase 
inhibitors. Breast Cancer Research and Treatment 91(2), 187-201. doi: 
10.1007/s10549-004-7715-1. 
 
Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, 
P., Hur, M.H., Diebel, M.E., Monville, F., Dutcher, J., Brown, M., Viens, 
P., Xerri, L., Bertucci, F., Stassi, G., Dontu, G., Birnbaum, D., Wicha, M.S. 
(2009). Breast Cancer Cell Lines Contain Functional Cancer Stem Cells 
with Metastatic Capacity and a Distinct Molecular Signature. Cancer 
Research, 69(4), 1302-1313. doi: 10.1158/0008-5472.can-08-2741. 
 
Cheang, M.C., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, 
M., Davies, S., Bernard, P.S., Parker, J.S., Perou, C.M., Ellis, 
M.J., Nielsen, T.O. (2009). Ki67 Index, HER2 Status, and Prognosis of 
Women With Luminal B Breast Cancer. Journal of the National Cancer 
Institute, 101(10), 736-750. doi: 10.1093/jnci/djp082. 
 
Chen, A.C., Migliaccio, I., Rimawi, M., Lopez-Tarruella, S., Creighton, 





M.C., Osborne, C.K., Schiff, R. (2012). Upregulation of Mucin4 in ER-
positive/HER2-Overexpressing Breast Cancer Xenografts with Acquired 
Resistance to Endocrine and HER2-Targeted Therapies. Breast Cancer 
Research and Treatment, 134(2), 583-593. doi: 10.1007/s10549-012-2082-
9. 
 
Chen, Y., Fischer, W.H., Gill, G.N. (1997). Regulation of the ERBB-2 Promoter by 
RBPJkappa and NOTCH. Journal of Biological Chemistry, 272(22), 14110-
14114.  
 
Chiba, S. (2006). Concise Review: Notch Signaling in Stem Cell Systems. Stem 
Cells, 24(11), 2437-2447. doi: 10.1634/stemcells.2005-0661. 
 
Cho, H-S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W. 
Jr., Leahy, D.J. (2003). Structure of the extracellular region of HER2 alone 
and in complex with the Herceptin Fab. Nature, 421(6924), 753-756. doi: 
10.1038/nature01423. 
 
Choi, Y.J., Xiaoyu, L., Hydbring, P., Sanda, T., Stefano, J., Christie, 
A.L., Signoretti, S., Look, A.T., Kung, A.L., von Boehmer, H., Sicinski, P. 
(2012). The Requirement for Cyclin D Function in Tumor Maintenance. 
Cancer Cell, 22(4), 438-451. doi: 10.1016/j.ccr.2012.09.015. 
 
Chung, J-H., Ginn-Pease, M.E., Eng, C. (2005a). Phosphatase and Tensin 
Homologue Deleted on Chromosome 10 (PTEN) Has Nuclear Localization 
Signal–Like Sequences for Nuclear Import Mediated by Major Vault Protein. 
Cancer Research, 65(10), 4108-4116. doi: 10.1158/0008-5472.CAN-05-
0124. 
 
Chung, J-H., Eng, C. (2005b). Nuclear-Cytoplasmic Partitioning of Phosphatase 
and Tensin Homologue Deleted on Chromosome 10 (PTEN) Differentially 
Regulates the Cell Cycle and Apoptosis. Cancer Research, 65(18), 8096-
8100. doi: 10.1158/0008-5472.CAN-05-1888. 
 
Cizkova, M., Susini, A., Vacher, S., Cizeron-Clairac, G., Andrieu, C., Driouch, 
K., Fourme, E., Lidereau, R., Bièche, I. (2012). PIK3CA mutation impact on 
survival in breast cancer women and in ERα, PR and ERBB2-based 
subgroups. Breast Cancer Research, 14(1), R28-R28. doi: 
10.1186/bcr3113. 
 
Clarke, E.E., Churcher, I., Ellis, S., Wrigley, J.D. Lewis, H.D., Harrison, 
T., Shearman, M.S., Beher, D. (2006). Intra- or Intercomplex Binding to the 





Biological Chemistry, 281(42), 31279-31289. doi: 
10.1074/jbc.M605051200. 
 
Clementz, A.G., Rogowski, A., Pandya, K., Miele, L., Osipo, C. (2011). NOTCH-1 
and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel 
therapeutic implications. Breast Cancer Research, 13(3), R63. doi: 
10.1186/bcr2900. 
 
Clough, K.B., Kaufman, G.J., Nos, C., Buccimazza, I., Sarfati, I.M. (2010). 
 Improving  Breast Cancer Surgery: A Classification and Quadrant per 
 Quadrant  Atlas for Oncoplastic Surgery. Annals of Surgical Oncology, 
 17(5), 1375- 1391. doi: 10.1245/s10434-009-0792-y. 
 
Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, 
L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., Slamon, D.J. (1999). 
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 
Monoclonal Antibody in Women who have HER2-Overexpressing 
Metastatic Breast Cancer that has Progressed after Chemotherapy for 
Metastatic Disease. Journal of Clinical Oncology, 17(9), 2639-2648. doi: 
10.1200/jco.1999.17.9.2639. 
 
Cohen, B., Shimizu, M., Izrailit, J., Ng, N.F. Buchman, Y., Pan, J.G., Dering, 
J., Reedijk, M. (2009). Cyclin D1 is a direct target of JAG1-mediated Notch 
signaling in breast cancer. Breast Cancer Research and Treatment, 123(1), 
113-124. doi: 10.1007/s10549-009-0621-9. 
 
Collins, D. M., O'Donovan, N., McGowan, P. M., O'Sullivan, F., Duffy, M.J., Crown, 
J. (2011). Trastuzumab induces antibody-dependent cell-mediated 
cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Annals 
of Oncology, 23(7), 1788-1795. doi: 10.1093/annonc/mdr484. 
 
Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A., Casado, A., Massutí, 
B., Cortés-Funes, H., Lloveras, B. (2000). Circulating HER2 Extracellular 
Domain and Resistance to Chemotherapy in Advanced Breast Cancer. 
Clinical Cancer Research, 6(6), 2356.  
 
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC).  
2015; Available from: https://clinicaltrials.gov/ct2/show/NCT02662608. 
 
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, 
C., Inui, M., Montagner, M., Parenti, A.R., Poletti, A., Daidone, 
M.G., Dupont, S., Basso, G., Bicciato, S., Piccolo, S. (2011). The Hippo 
Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast 






Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, 
J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U., 
Levinson, A., Ullrich, A. (1985). Tyrosine kinase receptor with extensive 
homology to EGF receptor shares chromosomal location with neu 
oncogene. Science, 230(4730), 1132-1139.  
 
Crawford, A., Nahta, R. (2011). Targeting Bcl-2 in Herceptin-Resistant Breast 
Cancer Cell Lines. Current pharmacogenomics and personalized medicine, 
9(3), 184-190.  
 
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V.M., Sjolund, 
A., Rimm, D.L., Wong, H., Rodriguez, A., Herschkowitz, J.I., Fan, 
C., Zhang, X., He, X., Pavlick, A., Gutierrez, M.C., Renshaw, L., Larionov, 
A.A., Faratian, D., Hilsenbeck, S.G., Perou, C.M., Lewis, M.T., Rosen, 
J.M., Chang, J.C. (2009). Residual breast cancers after conventional 
therapy display mesenchymal as well as tumor-initiating features. 
Proceedings of the National Academy of Sciences, 106(33), 13820-13825. 
doi: 10.1073/pnas.0905718106. 
 
Cuello, M., Ettenberg, S.A., Clark, A.S., Keane, M.M., Posner, R.H., Nau, 
M.M., Dennis, P.A., Lipkowitz, S. (2001). Down-Regulation of the erbB-2 
Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-
related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and 
Ovarian Cancer Cell Lines that Overexpress erbB-2. Cancer Research, 
61(12), 4892-4900.  
 
Curtis, C., Shah, S.P., Chin, S-F., Turashvili, G., Rueda, O.M., Dunning, 
M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, 
G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., METABRIC 
Group, Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, 
S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, 
A., Børresen-Dale, A.L., Brenton, J.D., Tavaré, S., Caldas, C., Aparicio, S. 
(2012). The genomic and transcriptomic architecture of 2,000 breast 
tumours reveals novel subgroups. Nature, 486(7403), 346-352. doi: 
10.1038/nature10983. 
 
Dave, B., Migliaccio, I., Gutierrez, M.C., Wu, M.F., Chamness, G.C., Wong, 
H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S.G., Huang, J., Rimawi, 
M., Schiff, R., Arteaga, C., Osborne, C.K., Chang, J.C. (2010). Loss of 
Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation 
and Response to Trastuzumab or Lapatinib in Human Epidermal Growth 





Journal of Clinical Oncology, 29(2), 166-173. doi: 
10.1200/jco.2009.27.7814. 
 
Davis, J. M., Navolanic, P. M., Weinstein-Oppenheimer, C. R., Steelman, L. S., 
Hu, W., Konopleva, M., Blagosklonny, M.V., McCubrey, J.A. (2003). Raf-1 
and Bcl-2 Induce Distinct and Common Pathways That Contribute to Breast 
Cancer Drug Resistance. Clinical Cancer Research, 9(3), 1161-1170.  
 
Dawson, J.P., Berger, M.B., Schlessinger, J., Lemmon, M.A., Ferguson, K.M. 
(2005). Epidermal growth factor receptor dimerization and activation require 
ligand-induced conformational changes in the dimer interface. Molecular 
and Cellular Biology 25(17). 7734-7742. doi:10.1128/MCB.25.17.7734–
7742.2005. 
 
De, P., Hasmann, M., Leyland-Jones, B. (2013). Molecular determinants of 
trastuzumab efficacy: What is their clinical relevance? Cancer Treatment 
Reviews, 39(8), 925-934. doi: 10.1016/j.ctrv.2013.02.006. 
 
Desta, Z., Ward, B.A., Soukhova, N.V., Flockhart, D.A. (2004). Comprehensive 
Evaluation of Tamoxifen Sequential Biotransformation by the Human 
Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and 
CYP2D6. Journal of Pharmacology and Experimental Therapeutics, 310(3), 
1062-1075. doi: 10.1124/jpet.104.065607. 
 
Dickler, M.N., Cobleigh, M.A., Miller, K.D., Klein, P.M., Winer, E.P. (2008). Efficacy 
and safety of erlotinib in women with locally advanced or metastatic breast 
cancer. Breast Cancer Research and Treatment, 115(1), 115-121. doi: 
10.1007/s10549-008-0055-9. 
 
Diermeier, S., Horváth, G., Knuechel-Clarke, R., Hofstaedter, F., Szöllosi, 
J., Brockhoff, G. (2005). Epidermal growth factor receptor coexpression 
modulates susceptibility to Herceptin in HER2/neu overexpressing breast 
cancer cells via specific erbB-receptor interaction and activation. 
Experimental Cell Research, 304(2), 604-619. doi: 
10.1016/j.yexcr.2004.12.008. 
 
Dievart, A., Beaulieu, N.B., Jolicoeur, P. (1999). Involvement of Notch1 in the 
development of mouse mammary tumors. Oncogene, 18(44), 5973-5981.  
 
Ding, Q., Mracek, T., Gonzalez-Muniesa, P., Kos, K., Wilding, J., Trayhurn, 
P., Bing, C. (2009). Identification of Macrophage Inhibitory Cytokine-1 in 
Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes. 






Dontu, G., Al-Hajj, M., Abdallah, W.M., Clarke, M.F., Wicha, M.S. (2003). Stem 
cells in normal breast development and breast cancer. Cell Proliferation, 36, 
59-72. doi: 10.1046/j.1365-2184.36.s.1.6.x. 
 
Dontu, G., Jackson, K.W., McNicholas, E., Kawamura, M.J., Abdallah, 
W.M., Wicha, M.S. (2004). Role of Notch Signaling in Cell-Fate 
Determination of Human Mammary Stem/Progenitor Cells. Breast Cancer 
Research, 6(6), R605-R615. doi: 10.1186/bcr920. 
 
Drebin, J.A., Link, V.C., Weinberg, R.A., Greene, M.I. (1986). Inhibition of tumor 
growth by a monoclonal antibody reactive with an oncogene-encoded tumor 
antigen. Proceedings of the National Academy of Sciences, 83(23), 9129-
9133.  
 
Drew, P., Cawthorn, S., Michell, M., Denton, E. (2007). Interventional Ultrasound 
of the Breast. Informa Healthcare Ltd. 
 
Du, C., Yi, X., Liu, W., Han, T., Liu, Z., Ding, Z., Zheng, Z., Piao, Y., Yuan, J., Han, 
Y., Xie, M., Xie, X. (2014). MTDH mediates trastuzumab resistance in 
HER2 positive breast cancer by decreasing PTEN expression through an 
NFκB-dependent pathway. BMC Cancer, 14(869), 1-13. doi: 10.1186/1471-
2407-14-869. 
 
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, 
M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., Elvassore, 
N., Piccolo, S. (2011). Role of YAP/TAZ in mechanotransduction. Nature, 
474(7350), 179-183. doi: 10.1038/nature10137. 
 
Ebbesen, S.H., Scaltriti, M., Bialucha, C.U., Morse, N., Kastenhuber, E.R., Wen, 
H.Y., Dow, L.E., Baselga, J., Lowe, S.W. (2016). Pten loss promotes MAPK 
pathway dependency in HER2/neu breast carcinomas. Proceedings of the 
National Academy of Sciences, 113(11), 3030-3035. doi: 
10.1073/pnas.1523693113. 
 
Ebbing, E.A., Medema, J.P., Damhofer, H., Meijer, S.L., Krishnadath, K.K., van 
Berge Henegouwen, M.I., Bijlsma, M.F., van Laarhoven, H.W. (2016). 
ADAM-10-mediated release of heregulin confers resistance to trastuzumab 
by activating HER3. Oncotarget, 7(9), 10243-10254. doi: 
10.18632/oncotarget.7200. 
 
Ejlertsen, B., Mouridsen, H.T., Jensen, M-B., Andersen, J., Andersson, 
M., Kamby, C., Knoop, A.S., Danish Breast Cancer Cooperative Group. 
(2010). Cyclophosphamide, methotrexate, and fluorouracil; oral 





risk, premenopausal breast cancer. Cancer, 116(9), 2081-2089 doi: 
10.1002/cncr.24969. 
 
Ellisen, L.W., Bird, J., West, D.C., Soreng, A.L., Reynolds, T.C., Smith, S.D., Sklar, 
J. (1991). TAN-1, the Human Homoog of the Drosophila Notch Gene, is 
Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms. 
Cell, 66(4), 649-661.  
 
Engelmann, K., Shen, H., Finn, O.J. (2008). MCF7 Side Population Cells with 
Characteristics of Cancer Stem/Progenitor Cells Express the Tumor 
Antigen MUC1. Cancer Research, 68(7), 2419-2426. doi: 10.1158/0008-
5472.can-07-2249. 
 
Erickson, H.K., Park, P.U., Widdison, W.C., Koytun, Y.V., Garrett, L.M., Hoffman, 
K., Lutz, R.J., Goldmacher, V.S., Blättler, W.A. (2006). Antibody-
Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by 
Lysosomal Degradation and Linker-Dependent Intracellular Processing. 
Cancer Research, 66(8), 4426-4433. doi: 10.1158/0008-5472.can-05-4489. 
 
Esteva, F.J., Guo, H., Zhang S., Santa-Maria, C., Stone, S., Lanchbury, 
J.S., Sahin, A.A., Hortobagyi, G.N., Yu, D. (2010). PTEN, PIK3CA, p-AKT, 
and p-p70S6K Status Association with Trastuzumab Response and 
Survival in Women with HER2-Positive Metastatic Breast Cancer. The 
American Journal of Pathology, 177(4), 1647-1656. doi: 
10.2353/ajpath.2010.090885. 
 
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, 
A., Fangazio, M., Capello, D., Monti, S., Cresta, S., Gargiulo, E., Forconi, 
F., Guarini, A., Arcaini, L., Paulli, M., Laurenti, L., Larocca, L.M., Marasca, 
R., Gattei, V., Oscier, D., Bertoni, F., Mullighan, C.G., Foá, 
R., Pasqualucci, L., Rabadan, R., Dalla-Favera, R., Gaidano, G. (2011). 
Analysis of the chronic lymphocytic leukemia coding genome: role of 
NOTCH1 mutational activation. Journal of Experimental Medicine, 208(7), 
1389-1401. doi: 10.1084/jem.20110921. 
 
Fan , C., Oh , D.S., Wessels , L., Weigelt , B., Nuyten, D.S., Nobel, A.B., van't 
Veer, L.J., Perou, C.M. (2006). Concordance among Gene-Expression–
Based Predictors for Breast Cancer. New England Journal of Medicine, 
355(6), 560-569. doi:10.1056/NEJMoa052933. 
 
Fan, J., Yang, X., Wang, W., Wood, W. H. 3rd., Becker, K.G., Gorospe, M. (2002). 
Global analysis of stress-regulated mRNA turnover by using cDNA arrays. 
Proceedings of the National Academy of Sciences, 99(16), 10611-10616. 






Fan, X., Brezski, R.J., Fa, M., Deng, H., Oberholtzer, A., Gonzalez, A., Dubinsky, 
W.P., Strohl, W.R., Jordan, R.E., Zhang, N., An, Z. (2012). A single 
proteolytic cleavage within the lower hinge of trastuzumab reduces immune 
effector function and in vivo efficacy. Breast Cancer Research, 14(4), R116. 
doi: 10.1186/bcr3240. 
 
Fang, D., Hawke, D., Zheng, Y., Xia, Y., Meisenhelder, J., Nika, H., Mills, 
G.B., Kobayashi, R., Hunter, T., Lu, Z. (2007). Phosphorylation of β-
Catenin by Akt Promotes β-Catenin Transcriptional Activity. Journal of 
Biological Chemistry, 282(15), 11221-11229. doi: 
10.1074/jbc.M611871200. 
 
Feilotter, H.E., Coulon, V., McVeigh, J.L., Boag, A.H., Dorion-Bonnet, F., Duboué, 
B., Latham, W.C., Eng, C., Mulligan, L.M., Longy, M. (1999). Analysis of the 
10q23 chromosomal region and the PTEN gene in human sporadic breast 
carcinoma. British Journal of Cancer, 79(5-6), 718-723. doi: 
10.1038/sj.bjc.6690115. 
 
Ferguson, K.M., Berger, M.B. Mendrola, J.M., Cho, H.S., Leahy, D.J., Lemmon, 
M.A. (2003). EGF activates its receptor by removing interactions that 
autoinhibit ectodomain dimerization. Molecular Cell 11(2), 507-517.  
 
Fessler, S. P., Wotkowicz, M. T., Mahanta, S. K., Bamdad, C. (2009). MUC1* is a 
determinant of trastuzumab (Herceptin) resistance in breast cancer cells. 
Breast Cancer Research and Treatment, 118(1), 113-124. doi: 
10.1007/s10549-009-0412-3. 
 
Filardo, E.J., Quinn, J.A., Bland, K.I., Frackelton, A.R. Jr. (2000). Estrogen-
Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled 
Receptor Homolog, GPR30, and Occurs via Trans-Activation of the 
Epidermal Growth Factor Receptor through Release of HB-EGF. Molecular 
Endocrinology, 14(10), 1649-1660. doi:10.1210/mend.14.10.0532. 
 
Fillmore, C.M., Kuperwasser, C. (2008). Human breast cancer cell lines contain 
stem-like cells that self-renew, give rise to phenotypically diverse progeny 
and survive chemotherapy. Breast Cancer Research, 10(2), R25. doi: 
10.1186/bcr1982. 
 
Fiorentino, L., Pertica, C., Fiorini, M., Talora, C., Crescenzi, M., Castellani, 
L., Alemà, S., Benedetti, P., Segatto, O. (2000). Inhibition of ErbB-2 
Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal 
Transducer Which Binds to the ErbB-2 Kinase Domain. Molecular and 






Fujita, T., Doihara, H., Kawasaki, K., Takabatake, D., Takahashi, H., Washio, 
K., Tsukuda, K., Ogasawara, Y., Shimizu, N. (2006). PTEN activity could be 
a predictive marker of trastuzumab efficacy in the treatment of ErbB2-
overexpressing breast cancer. British Journal of Cancer, 94(2), 247-252. 
doi: 10.1038/sj.bjc.6602926. 
 
Gallahan, D., Callahan, R. (1987). Mammary tumorigenesis in feral mice: 
identification of a new int locus in mouse mammary tumor virus (Czech II)-
induced mammary tumors. Journal of Virology, 61(1), 66-74.  
 
Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, 
A., Adrover, E., Sánchez-Tejada, L., Giner, D., Ortiz-Martínez, F., Peiró, G. 
(2012). Increased signalling of EGFR and IGF1R, and deregulation of 
PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 
breast carcinomas. British Journal of Cancer, 106(8), 1367-1373. doi: 
10.1038/bjc.2012.85. 
 
Garrett, T.P., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, 
G.O., Kofler, M., Jorissen, R.N., Nice, E.C., Burgess, A.W., Ward, C.W. 
(2003). The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals 
an Active Conformation, Poised to Interact with Other ErbB Receptors. 
Molecular Cell, 11(2), 495-505. doi: 10.1016/s1097-2765(03)00048-0. 
 
Gelmon, K.A., Boyle, F., Kaufman, B., Huntsman, D., Manikhas, A., Di Leo, A., 
Martin, M., Schwartzberg, L.S., Dent, S.F., Ellard, S., Tonkin, K.S., 
Nagarwala, Y.M., Pritchard, K.I., Whelan, T.J., Nomikos, D., Chapman, J-
A. W., Parulekar, W. (2012). Open-label phase III randomized controlled 
trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or 
trastuzumab (T) as first-line therapy for women with HER2+ metastatic 
breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. 
Journal of Clinical Oncology, 30.  
 
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, 
E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., Oliviero, 
B., Ballardini, B., Da Prada, G., Zambelli, A., Costa, A. (2004). Pilot Study 
of the Mechanism of Action of Preoperative Trastuzumab in Women with 
Primary Operable Breast Tumors Overexpressing HER2. Clinical Cancer 
Research, 10(17), 5650-5655. doi: 10.1158/1078-0432.CCR-04-0225.  
 
Ghosh, R., Narasanna, A., Wang, S.E., Liu, S., Chakrabarty, A., Balko, 
J.M., González-Angulo, A.M., Mills, G.B., Penuel, E., Winslow, 
J., Sperinde, J., Dua, R., Pidaparthi, S., Mukherjee, A., Leitzel, K., Kostler, 





Preferential Activity against Breast Cancers Driven by HER2 Homodimers. 
Cancer Research, 71(5), 1871-1882. doi: 10.1158/0008-5472.can-10-1872. 
 
Gianni, L., Pienkowski, T., Im, Y-H., Tseng, L-M., Liu, M.C., Lluch, 
A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.A., Pedrini, 
J.L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, 
G.V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G., Valagussa, P. 
(2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in 
women with locally advanced, inflammatory, or early-stage HER2-positive 
breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised 
trial. The Lancet Oncology, 17(6), 791-800. doi: 10.1016/s1470-
2045(16)00163-7. 
 
Ginestier, C., Adelaide, J., Goncalves, A., Repellini, L., Sircoulomb, F., Letessier, 
A., Finetti, P., Geneix, J., Charafe-Jauffret, E., Bertucci, F., Jacquemier, 
J., Viens, P., Birnbaum, D. (2007a). ErbB2 Phosphorylation and 
Trastuzumab Sensitivity of Breast Cancer Cell Lines. Oncogene, 26, 7163-
7169. doi: 10.1038/sj.onc.1210528. 
 
Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, 
M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., Schott, A., Hayes, 
D., Birnbaum, D., Wicha, M.S., Dontu, G. (2007b). ALDH1 is a marker of 
normal and malignant human mammary stem cells and a predictor of poor 
clinical outcome. Cell Stem Cell, 1(5), 555-567. doi: 
10.1016/j.stem.2007.08.014. 
 
Giuliano, M., Hu, H., Wang, Y.C., Fu, X., Nardone, A., Herrera, S., Mao, 
S., Contreras, A., Gutierrez, C., Wang, T., Hilsenbeck, S.G., De Angelis, 
C., Wang, N.J., Heiser, L.M., Gray, J.W., Lopez-Tarruella, S., Pavlick, 
A.C., Trivedi, M.V., Chamness, G.C., Chang, J.C., Osborne, C.K., Rimawi, 
M.F., Schiff, R. (2015). Upregulation of ER Signaling as an Adaptive 
Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with 
Anti-HER2 Therapy. Clinical Cancer Research, 21(17), 3995-4003. doi: 
10.1158/1078-0432.ccr-14-2728. 
 
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., Song, E. 
(2011). Up-regulation of miR-21 Mediates Resistance to Trastuzumab 
Therapy for Breast Cancer. Journal of Biological Chemistry, 286(21), 
19127-19137. doi: 10.1074/jbc.M110.216887. 
 
Gordon, W.R., Arnett, K.L., Blacklow, S.C. (2008). The molecular logic of Notch 
signaling – a structural and biochemical perspective. Journal of Cell 






Gori, S., Sidoni, A., Colozza, M., Ferri, I., Mameli, M.G., Fenocchio, D., Stocchi, 
L., Foglietta, J., Ludovini, V., Minenza, E., De Angelis, V., Crinò, L. (2009). 
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: 
correlation with clinical outcome in HER2-positive metastatic breast cancer 
women treated with trastuzumab. Annals of Oncology, 20(4), 648-654. doi: 
10.1093/annonc/mdn681. 
 
Grabher, C., von Boehmer, H., Look, A.T. (2006). Notch1 Activation in the 
Molecular Pathogenesis of T-cell Acute Lymophoblastic Leukaemia. Nature 
Review Cancer, 6(5), 347-359. doi: 10.1038/nrc1880. 
 
Graus-Porta, D., Beerli, R.R., Daly, J.M., Hynes, N.E. (1997). ErbB-2, the preferred 
hetero-dimerization partner of all ErbB receptors, is a mediator of lateral 
signaling. The EMBO Journal, 16(7), 1647–1655.  
 
Graziani, I., Eliasz, S., De Marco, M.A., Chen, Y., Pass, H.I., De May, R.M., Strack, 
P.R., Miele, L., Bocchetta, M. (2008). Opposite Effects of Notch-1 and 
Notch-2 on Mesothelioma Cell Survival under Hypoxia Are Exerted through 
the Akt Pathway. Cancer Research, 68(23), 9678-9685. doi: 10.1158/0008-
5472.can-08-0969. 
 
Greene, S.B., Gunaratne, P.H., Hammond, S.M., Rosen, J.M. (2010). A putative 
role for microRNA-205 in mammary epithelial cell progenitors. Journal of 
Cell Science, 123(4), 606-618. doi: 10.1242/jcs.056812. 
 
Gril, B., Palmieri, D., Bronder, J.L., Herring, J.M., Vega-Valle, E., Feigenbaum, 
L., Liewehr, D.J., Steinberg, S.M., Merino, M.J., Rubin, S.D., Steeg, P.S. 
(2008). Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer 
Cells to the Brain. Journal of the National Cancer Institute, 100(15), 1092-
1103. doi: 10.1093/jnci/djn216. 
 
Grudzien, P., Lo, S., Albain, K., Robinson, P., Robinson, P., Rajan, P., Strack, 
P.R., Golde, T.E., Miele, L., Foreman, K.E. (2010). Inhibition of Notch 
Signaling Reduces the Stem-like Population of Breast Cancer Cells and 
Prevents Mammosphere Formation. Anticancer Research, 30, 3853-3868.  
 
Han, M., Liu, M., Wang, Y., Chen, X., Xu, J., Sun, Y., Zhao, L., Qu, H., Fan, Y., Wu, 
C. (2012). Antagonism of miR-21 Reverses Epithelial-Mesenchymal 
Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 
Inactivation by Targeting PTEN. PLoS ONE, 7(6), e39520. doi: 
10.1371/journal.pone.0039520. 
 
Harris, R.C., Chung, E., Coffey, R.J. (2003). EGF receptor ligands. Experimental 






Harrison, H., Farnie, G., Howell, S.J., Rock, R.E., Stylianou, S., Brennan, 
K.R., Bundred, N.J., Clarke, R.B. (2010). Regulation of Breast Cancer Stem 
Cell Activity by Signaling through the Notch4 Receptor. Cancer Research, 
70(2), 709-718. doi: 10.1158/0008-5472.can-09-1681. 
 
Harrison, H., Simões, B.M., Rogerson, L., Howell, S.J., Landberg, G., Clarke, R.B. 
(2013). Oestrogen increases the activity of oestrogen receptor negative 
breast cancer stem cells through paracrine EGFR and Notch signalling. 
Breast Cancer Research, 15(2), R21. doi: 10.1186/bcr3396. 
 
Hatzis, C., Pusztai, L., Valero, V., Booser, D.J., Esserman, L., Lluch, A., Vidaurre, 
T., Holmes, F., Souchon, E., Wang, H., Martin, M., Cotrina, J., Gomez, 
H., Hubbard, R., Chacón, J.I., Ferrer-Lozano, J., Dyer, R., Buxton, 
M., Gong, Y., Wu, Y., Ibrahim, N., Andreopoulou, E., Ueno, N.T., Hunt, 
K., Yang, W., Nazario, A., DeMichele, A., O'Shaughnessy, J., Hortobagyi, 
G.N., Symmans, W.F. (2011). A Genomic Predictor of Response and 
Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast 
Cancer. Journal of the American Medical Association, 305(18), 1873-1881. 
doi: 10.1001/jama.2011.593. 
 
Hicks, M., Macrae, E.R., Abdel-Rasoul, M., Layman, R., Friedman, S., Querry, 
J., Lustberg, M., Ramaswamy, B., Mrozek, E., Shapiro, C., Wesolowski, R. 
(2015). Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and 
Trastuzumab Improves Pathologic Complete Response in Women With 
Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized 
Prospective Clinical Trials. The Oncologist, 20(4), 337-343. doi: 
10.1634/theoncologist. 
 
Higashiyama, S., Iwabuki, H., Morimoto, C., Hieda, M., Inoue, H., Matsushita, N. 
(2008). Membrane-anchored growth factors, the epidermal growth factor 
family: beyond receptor ligands. Cancer Scince 99(2). 214-220. doi: 
10.1111/j.1349-7006.2007.00676.x. 
 
Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, 
L.A., Reynolds, E., Dressler, L., Nobel, A., Parker, J., Ewend, 
M.G., Sawyer, L.R., Wu, J., Liu, Y., Nanda, R., Tretiakova, M., Ruiz Orrico, 
A., Dreher, D., Palazzo, J.P., Perreard, L., Nelson, E., Mone, M., Hansen, 
H., Mullins, M., Quackenbush, J.F., Ellis, M.J., Olopade, O.I., Bernard, 
P.S., Perou, C.M. (2006). The molecular portraits of breast tumors are 







Hynes, N.E., Lane, H.A. (2005). ERBB receptors and cancer: the complexity of 
targeted inhibitors. Nature Reviews Cancer, 5(5), 341-354. doi: 
10.1038/nrc1609. 
 
Ichikawa, T., Sato, F., Terasawa, K., Tsuchiya, S., Toi, M., Tsujimoto, G., Shimizu, 
K. (2012). Trastuzumab Produces Therapeutic Actions by Upregulating 
miR-26a and miR-30b in Breast Cancer Cells. PLoS ONE, 7(2), e31422. 
doi: 10.1371/journal.pone.0031422. 
 
Ikenoue, T., Inoki, K., Zhao, B., Guan, K.L. (2008). PTEN Acetylation Modulates 
Its Interaction with PDZ Domain. Cancer Research, 68(17), 6908-6912. doi: 
10.1158/0008-5472.can-08-1107. 
 
Iriondo, O., Rábano, M., Domenici, G., Carlevaris, O., López-Ruiz, J.A., Zabalza, 
I., Berra, E., Vivanco, Md. (2015). Distinct breast cancer stem/progenitor 
cell populations require either HIF1α or loss of PHD3 to expand under 
hypoxic conditions. Oncotarget, 6(31), 31721-31739.  
 
Izrailit, J., Berman, H.K., Datti, A., Wrana, J.L., Reedijk, M. (2013). High 
Throughput Kinase Inhibitor Screen Reveals TRB3 and MAPK-ERK/TGFβ 
Pathways as Fundemental Notch Regulators in Breast Cancer. 
Proceedings of the National Academy of Sciences, 110(5), 1714-1719. doi: 
10.1073/pnas.1214014110. 
 
Jackson, A.L., Linsley, P.S. (2010). Recognizing and avoiding siRNA off-target 
effects for target identification and therapeutic application. Nature Reviews 
Drug Discovery, 9(1), 57-67. doi: 10.1038/nrd3010. 
 
Jackson-Fisher, A.J., Bellinger, G., Ramabhadran, R., Morris, J.K., Lee, 
K.F., Stern, D.F. (2004). ErbB2 is required for ductal morphogenesis of the 
mammary gland. Proceedings of the National Academy of Sciences, 
101(49), 17138-17143. doi: 10.1073/pnas.0407057101. 
 
Jensen, J.D., Knoop, A., Laenkholm, A.V., Grauslund, M., Jensen, M.B., Santoni-
Rugiu, E., Andersson, M., Ewertz, M. (2011). PIK3CA mutations, PTEN, 
and pHER2 expression and impact on outcome in HER2-positive early-
stage breast cancer women treated with adjuvant chemotherapy and 
trastuzumab. Annals of Oncology, 23(8), 2034-2042. doi: 
10.1093/annonc/mdr546. 
 
Jones, J.T., Akita, R.W., Sliwkowski, M.X. (1999). Binding specificities and 
affinities of egf domains for ErbB receptors. FEBS Letters, 447(2-3), 227-






Jordan, C.T., Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, 
M., Dutcher, J., Clouthier, S.G., Wicha, M.S. (2009). Regulation of 
Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling. PLoS 
Biology, 7(6), e1000121. doi: 10.1371/journal.pbio.1000121. 
 
Joshi, J.P., Brown, N.E., Griner, S.E., Nahta, R. (2011). Growth differentiation 
factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab 
sensitivity of HER2-overexpressing breast cancer cells. Biochemical 
Pharmacology, 82(9), 1090-1099. doi: 10.1016/j.bcp.2011.07.082. 
 
Joslin, E.J., Opresko, L.K., Wells, A., Wiley, H.S., Lauffenburger, D.A. (2007). 
EGF-receptor-mediated mammary epithelial cell migration is driven by 
sustained ERK signaling from autocrine stimulation. Journal of Cell 
Science, 120(20), 3688-3699. doi: 10.1242/jcs.010488. 
 
Ju, J.H., Yang, W., Oh, S., Nam, K., Lee, K.M., Noh, D.Y., Shin, I. (2013). HER2 
stabilizes survivin while concomitantly down-regulating survivin gene 
transcription by suppressing Notch cleavage. Biochemical Journal, 451(1), 
123-134. doi: 10.1042/bj20121716. 
 
Jung, E-J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., Di Leo, 
A., Le, X.F., Bast, R.C. Jr., Park, S.T., Pusztai, L., Calin, G.A. (2012). 
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and 
tumor presence in breast cancer women. Cancer, 118(10), 2603-2614. doi: 
10.1002/cncr.26565. 
 
Junttila, T.T., Akita, R.W., Parsons, K., Fields, C., Lewis Phillips, G.D., Friedman, 
L.S., Sampath, D., Sliwkowski, M.X. (2009). Ligand-Independent 
HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively 
Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell, 15(5), 429-440. doi: 
10.1016/j.ccr.2009.03.020. 
 
Junttila, T.T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, 
L., Pabonan, O., Baginski, T., Meng, G., Totpal, K., Kelley, 
R.F., Sliwkowski, M.X. (2010a). Superior In vivo Efficacy of Afucosylated 
Trastuzumab in the Treatment of HER2-Amplified Breast Cancer. Cancer 
Research, 70(11), 4481-4489. doi: 10.1158/0008-5472.can-09-3704. 
 
Junttila, T.T., Li, G., Parsons, K., Phillips, G.L., Sliwkowski, M.X. (2010b). 
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of 
trastuzumab and efficiently inhibits growth of lapatinib insensitive breast 







Karagiannis, P., Singer, J., Hunt, J., Gan, S.K. Rudman, S.M., Mechtcheriakova, 
D., Knittelfelder, R., Daniels, T.R., Hobson, P.S., Beavil, A.J., Spicer, 
J., Nestle, F.O., Penichet, M.L., Gould, H.J., Jensen-Jarolim, 
E., Karagiannis, S.N. (2008). Characterisation of an engineered 
trastuzumab IgE antibody and effector cell mechanisms targeting 
HER2/neu-positive tumour cells. Cancer Immunology, Immunotherapy, 
58(6), 915-930. doi: 10.1007/s00262-008-0607-1. 
 
Karagiannis, S.N., Josephs, D.H., Karagiannis, P., Gilbert, A.E., Saul, L., Rudman, 
S.M., Dodev, T., Koers, A., Blower, P.J., Corrigan, C., Beavil, A.J., Spicer, 
J.F., Nestle, F.O., Gould, H.J. (2011). Recombinant IgE antibodies for 
passive immunotherapy of solid tumours: from concept towards clinical 
application. Cancer Immunology, Immunotherapy, 61(9), 1547-1564. doi: 
10.1007/s00262-011-1162-8. 
 
Karunagaran, D., Tzahar, E., Beerli, R.R., Chen, X., Graus-Porta, D., Ratzkin, 
B.J., Seger, R., Hynes, N.E., Yarden, Y. (1996). ErbB-2 is a common 
auxiliary subunit of NDF and EGF receptors: implications for breast cancer. 
The EMBO Journal, 15(2), 254-264.  
 
Katoh, M., Katoh, M. (2007). Integrative genomic analysis on HES/HEY family: 
Notch-independent HES1, HES3 transcription in undifferentiated ES cells, 
and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in 
fetal tissues, adult tissues, or cancer. International Journal of Oncology, 
31(2), 461-466. 
 
Kaufman, B., Mackey, J.R., Clemens, M.R., Bapsy, P.P., Vaid, A., Wardley, 
A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., Révil, C., Jones, A. 
(2009). Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the 
Treatment of Postmenopausal Women With Human Epidermal Growth 
Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast 
Cancer: Results From the Randomized Phase III TAnDEM Study. Journal 
of Clinical Oncology, 27(33), 5529-5537. doi: 10.1200/jco.2008.20.6847. 
 
Kim, S-Y., Kang, J.W., Song, X., Kim, B.K., Yoo, Y.D., Kwon, Y.T., Lee, Y.J. 
(2013). Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of 
non-stem cancer cells into cancer stem-like cells. Cellular Signalling, 25(4), 
961-969. doi: 10.1016/j.cellsig.2013.01.007. 
 
Kim, S.J., Lee, H.W., Baek, J.H., Cho, Y.H., Kang, H.G., Jeong, J.S., Song, 
J., Park, H.S., Chun, K.H. (2015). Activation of nuclear PTEN by inhibition 
of Notch signaling induces G2/M cell cycle arrest in gastric cancer. 






Klinakis, A., Lobry, C., Abdel-Wahab, O., Oh, P., Haeno, H., Buonamici, S., van 
De Walle, I., Cathelin, S., Trimarchi, T., Araldi, E., Liu, C., Ibrahim, 
S., Beran, M., Zavadil, J., Efstratiadis, A., Taghon, T., Michor, F., Levine, 
R.L., Aifantis, I. (2011). A novel tumour-suppressor function for the Notch 
pathway in myeloid leukaemia. Nature, 473(7346), 230-233. doi: 
10.1038/nature09999. 
 
Knobbe, C.B., Lapin, V., Suzuki,  A., Mak, T.W. (2008). The roles of PTEN in 
development, physiology and tumorigenesis in mouse models: a tissue-by-
tissue survey. Oncogene, 27(41). doi: 10.1038/onc.2008.238. 
 
Kohrt, H.E., Houot, R., Weiskopf, K., Goldstein, M.J., Scheeren, F., Czerwinski, 
D., Colevas, A.D., Weng, W.K., Clarke, M.F., Carlson, R.W., Stockdale, 
F.E., Mollick, J.A., Chen, L., Levy, R. (2012). Stimulation of natural killer 
cells with a CD137-specific antibody enhances trastuzumab efficacy in 
xenotransplant models of breast cancer. Journal of Clinical Investigation, 
122(3), 1066-1075. doi: 10.1172/jci61226. 
 
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, 
Z., Wilson, C., Rong, H.M., Bauerfeind, I., Felber, M., Wang, H.J., Beryt, 
M., Seshadri, R., Hepp, H., Slamon, D.J. (2003). Quantitative Association 
Between HER-2/neu and Steroid Hormone Receptors in Hormone 
Receptor-Positive Primary Breast Cancer. Journal of the National Cancer 
Institute, 95(2), 142-153. doi: 10.1093/jnci/95.2.142. 
 
Konishi, J., Kawaguchi, K.S., Vo, H., Haruki, N., Gonzalez, A., Carbone, 
D.P., Dang, T.P. (2007). y-Secretase Inhibitor Prevents Notch3 Activation 
and Reduces Proliferation in Human Lung Cancers. Cancer Research, 
67(17), 8051-8057. doi: 10.1158/0008-5472.can-07-1022. 
 
Kopan, R.X., Ilagan, M.X. (2009). The Canonical Notch Signaling Pathway: 
Unfolding the Activation Mechanism. Cell, 137(2), 216-233. doi: 
10.1016/j.cell.2009.03.045. 
 
Koren, S., Reavie, L., Couto, J.P., De Silva, D., Stadler, M.B., Roloff, T., Britschgi, 
A., Eichlisberger, T., Kohler, H., Aina, O., Cardiff, R.D., Bentires-Alj, M. 
(2015). PIK3CA(H1047R) induces multipotency and multi-lineage 
mammary tumours. Nature, 525(7567), 114-118. doi: 
10.1038/nature14669. 
 
Korkaya, H., Paulson, A., Iovino, F., Wicha, M.S. (2008). HER2 regulates the 
mammary stem/progenitor cell population driving tumorigenesis and 






Kreso, A., Dick, J.E. (2014). Evolution of the Cancer Stem Cell Model. Cell Stem 
Cell, 14(3), 275-291. doi: 10.1016/j.stem.2014.02.006. 
 
Le, X-F., Claret, F-X., Lammayot, A., Tian, L., Deshpande, D., LaPushin, R., Tari, 
A.M., Bast, R.C. Jr. (2003). The Role of Cyclin-dependent Kinase Inhibitor 
p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor 
Growth Inhibition. Journal of Biological Chemistry, 278, 23441-23450. doi: 
10.1074/jbc.M300848200. 
 
Lee-Hoeflich, S.T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, 
K.P., Sliwkowski, M.X., Stern, H.M. (2008). A Central Role for HER3 in 
HER2-Amplified Breast Cancer: Implications for Targeted Therapy. Cancer 
Research, 68(14), 5878-5887. doi: 10.1158/0008-5472.can-08-0380. 
 
Lee-Hoeflich, S.T., Pham, T.Q., Dowbenko, D., Munroe, X., Lee, J., Li, L., Zhou, 
W., Haverty, P.M., Pujara, K., Stinson, J., Chan, S.M., Eastham-Anderson, 
J., Pandita, A., Seshagiri, S., Hoeflich, K.P., Turashvili, G., Gelmon, 
K.A., Aparicio, S.A., Davis, D.P., Sliwkowski, M.X., Stern, H.M. (2011). 
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance. 
Cancer Discovery, 1(4), 326-337. doi: 10.1158/2159-8290.cd-11-0062. 
 
Lee, C.W., Simin, K., Liu, Q., Plescia, J., Guha, M., Khan, A., Hsieh, C.C., Altieri, 
D.C. (2008). A functional Notch–survivin gene signature in basal breast 
cancer. Breast Cancer Research, 10(6), R97. doi: 10.1186/bcr2200. 
 
Lee, C.Y., Lin, Y., Bratman, S.V., Feng, W., Kuo, A.H., Scheeren, F.A., Engreitz, 
J.M., Varma, S., West, R.B., Diehn, M. (2013). Neuregulin Autocrine 
Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by 
Triggering HER2/HER3 Activation. Cancer Research, 74(1), 341-352. doi: 
10.1158/0008-5472.can-13-1055. 
 
Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., Harris, A.L. 
(1996). Association of Macrophage Infiltration with Angiogenesis and 
Prognosis in Invasive Breast Carcinoma. Cancer Research, 56(20), 4625.  
 
Lefort, K., Mandinova, A., Ostano, P., Kolev, V., Calpini, V., Kolfschoten, I., 
Devgan, V., Lieb, J., Raffoul, W., Hohl, D., Neel, V., Garlick, J., Chiorino, 
G., Dotto, G.P. (2007). Notch1 is a p53 target gene involved in human 
keratinocyte tumor suppression through negative regulation of ROCK1/2 
and MRCK  kinases. Genes and Development, 21(5), 562-577. doi: 
10.1101/gad.1484707. 
 
Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, 





cancer subtypes and preclinical models  for selection of targeted therapies. 
The Journal of Clinical Investigation,12(7), 2750-2767. doi: 
10.1172/JCI45014. 
 
Leitzel, K., Teramoto, Y., Konrad, K., Chinchilli, V.M., Volas, G., Grossberg, 
H., Harvey, H., Demers, L., Lipton, A. (1995). Elevated serum c-erbB-2 
antigen levels and decreased response to hormone therapy of breast 
cancer. Journal of Clinical Oncology, 13(5), 1129-1135. doi: 
10.1200/jco.1995.13.5.1129. 
 
Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, P.C., Altieri, 
D.C. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. 
Nature, 396(6711), 580-584. doi: 10.1038/25141. 
 
Li, G., Robinson, G.W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, 
N., Wagner, K.U., Wu, D.C., Lane, T.F., Liu, X., Hennighausen, L., Wu, H. 
(2002). Conditional loss of PTEN leads to precocious development and 
neoplasia in the mammary gland. Development, 129(17), 4159-4170.  
 
Li, H-J., Reinhardt, F., Herschman, H.R., Weinberg, R.A. (2012). Cancer-
stimulated mesenchymal stem cells create a carcinoma stem-cell niche via 
Prostaglandin E(2) signaling. Cancer Discovery, 2(9), 840-855. doi: 
10.1158/2159-8290.cd-12-0101. 
 
Li, H., Zhu, L., Xu, L., Qin, K., Liu, C., Yu, Y., Su, D., Wu, K., Sheng, Y. (2017). 
Long noncoding RNA linc00617 exhibits oncogenic activity in breast cancer. 
Molecular Carcinogenesis, 56(1), 3-17. doi: 10.1002/mc.22338. 
 
Li, L., Zhang, J., Xiong, N., Li, S., Chen, Y., Yang, H., Wu, C., Zeng, H., Liu, Y. 
(2016). Notch-1 signaling activates NF-κB in human breast carcinoma 
MDA-MB-231 cells via PP2A-dependent AKT pathway. Medical Oncology, 
33(33), doi:10.1007/s12032-016-0747-7. 
 
Li, X., Lewis, M.T., Huang, J., Gutierrez, C., Osborne, C.K., Wu, M.F., Hilsenbeck, 
S.G., Pavlick, A., Zhang, X., Chamness, G.C., Wong, H., Rosen, J., Chang, 
J.C. (2008). Intrinsic Resistance of Tumorigenic Breast Cancer Cells to 
Chemotherapy. Journal of the National Cancer Institute, 100(9), 672-679. 
doi: 10.1093/jnci/djn123. 
 
Li, Y., Podsypanina, K., Liu, X., Crane, A., Tan, L.K., Parsons, R., Varmus, H.E. 
(2001). Deficiency of Pten Accelerates Mammary Oncogenesis in MMTV-






Li, Z., Dong, X., Wang, Z., Liu, W., Deng, N., Ding, Y., Tang, L., Hla, T., Zeng, 
R., Li, L., Wu, D. (2005). Regulation of PTEN by Rho small GTPases. 
Nature Cell Biology, 7(4), 399-404. doi: 10.1038/ncb1236. 
 
Liang, Y., Hu, J., Li, J., Liu, Y.,  Yu, J., Zhuang, X., Mu, L., Kong, X., Hong, 
D., Yang, Q., Hu, G. (2015). Epigenetic Activation of TWIST1 by MTDH 
Promotes Cancer Stem-like Cell Traits in Breast Cancer. Cancer Research, 
75(17), 3672-3680. doi: 10.1158/0008-5472.can-15-0930. 
 
Lima-Fernandes, E., Enslen, H., Camand, E., Kotelevets, L., Boularan, C., Achour, 
L., Benmerah, A., Gibson, L.C., Baillie, G.S., Pitcher, J.A., Chastre, 
E., Etienne-Manneville, S., Marullo, S., Scott, M.G. (2011). Distinct 
functional outputs of PTEN signalling are controlled by dynamic association 
with β-arrestins. The EMBO Journal, 30(13), 2557-2568. doi: 
10.1038/emboj.2011.178. 
 
Linassier, C., Barin, C., Calais, G., Letortorec, S., Bremond, J.L., Delain, M., Petit, 
A., Georget, M.T., Cartron, G., Raban, N., Benboubker, L., Leloup, R., 
Binet, C., Lamagnere, J.R., Colombat, P. (2000). Early secondary acute 
myelogenous leukemia in breast cancer women after treatment with 
mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Annals 
of Oncology, 11(10), 1289-1294.  
 
Lipton, A., Goodman, L., Leitzel, K., Cook, J., Sperinde, J., Haddad, M., Köstler, 
W.J., Huang, W., Weidler, J.M., Ali, S., Newton, A., Fuchs, E.M., Paquet, 
A., Singer, C.F., Horvat, R., Jin, X., Banerjee, J., Mukherjee, A., Tan, 
Y., Shi, Y., Chenna, A., Larson, J., Lie, Y., Sherwood, T., Petropoulos, 
C.J., Williams, S., Winslow, J., Parry, G., Bates, M. (2013). HER3, 
p95HER2, and HER2 protein expression levels define multiple subtypes of 
HER2-positive metastatic breast cancer. Breast Cancer Research and 
Treatment, 141(1), 43-53. doi: 10.1007/s10549-013-2665-0. 
 
Liu, B., Sun, L., Song, E. (2013). Non-coding RNAs regulate tumor cell plasticity. 
Science China Life Sciences, 56(10), 886-890. doi: 10.1007/s11427-013-
4554-5. 
 
Liu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G.A., Fan, Y., Yin, D., Gu, F., Yao, 
Z., Fu, L. (2011). CD8+ cytotoxic T cell and FOXP3+ regulatory T cell 
infiltration in relation to breast cancer survival and molecular subtypes. 
Breast Cancer Research and Treatment, 130(2), 645-655. doi: 
10.1007/s10549-011-1647-3. 
 
Liu, J.C., Deng, T., Lehal, R.S., Kim, J., Zacksenhaus, E. (2007). Identification of 





Tumors. Cancer Research, 67(18), 8671-8681. doi: 10.1158/0008-
5472.can-07-1486. 
 
Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, 
L., McDermott, S.P., Landis, M.D., Hong, S., Adams, A., D'Angelo, 
R., Ginestier, C., Charafe-Jauffret, E. Clouthier, S.G., Birnbaum, D., Wong, 
S.T., Zhan, M., Chang, J.C., Wicha, M.S. (2014). Breast Cancer Stem Cells 
Transition between Epithelial and Mesenchymal States Reflective of their 
Normal Counterparts. Stem Cell Reports, 2(1), 78-91. doi: 
10.1016/j.stemcr.2013.11.009. 
 
Liu, Z.J., Xiao, M., Balint, K., Smalley, K.S. Brafford, P., Qiu, R., Pinnix, C.C., Li, 
X., Herlyn, M. (2006). Notch1 Signaling Promotes Primary Melanoma 
Progression by Activating Mitogen-Activated Protein 
Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-
Cadherin Expression. Cancer Research, 66(8), 4182-4190. doi: 
10.1158/0008-5472.can-05-3589. 
 
Loi, S., Michiels, S., Lambrechts, D., Salgado, R., Sirtaine, N., Fumagalli, D., 
Claes, B., Kellokumpu-Lehtinen, P-L., Bono, P., Kataja, V.V., Larsimont, D., 
Piccart-Gebhart, M.J., Joensuu, H., Sotiriou, C. (2012). Tumor PIK3CA 
mutations, lymphocyte infiltration, and recurrence-free survival in early 
breast cancer (BC): Results from the FinHER trial. Journal of Clinical 
Oncology, 30: 282-290. 
 
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, 
G., Francis, P., Crown, J.P., Hitre, E., de Azambuja, E., Quinaux, E., Di 
Leo, A., Michiels, S., Piccart, M.J., Sotiriou, C. (2013). Prognostic and 
Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III 
Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer 
Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-
Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31(7), 860-
867. doi: 10.1200/jco.2011.41.0902. 
 
Loibl, S., Darb-Esfahani, S., Huober, J., Klimowicz, A., Furlanetto, J., Lederer, 
B., Hartmann, A., Eidtmann, H., Pfitzner, B., Fasching, P.A., Tiemann, 
K., Jackisch, C., Mehta, K., von Minckwitz, G., Untch, M., Denkert, C. 
(2016). Integrated Analysis of PTEN and p4EBP1 Protein Expression as 
Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer 
Research, 22(11), 2675-2683. doi: 10.1158/1078-0432.CCR-15-0965. 
 
Lowell, S., Benchoua, A., Heavey, B., Smith, A.G. (2006). Notch Promotes Neural 
Lineage Entry by Pluripotent Embryonic Stem Cells. PLoS Biology, 4(5), 






Lu, J., Jeong, H.W., Kong, N., Yang, Y., Carroll, J., Luo, H.R., Silberstein, 
L.E., Yupoma, Chai, L. (2009). Stem Cell Factor SALL4 Represses the 
Transcriptions of PTEN and SALL1 through an Epigenetic Repressor 
Complex. PLoS ONE, 4(5), e5577. doi: 10.1371/journal.pone.0005577. 
 
Lu, P., Weaver, V. M., Werb, Z. (2012). The extracellular matrix: A dynamic niche 
in cancer progression. The Journal of Cell Biology, 196(4), 395-406. doi: 
10.1083/jcb.201102147. 
 
Lu, Y., Yu, Q., Liu, J.H., Zhang, J., Wang, H., Koul, D., McMurray, J.S., Fang, 
X., Yung, W.K., Siminovitch, K.A., Mills, G.B. (2003). Src Family Protein-
tyrosine Kinases Alter the Function of PTEN to Regulate 
Phosphatidylinositol 3-Kinase/AKT Cascades. Journal of Biological 
Chemistry, 278(41), 40057-40066. doi: 10.1074/jbc.M303621200. 
 
Lu, Y., Zi, X., Pollak, M. (2004). Molecular mechanisms underlying IGF-1-induced 
attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on 
SkBr3 breast cancer cells. International Journal of Cancer, 108(3), 334-341. 
doi: 10.1002/ijc.11445. 
 
Luyendyk, J.P., Schabbauer, G.A., Tencati, M., Holscher, T., Pawlinski, 
R., Mackman, N. (2008). Genetic Analysis of the Role of the PI3K-Akt 
Pathway in Lipopolysaccharide-Induced Cytokine and Tissue Factor Gene 
Expression in Monocytes/Macrophages. Jounal of Immunology, 180(6). 
4218-4226. 
 
Ma, F., Chen, D., Chen, F., Chi, Y., Han, Z., Feng, X., Li, X., Han, Z. (2015). 
Human Umbilical Cord Mesenchymal Stem Cells Promote Breast Cancer 
Metastasis by Interleukin-8- and Interleukin-6-Dependent Induction of 
CD44+/CD24- Cells. Cell Transplantation, 24(12), 2585-2599. doi: 
10.3727/096368915x687462. 
 
Ma, J., Meng, Y., Kwiatkowski, D.J., Chen, X., Peng, H., Sun, Q., Zha, X., Wang, 
F., Wang, Y., Jing, Y., Zhang, S., Chen, R., Wang, L., Wu, E., Cai, 
G., Malinowska-Kolodziej, I., Liao, Q., Liu, Y., Zhao, Y., Sun, Q., Xu, 
K., Dai, J., Han, J., Wu, L., Zhao, R.C., Shen, H., Zhang, H. (2010). 
Mammalian target of rapamycin regulates murine and human cell 
differentiation through STAT3/p63/Jagged/Notch cascade. The Journal of 
Clinical Investigation, 120(1), 103-114. doi: 10.1172/JCI37964. 
 
Machleidt, A., Buchholz, S., Diermeier-Daucher, S., Zeman, F., Ortmann, 





expression in triple-negative and Her2 positive breast cancer women. BMC 
Cancer, 13(437). doi: 10.1186/1471-2407-13-437. 
 
Macias, H., Hinck, L. (2012). Mammary Gland Development. Wiley interdisciplinary 
reviews. Developmental biology, 1(4), 533-557. doi: 10.1002/wdev.35. 
 
Magnifico, A., Albano, L., Campaner, S., Delia, D., Castiglioni, F., Gasparini, 
P., Sozzi, G., Fontanella, E., Menard, S., Tagliabue, E. (2009). Tumor-
Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest 
Oncoprotein Levels and Are Sensitive to Trastuzumab. Clinical Cancer 
Research, 15(6), 2010-2021. doi: 10.1158/1078-0432.ccr-08-1327. 
 
Majewski, I.J., Nuciforo, P., Mittempergher, L., Bosma, A.J., Eidtmann, 
H., Holmes, E., Sotiriou, C., Fumagalli, D., Jimenez, J., Aura, C., Prudkin, 
L., Díaz-Delgado, M.C., de la Peña, L., Loi, S., Ellis, C., Schultz, N., de 
Azambuja, E., Harbeck, N., Piccart-Gebhart, M., Bernards, R., Baselga, J. 
(2015). PIK3CA Mutations Are Associated With Decreased Benefit to 
Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted 
Therapies in Breast Cancer. Journal of Clinical Oncology, 33(12), 1334-
1339. doi: 10.1200/jco.2014.55.2158. 
 
Malmgren, J.A., Calip, G.S., Pyott, S.M., Atwood, M.K., Kaplan, H.G. (2016). 
Therapy-related myelodysplastic syndrome following primary breast 
cancer. Leukemia Research, 47, 178-184. doi: 
10.1016/j.leukres.2016.06.005. 
 
Mani, S.A., Guo, W., Liao, M-J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, 
M., Reinhard, F., Zhang, C.C., Shipitsin, M., Campbell, L.L., Polyak, 
K., Brisken, C., Yang, J., Weinberg, R.A. (2008). The Epithelial-
Mesenchymal Transition Generates Cells with Properties of Stem Cells. 
Cell, 133(4), 704-715. doi: 10.1016/j.cell.2008.03.027. 
 
Mani, S.A., Yang, J., Brooks, M., Schwaninger, G., Zhou, A., Miura, N., Kutok, 
J.L., Hartwell, K., Richardson, A.L., Weinberg, R.A. (2007). Mesenchyme 
Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with 
aggressive basal-like breast cancers. Proceedings of the National Academy 
of Sciences, 104(24), 10069-10074. doi: 10.1073/pnas.0703900104. 
 
Mao, J., Song,  B., Shi, Y., Wang, B., Fan, S., Yu, X., Tang, J., Li, L. (2013). 
ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel. 







Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, 
M., Chan, S., Grimes, D., Antón, A., Lluch, A., Kennedy, J., O'Byrne, 
K., Conte, P., Green, M., Ward, C., Mayne, K., Extra, J.M. (2005). 
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab 
Combined With Docetaxel in Women With Human Epidermal Growth Factor 
Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line 
Treatment: The M77001 Study Group. Journal of Clinical Oncology, 23(19), 
4265-4274. doi: 10.1200/jco.2005.04.173. 
 
Mathew, A., Davidson, N.E. (2015). Adjuvant endocrine therapy for 
premenopausal women with hormone-responsive breast cancer. The 
Breast, 24, S120-S125. doi: 10.1016/j.breast.2015.07.027. 
 
Mathieu, J., Zhang, Z., Zhou, W., Wang, A.J., Heddleston, J.M., Pinna, 
C.M., Hubaud, A., Stadler, B., Choi, M., Bar, M., Tewari, M., Liu, 
A., Vessella, R., Rostomily, R., Born, D., Horwitz, M., Ware, C., Blau, 
C.A., Cleary, M.A., Rich, J.N., Ruohola-Baker, H. (2011). HIF Induces 
Human Embryonic Stem Cell Markers in Cancer Cells. Cancer Research, 
71(13), 4640-4652. doi: 10.1158/0008-5472.can-10-3320. 
 
May, L.T., Hill, S.J. (2008). ERK phosphorylation: Spatial and temporal regulation 
by G protein-coupled receptors. The International Journal of Biochemistry 
and Cell Biology, 40(10), 2013-2017. doi: 10.1016/j.biocel.2008.04.001. 
 
Meurette, O., Stylianou, S., Rock, R., Collu, G.M., Gilmore, A.P., Brennan, K. 
(2009). Notch Activation Induces Akt Signaling via an Autocrine Loop to 
Prevent Apoptosis in Breast Epithelial Cells. Cancer Research, 69(12), 
5015-5022. doi: 10.1158/0008-5472.can-08-3478. 
 
Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, 
D., Cobleigh, M., Di Leo, A., Johnston, S., Gasparini, G., Kaufman, 
B., Marty, M., Nekljudova, V., Paluch-Shimon, S., Penault-Llorca, 
F., Slamon, D., Vogel, C., von Minckwitz, G., Buyse, M., Piccart M. (2016). 
Progression-free survival as surrogate end point for overall survival in 
clinical trials of HER2-targeted agents in HER2-positive metastatic breast 
cancer. Annals of Oncology, 27(6), 1029-1034. doi: 
10.1093/annonc/mdw132. 
 
Minaguchi, T., Waite, K.A., Eng, C. (2006). Nuclear Localization of PTEN Is 
Regulated by Ca2+ through a Tyrosil Phosphorylation-Independent 
Conformational Modification in Major Vault Protein. Cancer Research, 






Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O'Brien, 
T., Mendoza, A.D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, 
B., Jankowski, T., Zuziak, D., Zok, J., Szostakiewicz, B., Foszczyńska-
Kłoda, M., Tempińska-Szałach, A., Rossi, E., Varella-Garcia, M. (2012). 
Increased MET and HGF gene copy numbers are associated with 
trastuzumab failure in HER2-positive metastatic breast cancer. British 
Journal of Cancer, 107(5), 793-799. doi: 10.1038/bjc.2012.335. 
 
Mitra, D., Brumlik, M.J., Okamgba, S.U., Zhu, Y., Duplessis, T.T., Parvani, 
J.G., Lesko, S.M., Brogi, E., Jones, F.E. (2009). An oncogenic isoform of 
HER2 associated with locally disseminated breast cancer and trastuzumab 
resistance. Molecular Cancer Therapeutics, 8(8), 2152-2162. doi: 
10.1158/1535-7163.mct-09-0295. 
 
Mittal, S., Sharma, A., Balaji, S.A., Gowda, M.C., Dighe, R.R., Kumar, 
R.V., Rangarajan, A. (2014). Coordinate Hyperactivation of Notch1 and 
Ras/MAPK Pathways Correlates with Poor Women Survival: Novel 
Therapeutic Strategy for Aggressive Breast Cancers. Molecular Cancer 
Therapeutics, 13(12), 3198-3209. doi: 10.1158/1535-7163.mct-14-0280. 
 
Mittal, S., Subramanyam, D., Dey, D., Kumar, R.V., Rangarajan, A. (2009). 
Cooperation of Notch and Ras/MAPK signaling pathways in human breast 
carcinogenesis. Molecular Cancer, 8(1), 128. doi: 10.1186/1476-4598-8-
128. 
 
Mittendorf, E.A., Clifton, G.T., Holmes, J.P., Clive, K.S., Patil, R., Benavides, 
L.C., Gates, J.D., Sears, A.K., Stojadinovic, A., Ponniah, S., Peoples, G.E. 
(2012). Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast 
cancer recurrence in high-risk women. Cancer, 118(10), 2594-2602. doi: 
10.1002/cncr.26574. 
 
Mittendorf, E.A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K.K., Dawood, 
S., Esteva, F.J., Buzdar, A.U., Chen, H., Eksambi, S., Hortobagyi, 
G.N., Baselga, J., Gonzalez-Angulo, A.M. (2009). Loss of HER2 
Amplification Following Trastuzumab-Based Neoadjuvant Systemic 
Therapy and Survival Outcomes. Clinical Cancer Research, 15(23), 7381-
7388. doi: 10.1158/1078-0432.ccr-09-1735. 
 
Mohd Nafi, S.N., Generali, D., Kramer-Marek, G., Gijsen, M., Strina, 
C., Cappelletti, M., Andreis, D., Haider, S., Li, J.L., Bridges, E., Capala, 
J., Ioannis, R., Harris, A.L., Kong, A. (2014). Nuclear HER4 mediates 
acquired resistance to trastuzumab and is associated with poor outcome in 







Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J. 
(2001). Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor 
Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain 
Cleavage in Breast Cancer Cells. Cancer Research, 61(12), 4744-4749.  
 
Montemurro, F., Rossi, V., Cossu Rocca, M., Martinello, R., Verri, E., Redana, 
S., Adamoli, L., Valabrega, G., Sapino, A., Aglietta, M., Viale, 
G., Goldhirsch, A., Nolè, F. (2012). Hormone-receptor expression and 
activity of trastuzumab with chemotherapy in HER2-positive advanced 
breast cancer women. Cancer, 118(1), 17-26. doi: 10.1002/cncr.26162. 
 
Moore K., Persaud, T. (1998). The Developing Human—Clinically Oriented 
Embryology (6 ed.). Philadelphia: WB Saunders Company. 
 
Morel, A-P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., Puisieux, A. (2008). 
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal 
Transition. PLoS ONE, 3(8), e2888. doi: 10.1371/journal.pone.0002888. 
 
Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, 
J.F., Arteaga, C.L. (2001). Epidermal Growth Factor Receptor (HER1) 
Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2)-
overexpressing Breast Cancer Cells in Vitro and in Vivo. Cancer Research, 
61(24), 8887-8895.  
 
Mungamuri, S.K., Yang, X., Thor, A.D., Somasundaram, K. (2006). Survival 
Signaling by Notch1: Mammalian Target of Rapamycin (mTOR)-Dependent 
Inhibition of p53. Cancer Research, 66(9), 4715-4724. doi: 10.1158/0008-
5472.can-05-3830. 
 
Muthuswamy, S.K., Li, D., Lelievre, S., Bissell, M.J., Brugge, J.S. (2001). ErbB2, 
but not ErbB1, Reinitiates Proliferation and Induces Luminal Repopulation 
in Epithelial Acini. Nature Cell Biology, 3(9), 785-792. doi: 
10.1038/ncb0901-785. 
 
Nagata, Y., Lan, K-H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Klos, K.S., Li, 
P., Monia, B.P., Nguyen, N.T., Hortobagyi, G.N., Hung, M.C., Yu, D. 
(2004). PTEN activation contributes to tumor inhibition by trastuzumab, and 
loss of PTEN predicts trastuzumab resistance in women. Cancer Cell, 6(2), 
117-127. doi: 10.1016/j.ccr.2004.06.022. 
 
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K.L., Isola, 





ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer 
Cell Line. Cancer Research, 65(2), 473-482.  
 
Nahta, R., Yuan, L.X.H., Zhang, B., Kobayashi, R., Esteva, F.J. (2005). Insulin-
like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 
Hetero-dimerization Contributes to Trastuzumab Resistance of Breast 
Cancer Cells. Cancer Research, 65(23), 11118-11128. doi: 10.1158/0008-
5472.can-04-3841. 
 
Nahta, R., Takahashi, T., Ueno, N.T., Hung, M-C., Esteva, F.J. (2004). P27(kip1) 
Down-Regulation Is Associated with Trastuzumab Resistance in Breast 
Cancer Cells. [10.1158/0008-5472.CAN-03-3900]. Cancer Research, 
64(11), 3981.  
 
Nair, R., Roden, D.L., Teo, W.S., McFarland, A., Junankar, S., Ye, S., Nguyen, 
A., Yang, J., Nikolic, I., Hui, M., Morey, A., Shah, J., Pfefferle, A.D., Usary, 
J., Selinger, C., Baker, L.A., Armstrong, N., Cowley, M.J., Naylor, 
M.J., Ormandy, C.J., Lakhani, S.R., Herschkowitz, J.I., Perou, 
C.M., Kaplan, W., O'Toole, S.A., Swarbrick, A. (2013a). c-Myc and Her2 
cooperate to drive a stem-like phenotype with poor prognosis in breast 
cancer. Oncogene, 33(30), 3992-4002. doi: 10.1038/onc.2013.368. 
 
Nair, J.S., Sheikh, T., Ho, A.L., Schwartz, G.K. (2013b). PTEN Regulates 
Sensitivity of Meanoma Cells to RO4929097, the γ-secretase Inhibitor. 
Anticancer Research, 33(4), 1307-1316.  
 
Nam, Y., Sliz, P., Pear, W.S., Aster, J.C., Blacklow, S.C. (2007). Cooperative 
Assembly of higher-order Notch complexes functions as a switch to induce 
transcription. Proceedings of the National Academy of Sciences, 104(7), 
2103-2108. doi: 10.1073/pnas.0611092104. 
 
Nguyen, D.H., Webb, D.J., Catlingi, A.D., Song, Q., Dhakephalkar, A., Weber, 
M.J., Ravichandran, K.S., Gonias, S.L. (2000). Urokinase-type 
Plasminogen Activator Stimulates the Ras/Extracellular Signal-regulated 
Kinase (ERK) Signaling Pathway and MCF-7 Cell Migration by a 
Mechanism That Requires Focal Adhesion Kinase, Src, and Shc. Journal 
of Biological Chemistry, 275(25), 19382–19388. doi: 
10.1074/jbc.M909575199. 
 
Nickoloff, B.J., Osborne, B.A., Miele, L. (2003). Notch signaling as a therapeutic 
target in cancer: a new approach to the development of cell fate modifying 






NCI’s SEER cancer statistics review. (2015), from 
http://seer.cancer.gov/statfacts/html/breast.html. 
 
O'Connor, D.S., Grossman, D., Plescia, J., Li, F., (2000). Regulation of apoptosis 
at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the 
National Academy of Sciences, 97(24), 13103-13107. doi: 
10.1073/pnas.240390697. 
 
O'Neill, C.F., Urs, S., Cinelli, C., Lincoln, A., Nadeau, R.J., León, R., Toher, 
J., Mouta-Bellum, C., Friesel, R.E., Liaw, L. (2007). Notch2 Signaling 
Induces Apoptosis and Inhibits Human MDA-MB-231 Xenograft Growth. 
The American Journal of Pathology, 171(3), 1023-1036. doi: 
10.2353/ajpath.2007.061029. 
 
O’Regan R.M., Cisneros A., England G.M., MacGregor J.I., Muenzner, 
H.D., Assikis, V.J., Bilimoria, M.M., Piette, M., Dragan, Y.P., Pitot, 
H.C., Chatterton, R., Jordan, V.C. (1998).  Effects of the Antiestrogens 
Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth. 
Journal of the National Cancer Institute 90(20). 1552-1558. 
 
O’Reilly, S.M., Barnes, D.M., Camplejohn, R.S., Bartkova, J., Gregory, 
 W.M., Richards, M.A. (1991). The relationship between c-erbB-2 
 expression, S-phase fraction and  prognosis in breast cancer. British 
 Journal of Cancer 63(3). 444-446. 
 
Odriozola, L., Singh, G., Hoang, T., Chan, A. M. (2006). Regulation of PTEN 
Activity by Its Carboxyl-terminal Autoinhibitory Domain. Journal of Biological 
Chemistry, 282(32), 23306–23315. doi: 10.1074/jbc.M611240200. 
 
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.H., Saito, 
 K., Sakamoto, A., Inoue, M., Shirouzu, M., Yokoyama, S. (2002). Crystal 
 Structure of  the Complex of Human Epidermal Growth Factor and 
 Receptor Extracellular Domains. Cell 110(6), 775-787. 
 
Okumura, K., Mendoza, M., Bachoo, R.M., DePinho, R.A., (2006). PCAF 
Modulates PTEN Activity. Journal of Biological Chemistry, 281(36), 26562–
26568. doi: 10.1074/jbc.M605391200. 
 
Olayioye, M.A., Graus-Porta, D., Beerli, R.R., Rohrer, J., Gay, B., Hynes, N.E. 
(1998). ErbB-1 and ErbB-2 acquired distinct signaling properties dependent 







Osipo, C., Patel, P., Rizzo, P., Clementz, A.G., Hao, L., Golde, T.E., Miele, L. 
(2008). ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer 
cells to a γ-secretase inhibitor. Oncogene, 27(37), 5019-5032. doi: 
10.1038/onc.2008.149. 
 
Oswald, F., Tauber, B., Dobner, T., Bourteele, S., Kostezka, U., Adler, G., Liptay, 
S., Schmid, R.M. (2001). p300 acts as a transcriptional coactivator for 
mammalian Notch-1. Molecular and Cellular Biology, 21(22), 7761-7774. 
doi: 10.1128/MCB.21.22.7761-7774.2001. 
 
Oswald, F., Winkler, M., Cao, Y., Astrahantseff, K., Bourteele, S., Knöchel, 
W., Borggrefe, T. (2005). RBP-J /SHARP Recruits CtIP/CtBP Corepressors 
To Silence Notch Target Genes. Molecular and Cellular Biology, 25(23), 
10379-10390. doi: 10.1128/mcb.25.23.10379-10390.2005. 
 
Packeisen, J., Kaup-Franzen, C.H., Knieriem, H-J. (2009). Detection of Surface 
Antigen 17-1A in Breast and Colorectal Cancer. Hybridoma, 18(1), 37-40. 
doi: 10.1089/hyb.1999.18.37. 
 
Paik , S., Kim , C., Wolmark , N. (2008). HER2 Status and Benefit from Adjuvant 
Trastuzumab in Breast Cancer. New England Journal of Medicine, 358(13), 
1409-1411. doi: doi:10.1056/NEJMc0801440. 
 
Palmeirim, I., Henrique, D., Ish-Horowicz, D., Pourquie, O. (1997). Avian hairy 
Gene Expression Identifies a Molecular Clock Linked to Vertebrate 
Segmentation and Somitogenesis. Cell, 91, 639–648.  
 
Palomero, T., Sulis, M.L., Cortina, M., Real, P.J., Barnes, K., Ciofani, 
M., Caparros, E., Buteau, J., Brown, K., Perkins, S.L., Bhagat, G., Agarwal, 
A.M., Basso, G., Castillo, M., Nagase, S., Cordon-Cardo, C., Parsons, 
R., Zúñiga-Pflücker, J.C., Dominguez, M., Ferrando, A.A. (2007). 
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell 
leukemia. Nature Medicine, 13(10), 1203-1210. doi: 10.1038/nm1636. 
 
Pandya, K., Meeke, K., Clementz, A.G., Rogowski, A., Miele, L., Albain, 
K.S., Osipo, C. (2011). Targeting both Notch and ErbB-2 signalling 
pathways is required for prevention of ErbB-2-positive breast tumour 
recurrence. British Journal of Cancer, 105(6), 796-806. doi: 
10.1038/bjc.2011.321. 
 
Pandya, S., Moore, R.G. (2011). Breast Development and Anatomy. Clinical 






Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, 
X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., Liu, Y., Tang, J., Wang, 
S., Fu, Y.X. (2010a). The Therapeutic Effect of Anti-HER2/neu Antibody 
Depends on Both Innate and Adaptive Immunity. Cancer Cell, 18(2), 160-
170. doi: 10.1016/j.ccr.2010.06.014. 
 
Park, S.Y., Lee, H.E., Li, H., Shipitsin, M., Gelman, R., Polyak, K. (2010b). 
Heterogeneity for stem cell-related markers according to tumor subtype and 
histologic stage in breast cancer. Clinical cancer research, 16(3), 876-887. 
doi: 10.1158/1078-0432.ccr-09-1532. 
 
Park, Y.H., Jung, H.A., Choi, M.K., Chang, W., Choi, Y.L., Do, I.G., Ahn, J.S., Im, 
Y.H. (2014). Role of HER3 expression and PTEN loss in women with HER2-
overexpressing metastatic breast cancer (MBC) who received taxane plus 
trastuzumab treatment. British Journal of Cancer, 110(2), 384-391. doi: 
10.1038/bjc.2013.757. 
 
Parr C., Watkins, G., Jiang W.G. (2004). The possible correlation of Notch-1 and 
Notch-2 with clinical outcome and tumour clinicopathological parameters in 
human breast cancer. International Journal of Molecular Medecine 14(5), 
779–786. doi: 10.3892/ijmm.14.5.779. 
 
Parra-Palau, J.L., Morancho, B., Peg, V., Escorihuela, M., Scaltriti, M., Vicario, 
R., Zacarias-Fluck, M., Pedersen, K., Pandiella, A., Nuciforo, P., Serra, 
V., Cortés, J., Baselga, J., Perou, C.M., Prat, A., Rubio, I.T., Arribas, J. 
(2014). Effect of p95HER2/611CTF on the Response to Trastuzumab and 
Chemotherapy. Journal of the National Cancer Institute, 106(11), dju291. 
doi: 10.1093/jnci/dju291. 
 
Pasinia, A., Henriqueb, D., Wilkinsona, D.G. (2001). The zebrafsh Hairy/Enhancer-
of-split-related gene her6 is segmentally expressed during the early 
development of hindbrain and somites. Mechanisms of Development, 100, 
317-321.  
 
Pearson, G., Robinson, F., Beers Gibson, T.B., Xu, B.E., Karandikar, M., Berman, 
K., Cobb, M.H. (2001). Mitogen-Activated Protein (MAP) Kinase Pathways: 
Regulation and Physiological Functions. Endocrine Reviews, 22(2), 153-
183. doi: doi:10.1210/edrv.22.2.0428. 
 
Pece, S., Serresi, M., Santolini, E., Capra, M., Hulleman, E., Galimberti, 
V., Zurrida, S., Maisonneuve, P., Viale, G., Di Fiore, P.P. (2004). Loss of 
negative regulation by Numb over Notch is relevant to human breast 







Pece, S., Tosoni, D., Confalonieri, S., Mazzarol, G., Vecchi, M., Ronzoni, 
S., Bernard, L., Viale, G., Pelicci, P.G., Di Fiore, P.P. (2010). Biological and 
Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer 
Stem Cell Content. Cell, 140(1), 62-73. doi: 10.1016/j.cell.2009.12.007. 
 
Pedersen, K., Angelini, P-D., Laos, S., Bach-Faig, A., Cunningham, M.P., Ferrer-
Ramón, C., Luque-García, A., García-Castillo, J., Parra-Palau, 
J.L., Scaltriti, M., Ramón y Cajal, S., Baselga, J., Arribas, J. (2009). A 
Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes 
Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 
29(12), 3319-3331. doi: 10.1128/mcb.01803-08. 
 
Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, 
D., Baly, D., Baughman, S.A., Twaddell, T., Glaspy, J.A., Slamon, D.J. 
(1998). Phase II Study of Receptor-Enhanced Chemosensitivity Using 
Recombinant Humanized Anti-p185HER2/neu Monoclonal Antibody Plus 
Cisplatin in Women With HER2/neu-Overexpressing Metastatic Breast 
Cancer Refractory to Chemotherapy Treatment. Journal of Clinical 
Oncology, 16, 2659-2671. doi: 10.1200/jco.1998.16.8.2659. 
 
Perou, C.M., Sùrlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, 
C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., Fluge, 
O., Pergamenschikov, A., Williams, C., Zhu, S.X., Lønning, P.E., Børresen-
Dale, A.L., Brown, P.O., Botstein, D. (2000). Molecular portraits of human 
breast tumours. Nature, 406, 747-752. doi: 10.1038/35021093. 
 
Persson, L.M., Wilson, A.C. (2010). Wide-Scale Use of Notch Signaling Factor 
CSL/RBP-J  in RTA-Mediated Activation of Kaposi's Sarcoma-Associated 
Herpesvirus Lytic Genes. Journal of Virology, 84(3): 1334-1347. doi: 
10.1128/JVI.01301-09. 
 
Phillips, T.M., McBride, W.H., Pajonk, F. (2006). The Response of CD24-
/low/CD44+ Breast Cancer-Initiating Cells to Radiation. Journal of the 
National Cancer Institute, 98(24), 1777-1785. doi: 10.1093/jnci/djj495. 
 
Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, 
M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, 
D., Dowsett, M., Barrios, C.H., Steger, G., Huang, C.S., Andersson, 
M., Inbar, M., Lichinitser, M., Láng, I., Nitz, U., Iwata, H., Thomssen, 
C., Lohrisch, C., Suter, T.M., Rüschoff, J., Suto, T., Greatorex, V., Ward, 
C., Straehle, C., McFadden, E., Dolci, M.S., Gelber, 
R.D., Herceptin Adjuvant (HERA) Trial Study Team. (2005). Trastuzumab 





England Journal of Medicine, 353(16), 1659-1672. doi: 
10.1056/NEJMoa052306. 
 
Piccart-Gebhart, M.J., Holmes, A.P., Baselga, J., De Azambuja, E., Dueck, A.C., 
Viale, G., Zujewski, J.A., Goldhirsch, A., Santillana, S., Pritchard, K.I., Wolff, 
A.C., Jackisch, C., Lang, I., Untch, M., Smith, I.E., Boyle, F., Xu, B., Gomez, 
H.L., Gelber, R.D., Perez, E.A. (2014). First results from the phase III 
ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of 
anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their 
sequence (T → L), or their combination (T+L) in the adjuvant treatment of 
HER2- positive early breast cancer (EBC). Journal of Clinical Oncology, 
32(5s).  
 
Piva, M., Domenici, G., Iriondo, O., Rabano, M., Simões, B.M., Comaills, 
V., Barredo, I., López-Ruiz, J.A., Zabalza, I., Kypta, R., Vivanco, Md. 
(2014). Sox2 Promotes Tamoxifen Resistance in Breast Cancer. EMBO 
Molecular Medicine, 6(1), 66-79. doi: 10.1002/emmm.201303411. 
 
Pogue-Geile, K.L., Song, N., Jeong, J-H., Gavin, P.G., Kim, S.R., Blackmon, 
N.L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E.P., Swain, 
S.M., Wickerham, D.L., Geyer, C.E. Jr., Costantino, J.P., Wolmark, 
N., Paik, S. (2015). Intrinsic Subtypes, PIK3CA Mutation, and the Degree 
of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. Journal of 
Clinical Oncology, 33(12), 1340-1347. doi: 10.1200/jco.2014.56.2439. 
 
Pradeep, C.R., Köstler, W.J., Lauriola, M., Granit, R.Z., Zhang, F., Jacob-Hirsch, 
J., Rechavi, G., Nair, H.B., Hennessy, B.T., Gonzalez-Angulo, 
A.M., Tekmal, R.R., Ben-Porath, I., Mills, G.B., Domany, E., Yarden, Y. 
(2011). Modeling ductal carcinoma in situ: a HER2–Notch3 collaboration 
enables luminal filling. Oncogene, 31(7), 907-917. doi: 
10.1038/onc.2011.279. 
 
Prat, A., Parker, J.S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J.I., He, 
X., Perou, C.M. (2010). Phenotypic and molecular characterization of the 
claudin-low intrinsic subtype of breast cancer. Breast Cancer Research, 
12(5), R68-R68. doi: 10.1186/bcr2635. 
 
Price-Schiavi, S.A., Jepson, S., Li, P., Arango, M., Rudland, P.S., Yee, 
L., Carraway, K.L. (2002). Rat Muc4 (sialomucin complex) reduces binding 
of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for 







Qi, X., Yin, N., Ma, S., Lepp, A., Tang, J., Jing, W., Johnson, B., Dwinell, 
M.B., Chitambar, C.R., Chen, G. (2015). p38γ MAPK is a Therapeutic 
Target for Triple Negative Breast Cancer by Stimulation of Cancer Stem-
Like Cell Expansion. Stem Cells, 33(9), 2738-2747. doi: 
10.1002/stem.2068. 
 
Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, 
H., Aster, J.C., Krishna, S., Metzger, D., Chambon, P., Miele, L., Aguet, 
M., Radtke, F., Dotto, G.P. (2001). Notch signaling is a direct determinant 
of keratinocyte growth arrest and entry into differentiation. EMBO Journal, 
20(13), 3427-3436. doi: 10.1093/emboj/20.13.3427. 
 
Rao, X., Huang, X., Zhou, Z., Lin, X. (2013). An improvement of the 2^(-delta delta 
CT) method for quatitative real-time polymerase chain reaction data 
analysis. Biostatistics Bioinformatics Biomathematics, 3(3), 71-85. 
 
Rasband W.S., ImageJ. Bethesda, Maryland: U. S. National Institutes of Health; 
1997-2016. 
 
Razis, E., Bobos, M., Kotoula, V., Eleftheraki, A.G., Kalofonos, H.P., Pavlakis, 
K., Papakostas, P., Aravantinos, G., Rigakos, G., Efstratiou, I., Petraki, 
K., Bafaloukos, D., Kostopoulos, I., Pectasides, D., Kalogeras, 
K.T., Skarlos, D., Fountzilas, G. (2011). Evaluation of the association of 
PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in 
metastatic breast cancer. Breast Cancer Research and Treatment, 128(2), 
447-456. doi: 10.1007/s10549-011-1572-5. 
 
Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, 
D.R., Lockwood, G., Egan, S.E. (2005). High-level Coexpression of JAG1 
and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with 
Poor Overall Survival. Cancer Research, 65, 7. doi: 10.1158/0008-
5472.CAN-05-1069. 
 
Rexer, B.N., Shyr, Y., Arteaga, C.L., Phosphatase and Tensin Homolog Deficiency 
and Resistance to Trastuzumab and Chemotherapy. (2013) Journal of 
Clinical Oncology, 31(17), 2073-2075. doi: 10.1200/JCO.2012.48.5243. 
 
Riese, D.J., Kim, E.D., Elenius, K., Buckley, S., Klagsbrun, M., Plowman, 
G.D., Stern, D.F. (1996). The Epidermal Growth Factor Receptor Couples 
Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-
like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4. Jouranl of 






Ritter, C.A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, 
J.A., Arteaga, C.L. (2007). Human Breast Cancer Cells Selected for 
Resistance to Trastuzumab In Vivo Overexpress Epidermal Growth Factor 
Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor 
Network. Clinical Cancer Research, 13(16), 4909-4919. doi: 10.1158/1078-
0432.CCR-07-0701. 
 
Roberts, P.J., Bisi, J.E., Strum, J.C., Combest, A.J., Darr, D.B., Usary, 
J.E., Zamboni, W.C., Wong, K.K., Perou, C.M., Sharpless, N.E. (2012). 
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer 
Therapy. Journal of the National Cancer Institute, 104(6), 476-487. doi: 
10.1093/jnci/djs002. 
 
Rogowski, A.S. (2011). Notch-1 Specifically Activates ERK1/2 in Multiple Breast 
Cancer Subtypes. Master’s Theses, 571, 
http://ecommons.luc.edu/luc_theses/571. 
 
Rommel, C., Radziwill, G., Moelling, K., Hafen, E. (1997). Negative regulation of 
Raf activity by binding of 14-3-3 to the amino terminus of Raf in vivo. 
Mechanisms of Development, 64, 95-104.  
 
Rose, S.L., Kunnimalaiyaan, M., Drenzek, J., Seiler, N. (2010). Notch 1 signaling 
is active in ovarian cancer. Gynecologic Oncology, 117(1), 130-133. doi: 
10.1016/j.ygyno.2009.12.003. 
 
Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, 
K., Hess, K.R., Stec, J., Ayers, M., Wagner, P., Morandi, P., Fan, 
C., Rabiul, I., Ross, J.S., Hortobagyi, G.N., Pusztai, L. (2005). Breast 
Cancer Molecular Subtypes Respond Differently to Preoperative 
Chemotherapy. Clinical Cancer Research, 11(16), 5678-5685. doi: 
10.1158/1078-0432.CCR-04-2421. 
 
Rumman, M., Dhawan, J., Kassem, M. (2015). Concise Review: Quiescence in 
Adult Stem Cells: Biological Significance and Relevance to Tissue 
Regeneration. Stem Cells, 33(10), 2903-2912. doi: 10.1002/stem.2056. 
 
Saal, L.H., Gruvberger-Saal, S.K., Persson, C., Lövgren, K., Jumppanen, 
M., Staaf, J., Jönsson, G., Pires, M.M., Maurer, M., Holm, K., Koujak, 
S., Subramaniyam, S., Vallon-Christersson, J., Olsson, H., Su, T., Memeo, 
L., Ludwig, T., Ethier, S.P., Krogh, M., Szabolcs, M., Murty, V.V., Isola, 
J., Hibshoosh, H., Parsons, R., Borg, A. (2008). Recurrent gross mutations 
of the PTEN tumor suppressor gene in breast cancers with deficient DSB 






Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., Semenza, G.L. (2014). 
Hypoxia-inducible factors are required for chemotherapy resistance of 
breast cancer stem cells. Proceedings of the National Academy of 
Sciences, 111(50), E5429-E5438. doi: 10.1073/pnas.1421438111. 
 
Sansone, P., Storci, G., Tayolari, S., Guarnieri, T., Giovannini, C., Taffurelli, 
M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K.B., Chieco, P., Bonafè, 
M. (2007). IL-6 triggers malignant features in mammospheres from human 
ductal breast carcinoma and normal mammary gland. Journal of Clinical 
Investestigation, 117(12), 3988–4002 doi: 10.1172/jci32533ds1. 
 
Santen, R.J., Harvey, H.A. (1999). Use of aromatase inhibitorsin breast 
carcinomas. Endocrine-Related Cancer 6(1), 75-92. 
 
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, 
P.D., Sánchez, G., Guzman, M., Parra, J.L., Ellis, C., Gagnon, R., Koehler, 
M., Gomez, H., Geyer, C., Cameron, D., Arribas, J., Rosen, N., Baselga, J. 
(2010). Clinical benefit of lapatinib-based therapy in women with HER2-
positive breast tumors co-expressing the truncated p95HER2 receptor. 
Clinical Cancer Research, 16(9), 2688-2695. doi: 10.1158/1078-0432.ccr-
09-3407. 
 
Scaltriti, M., Eichhorn, P.J., Cortés, J., Prudkin, L., Aura, C., Jiménez, 
J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y.H., Guzmán, M., Gili, 
M., Rodríguez, O., Rodríguez, S., Pérez, J., Green, S.R., Mai, S., Rosen, 
N., Hudis, C., Baselga, J. (2011). Cyclin E amplification/overexpression is a 
mechanism of trastuzumab resistance in HER2(+) breast cancer women. 
Proceedings of the National Academy of Sciences, 108(9), 3761-3766. doi: 
10.1073/pnas.1014835108. 
 
Scaltriti, M., Rojo, F., Ocaña, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, 
S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., Baselga, J. (2007). 
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and 
Response to Anti-HER2 Therapies in Breast Cancer. Journal of the National 
Cancer Institute, 99(8), 628-638. doi: 10.1093/jnci/djk134. 
 
Schabath, H., Runz, S., Joumaa, S., Altevogt, P. (2006). CD24 affects CXCR4 
function in pre-B lymphocytes and breast carcinoma cells. Journal of Cell 
Science, 119(2), 314-325. doi: 10.1242/jcs.02741. 
 
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., Hasmann, M. 
(2009). Strongly Enhanced Antitumor Activity of Trastuzumab and 





Tumor Models. Cancer Research, 69(24), 9330-9336. doi: 10.1158/0008-
5472.CAN-08-4597. 
 
Schneeweiss, A., Chia, S., Hegg, R., Tausch, C., Deb, R., Ratnayake, J., McNally, 
V., Ross, G., Kiermaier, A., Cortés, J. (2014). Evaluating the predictive 
value of biomarkers for efficacy outcomes in response to pertuzumab- and 
trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA 
study. Breast Cancer Research, 16(4), R73-R73. doi: 10.1186/bcr3690. 
 
Sengupta, A., Molkentin, J.D., Paik, J-H., DePinho, R.A., Yutzey, K.E. (2011). 
FoxO Transcription Factors Promote Cardiomyocyte Survival upon 
Induction of Oxidative Stress. Journal of Biological Chemistry, 286(9), 7468-
7478. doi: 10.1074/jbc.M110.179242. 
 
Seo, A.N., Lee, H.J., Kim, E.J., Kim, H.J., Jang, M.H., Lee, H.E., Kim, Y.J., Kim, 
J.H., Park, S.Y. (2013). Tumour-infiltrating CD8+ lymphocytes as an 
independent predictive factor for pathological complete response to primary 
systemic therapy in breast cancer. British Journal of Cancer, 109(10), 2705-
2713. doi: 10.1038/bjc.2013.634. 
 
Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P.J., Ibrahim, Y.H., Chandarlapaty, 
S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., Gili, 
M., Russillo, M., Parra, J.L., Singh, S., Arribas, J., Rosen, N., Baselga, J. 
(2011). PI3K inhibition results in enhanced HER signaling and acquired 
ERK dependency in HER2-overexpressing breast cancer. Oncogene, 
30(22), 2547-2557. doi: 10.1038/onc.2010.626. 
 
Sethi, N., Dai, X., Winter, C.G., Kang, Y. (2011). Tumor-Derived Jagged1 
Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch 
Signaling in Bone Cells. Cancer Cell, 19(2), 192-205. doi: 
10.1016/j.ccr.2010.12.022. 
 
Shackleton, M., Vaillant, F., Simpson, K.J., Stingl, J., Smyth, G.K., Asselin-Labat, 
M.L., Wu, L., Lindeman, G.J., Visvader, J.E. (2006). Generation of a 
functional mammary gland from a single stem cell. Nature, 439(7072), 84-
88. doi: 10.1038/nature04372. 
 
Sharma, S.V., Fischbach, M.A., Haber, D.A., Settleman, J. (2006). "Oncogenic 
Shock": Explaining Oncogene Addiction through Differential Signal 
Attenuation. Clinical Cancer Research, 12(14), 4392s-4395s. doi: 
10.1158/1078-0432.ccr-06-0096. 
 
Shattuck, D.L., Miller, J.K., Carraway, K.L., Sweeney, C. (2008). Met Receptor 





Cancer Cells. Cancer Research, 68(5), 1471. doi: 10.1158/0008-
5472.CAN-07-5962. 
 
Shaw, F.L., Harrison, H., Spence, K., Ablett, M.P., Simões, B.M., Farnie, 
G., Clarke, R.B. (2012). A Detailed Mammosphere Assay Protocol for the 
Quantification of Breast Cancer Stem Cell Activity. Journal of Mammary 
Gland Biology and Neoplasia 17(2), 111-117. doi: 10.1007/s10911-012-
9255-3. 
 
Shen, W. H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolfi, P.P., Yin, Y. 
(2007). Essential Role for Nuclear PTEN in Maintaining Chromosomal 
Integrity. Cell, 128(1), 157-170. doi: 10.1016/j.cell.2006.11.042. 
 
Shimizu, K., Chiba, S., Saito, T., Kumano, K., Hamada, Y., Hirai, H. (2002). 
Functional Diversity among Notch1, Notch2, and Notch3 Receptors. 
Biochemical and Biophysical Research Communications, 291(4), 775-779. 
doi: 10.1006/bbrc.2002.6528. 
 
Siddiqa, A., Long, L.M., Li, L., Marciniak, R.A., Kazhdan, I. (2008). Expression of 
HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins 
Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and 
phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer, 8(1), 
129. doi: 10.1186/1471-2407-8-129. 
 
Siegel, P.M., Muller, W.J. (1996). Mutations affecting conserved cysteine residues 
within the extracellular domain of Neu promote receptor dimerization and 
activation. Proceedings of the National Academy of Sciences, 93(17), 8878-
8883.  
 
Simmons, M.J., Serra, R., Hermance, N., Kelliher, M.A. (2012). NOTCH1 inhibition 
in vivo results in mammary tumor regression and reduced mammary 
tumorsphere-forming activity in vitro. Breast Cancer Research, 14(5), R126. 
doi: 10.1186/bcr3321. 
 
Singh, J.K., Farnie, G., Bundred, N.J., Simões, B.M., Shergill, A., Landberg, 
G., Howell, S.J., Clarke, R.B. (2013). Targeting CXCR1/2 Significantly 
Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of 
Inhibiting HER2 via HER2-dependent and -independent Mechanisms. 
Clinical cancer research, 19(3), 643-656. doi: 10.1158/1078-0432.ccr-12-
1063. 
 
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L. 
(1987). Human Breast Cancer: Correlation of Relapse and Survival with 






Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, 
A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, 
L. (2001). Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 
for Metastatic Breast Cancer that Overexpresses HER2. New England 
Journal of Medicine, 344(11), 783-792. doi: 
10.1056/NEJM200103153441101. 
 
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A.M., Yu, J., Klijn, J.G., Foekens, 
J.A., Martens, J.W. (2008). Subtypes of Breast Cancer Show Preferential 
Site of Relapse. Cancer Research, 68(9), 3108-3114. doi: 10.1158/0008-
5472.CAN-07-5644. 
 
Smith, A.L., Robin, T.P., Ford, H.L. (2012). Molecular Pathways: Targeting the 
TGF-β Pathway for Cancer Therapy. Clinical Cancer Research, 18(17), 
4514-4521. doi: 10.1158/1078-0432.CCR-11-3224. 
 
Somlo, G., Martel, C.L., Lau, S.K., Frankel, P., Ruel, C., Gu, L., Hurria, A., Chung, 
C., Luu, T., Morgan, R. Jr., Leong, L., Koczywas, M., McNamara, 
M., Russell, C.A., Kane, S.E. (2012). A phase I/II prospective, single arm 
trial of gefitinib, trastuzumab, and docetaxel in women with stage IV HER-2 
positive metastatic breast cancer. Breast Cancer Research and Treatment, 
131(3), 899-906. doi: 10.1007/s10549-011-1850-2. 
 
Song, K., Cornelius, S.C., Reiss, M., Danielpour, D. (2003). Insulin-like Growth 
Factor-I Inhibits Transcriptional Responses of Transforming Growth Factor- 
by Phosphatidylinositol 3-Kinase/Aktdependent Suppression of the 
Activation of Smad3 but Not Smad2*. Journal of Biological Chemistry, 
278(40), 38342–38351. doi: 10.1074/jbc.M304583200. 
 
Song, M.S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, 
J., Pandolfi, P.P. (2008). The deubiquitinylation and localization of PTEN 
are regulated by a HAUSP–PML network. Nature, 455(7214), 813-817. doi: 
10.1038/nature07290. 
 
Songyang, Z., Gish, G., Mbamalu, G., Pawson, T., Cantley, L.C. (1995). A single 
 point  mutation switches the specificity of group III Src homology (SH) 2 
 domains to that of group I SH2 domains. Journal of Biological 
 Chemistry, 270(44), 26029-26032. 
 
Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, 
T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Thorsen, T., Quist, 
H., Matese, J.C., Brown, P.O., Botstein, D., Lønning, P.E., Børresen-Dale, 





tumor subclasses with clinical implications. Proceedings of the National 
Academy of Sciences, 98(19), 10869-10874. doi: 
10.1073/pnas.191367098. 
 
Sotiriou, C., Neo, S-Y., McShane, L.M., Korn, E.L., Long, P.M., Jazaeri, A., Martiat, 
P., Fox, S.B., Harris, A.L., Liu, E.T. (2003). Breast cancer classification and 
prognosis based on gene expression profiles from a population-based 
study. Proceedings of the National Academy of Sciences, 100(18), 10393-
10398. doi: 10.1073/pnas.1732912100. 
 
Speir, E., Yu, Z.X., Takeda, K., Ferrans, V.J., Cannon, R.O. 3rd. (2000), 
Competition for p300 regulates transcription by estrogen receptors and 
nuclear factor kappaB in human coronary smooth muscle cells. Circulation 
Research, 87(11), 1006-1011.  
 
Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A., Neve, R.M., Kuo, 
W.L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., Symmans, 
W.F., Pusztai, L., Nolden, L.K., Horlings, H., Berns, K., Hung, M.C., van de 
Vijver, M.J., Valero, V., Gray, J.W., Bernards, R., Mills, G.B., Hennessy, 
B.T. (2008). An Integrative Genomic and Proteomic Analysis of PIK3CA, 
PTEN, and AKT Mutations in Breast Cancer. Cancer Research, 68(15), 
6084-6091. doi: 10.1158/0008-5472.CAN-07-6854. 
 
Stern, H.M., Gardner, H., Burzykowski, T., Elatre, W., O'Brien, C., Lackner, 
M.R., Pestano, G.A., Santiago, A., Villalobos, I., Eiermann, 
W., Pienkowski, T., Martin, M., Robert, N., Crown, J., Nuciforo, P., Bee, 
V., Mackey, J., Slamon, D.J., Press, M.F. (2015). PTEN Loss is Assoicaited 
with Worse Outcome in HER2-Amplified Breat Cancer Patients but is Not 
Associated with Trastuzumab Resistance. Clinical Cancer Research, 21(9), 
2065-2074. doi: 10.1158/1078-0432.CCR-14-2993. 
 
Stuart-Harris, R., Caldas, C., Pinder, S.E., Pharoah, P. (2008). Proliferation 
markers and survival in early breast cancer: A systematic review and meta-
analysis of 85 studies in 32,825 women. The Breast, 17(4), 323-334. doi: 
10.1016/j.breast.2008.02.002. 
 
Stylianou, S., Clarke, R.B., Brennan, K. (2006). Aberrant Activation of Notch 
Signaling in Human Breast Cancer. Cancer Research, 66(3), 1517-1525. 
doi: 10.1158/0008-5472.can-05-3054. 
 
Sweeney C., Lai C., Riese D.J. 2nd, Diamonti A.J., Cantley, L.C., Carraway, K.L. 
3rd. (2000). Ligand discrimination in signaling through an ErbB4 receptor 







Talotta, F., Cimmino, A., Matarazzo, M.R., Casalino, L., De Vita, G., D'Esposito, 
M., Di Lauro, R., Verde, P. (2008). An autoregulatory loop mediated by miR-
21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene, 
28(1), 73-84. doi: 10.1038/onc.2008.370. 
 
The Cancer Genome Atlas (TCGA). (2012). Comprehensive molecular portraits of 
human breast tumours. Nature, 490(7418), 61-70. doi: 
10.1038/nature11412. 
 
Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. 
Nature Review Cancer, 2(6), 442-454. doi: 10.1038/nrc822. 
 
Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Watanabe, 
S., Terada, M., Yamamoto, H. (1990). Correlation between histologic grade 
of milignancy and copy number of c-erb-2 gene in breast carcinoma. A 
retrospective analysis of 176 cases. Cancer, 65(8), 1794-1800.  
 
Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., Luu, T., Li, A.X., Wu, 
X., Ye, W., Chen, S., Zhou, W., Yu, Y., Wang, Y.Z., Ren, X., Li, H., Scherle, 
P., Kuroki, Y., Wang, S.E. (2012). CCL2 mediates crosstalk between 
cancer cells and stromal fibroblasts that regulates breast cancer stem cells. 
Cancer Research, 72(11), 2768-2779. doi: 10.1158/0008-5472.can-11-
3567. 
 
Tzahar, E., Pinkas-Kramarski, R., Moyer, J.D., Klapper, L.N., Alroy, I., Levkowitz, 
G., Shelly, M., Henis, S., Eisenstein, M., Ratzkin, B.J., Sela, M., Andrews, 
G.C., Yarden, Y. (1997). Bivalence of EGF-like ligands drives the ErbB 
signaling network. The EMBO Journal, 16(16), 4938–4950. doi: 
10.1093/emboj/16.16.4938. 
 
United States National Library of Medicine (USNLM). (2011). Genetics Home 




Untch, M.,  Fasching, P.A., Konecny, G.E., Hasmuller, S., Lebeau, A., Kreienberg, 
R., Camara, O., Müller, V., du Bois, A., Kühn, T., Stickeler, E., Harbeck, 
N., Höss, C., Kahlert, S., Beck, T., Fett, W., Mehta, K.M., von Minckwitz, 
G., Loibl, S. (2011). Pathologic Complete Response After Neoadjuvant 
Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human 
Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: 





Journal of Clinical Oncology, 29(25), 3351-3357. doi: 
10.1200/jco.2010.31.4930. 
 
Vaillant, F., Asselin-Labat, M-L., Shackleton, M., Forrest, N.C., Lindeman, 
G.J., Visvader, J.E. (2008). The Mammary Progenitor Marker CD61/β3 
Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary 
Tumorigenesis. Cancer Research, 68(19), 7711. doi: 10.1158/0008-
5472.CAN-08-1949. 
 
van de Vivjer, M.J., Peterse, J.L., Mooi, W.J., Wisman, P., Lomans, J., Dalesio, 
O., Nusse, R. (1988). Neu- Protein Overexpression in Breast Cancer. 
Association with comedo-type ductal carcinoma in situ and limited 
prognostic value in stage II breast cancer. New England Journal of 
Medicine, 319(19), 1239-1245. doi: 10.1056/NEJM198811103191902. 
 
van Diepen, M.T., Parsons, M., Downes, C.P., Leslie, N.R., Hindges, R., Eickholt, 
B.J. (2009). MyosinV controls PTEN function and neuronal cell size. Nature 
Cell Biology, 11(10), 1191-1196. doi: 10.1038/ncb1961. 
 
Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, 
M., Oh, D.Y., Diéras, V., Guardino, E., Fang, L., Lu, M.W., Olsen, 
S., Blackwell, K., EMILIA Study Group. (2012). Trastuzumab Emtansine for 
HER2-Positive Advanced Breast Cancer. The New England journal of 
medicine, 367(19), 1783-1791. doi: 10.1056/NEJMoa1209124. 
 
von Lintig, F.C., Dreilinger, A.D., Varki, N.M., Wallace, A.M., Casteel, D.E., Boss, 
G.R. (2000). Ras Activation in Human Breast Cancer. Breast Cancer 
Research and Treatment, 62(1), 51-62.  
 
Wang, F., Weaver, V.M., Petersen, O.W., Larabell, C.A., Dedhar, S., Briand, 
P., Lupu, R., Bissell, M.J. (1998). Reciprocal Interactions between β1-
Integrin and Epidermal Growth Factor Receptor I Three-Dimensional 
Basememnt Membrane Breast Cultures: A Different Perspective in 
Epithelial Biology. Proceedings of the National Academy of Sciences, 
95(25), 14821-14826.  
 
Wang, X., Trotman, L., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, 
J., Erdjument-Bromage, H., Tempst, P., Cordon-Cardo, C., Pandolfi, 
P.P., Jiang, X. (2007). NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for 
PTEN. Cell, 128(1), 129-139. doi: 10.1016/j.cell.2006.11.039. 
 
Weijzen, S., Rizzo, P., Braid, M., Vaishnav, R., Jonkheer, S.M., Zlobin, 
A., Osborne, B.A., Gottipati, S., Aster, J.C., Hahn, W.C., Rudolf, 





signaling maintains the neoplastic phenotype in human Ras-transformed 
cells. Nature Medicine, 8(9), 979-986. doi: 10.1038/nm754. 
 
Weinstein-Oppenheimer, C.R., Henríquez-Roldán, C.F., Davis, J.M., Navolanic, 
P.M., Saleh, O.A., Steelman, L.S., Franklin, R.A., Robinson, 
P.J., McMahon, M., McCubrey, J.A. (2001). Role of the Raf Signal 
Transduction Cascade in the in vitro Resistance to the Anticancer Drug 
Doxorubicin. Clinical Cancer Research, 7(9), 2898-2907.  
 
Weng, A.P., Nam, Y., Wolfe, M.S., Pear, W.S., Griffin, J.D., Blacklow, S.C., Aster, 
J.C. (2003). Growth suppression of pre-T acute lymphoblastic leukemia 
cells by inhibition of notch signaling. Molecular and Cellular Biology, 23(2), 
655-664. doi: 10.1128/MCB.23.2.655–664.2003. 
 
Weng, L-P., Brown, J.L., Eng, C. (2001). PTEN coordinates G1 arrest by down-
regulating cyclin D1 via its protein phosphatase activity and up-regulating 
p27 via its lipid phosphatase activity in a breast cancer model. Human 
Molecular Genetics, 10(6), 599-604. doi: 10.1093/hmg/10.6.599. 
 
Whelan, J.T., Forbes, S.L., Bertrand, F.E. (2007). CBF-1 (RBP-Jκ) Binds to the 
PTEN Promoter and Regulates PTEN Gene Expression. Cell Cycle, 6(1), 
80-84. doi: 10.4161/cc.6.1.3648. 
 
Whyte, J., Bergin, O., Bianchi, A., McNally, S., Martin, F. (2009). Key signalling 
nodes in mammary gland development and cancer. Mitogen-activated 
protein kinase signalling in experimental models of breast cancer 
progression and in mammary gland development. Breast Cancer Research, 
11(5), 209-209. doi: 10.1186/bcr2361. 
 
Wilson, T.R., Lee, D.Y., Berry, L., Shames, D.S., Settleman, J. (2011). Neuregulin-
1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase 
Inhibitors in a Subset of Human Cancers. Cancer Cell, 20(2), 158-172. doi: 
10.1016/j.ccr.2011.07.011. 
 
Witkiewicz, A.K., Cox, D., Knudsen, E.S. (2014). CDK4/6 inhibition provides 
 a potent adjunct to Her2-targeted therapies in preclinical breast cancer 
 models. Genes and Cancer, 5(7-8), 261-272. doi: 
 10.18632/genesandcancer.24. 
 
Wright, M.H., Calcagno, A.M., Salcido, C.D., Carlson, M.D., Ambudkar, 
S.V., Varticovski, L. (2008). Brca1 breast tumors contain distinct 
CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. 






Wulfkuhle, J.D., Berg, D., Wolff, C., Langer, R., Tran, K., Illi, J., Espina, 
V., Pierobon, M., Deng, J., DeMichele, A., Walch, A., Bronger, H., Becker, 
I., Waldhör, C., Höfler, H., Esserman, L., I-SPY 1 TRIAL 
Investigators, Liotta, L.A., Becker, K.F., Petricoin, E.F. 3rd. (2012). 
Molecular Analysis of HER2 Signaling in Human Breast Cancer by 
Functional Protein Pathway Activation Mapping. Clinical Cancer Research, 
18(23), 6426-6435. doi: 10.1158/1078-0432.CCR-12-0452. 
 
Xia, W., Mullin, R.J., Keith, B.R., Liu, L-H., Ma, H., Rusnak, D.W., Owens, 
G., Alligood, K.J., Spector, N.L. (2002). Anti-tumor activity of GW572016: a 
dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and 
downstream Erk1/2 and AKT pathways. Oncogene, 21(41), 6255 – 6263. 
doi: 10.1038/sj.onc.1205794. 
 
Xie, J., Xiao, Y., Zhu, X-Y., Ning, Z-Y., Xu, H.F., Wu, H.M. (2016). Hypoxia 
regulates stemness of breast cancer MDA-MB-231 cells. Medical Oncology, 
33(5), 42. doi: 10.1007/s12032-016-0755-7. 
 
Xu, M., Ren, Z., Wang, X., Comer, A., Frank, J.A., Ke, Z.J., Huang, Y., Zhang, 
Z., Shi, X., Wang, S., Luo, J. (2016). ErbB2 and p38γ MAPK Mediate 
Alcohol-Induced Increase in Breast Cancer Stem Cells and Metastasis. 
Molecular Cancer, 15(1), 52. doi: 10.1186/s12943-016-0532-4. 
 
Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., Arteaga, C.L. 
(2002). Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and 
Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and 
Antitumor Action. Cancer Research, 62(14), 4132-4141.  
 
Yamaguchi, N., Oyama, T., Ito, E., Satoh, H., Azuma, S., Hayashi, M., Shimizu, 
K., Honma, R., Yanagisawa, Y., Nishikawa, A., Kawamura, M., Imai, 
J., Ohwada, S., Tatsuta, K., Inoue, J., Semba, K., Watanabe, S. (2008). 
NOTCH3 Signaling Pathway Plays Crucial Roles in the Proliferation of 
ErbB2-Negative Human Breast Cancer Cells. Cancer Research, 68(6), 
1881-1888. doi: 10.1158/0008-5472.can-07-1597. 
 
Yamashita, H., Nishio, M., Toyama, T., Sugiura, H., Zhang, Z., Kobayashi, 
S., Iwase, H. (2004). Coexistence of HER2 over-expression and p53 protein 
accumulation is a strong prognostic molecular marker in breast cancer. 
Breast Cancer Research, 6(1), R24-30. doi: 10.1186/bcr738. 
 
Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T.H., Xiang, R., Markowitz, 
D., Reisfeld, R.A., Luo, Y. (2013). Tumor-Associated Macrophages 





EGFR/Stat3/Sox-2 Signaling Pathway. Stem Cells, 31(2), 248-258. doi: 
10.1002/stem.1281. 
 
Yang, X., Boehm, J.S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, 
R., Thomas, S.R., Alkan, O., Bhimdi, T., Green, T.M., Johannessen, 
C.M., Silver, S.J., Nguyen, C., Murray, R.R., Hieronymus, H., Balcha, 
D., Fan, C., Lin, C., Ghamsari, L., Vidal, M., Hahn, W.C., Hill, D.E., Root, 
D.E. (2011). A public genome-scale lentiviral expression library of human 
ORFs. Nature Methods 8(8), 659-661. doi: 10.1038/nmeth.1638. 
 
Yao, K., Rizzo, P., Rajan, P., Albain, K., Rychlik, K., Shah, S., Miele, L. (2012). 
Notch-1 and Notch-4 Receptors as Prognostic Markers in Breast Cancer. 
International Journal of Surgical Pathology, 19(5), 607 - 613. doi: 
10.1177/1066896910362080. 
 
Yarden, Y., Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. 
Nature Review Molecular Cell Biology, 2(2), 127-137. doi: 
10.1038/35052073. 
 
Yashiro-Ohtani, Y., He, Y., Ohtani, T., Jones, M.E., Shestova, O., Xu, L., Fang, 
T.C., Chiang, M.Y., Intlekofer, A.M., Blacklow, S.C., Zhuang, Y., Pear, W.S. 
(2009). Pre-TCR signaling inactivates Notch1 transcription by antagonizing 
E2A. Genes and Development, 23(14), 1665-1676. doi: 
10.1101/gad.1793709. 
 
Ye, X-M., Zhu, H-Y., Bai, W-D., Wang, T., Wang, L., Chen, Y., Yang, A.G., Jia, 
L.T. (2014). Epigenetic silencing of miR-375 induces trastuzumab 
resistance in HER2-positive breast cancer by targeting IGF1R. BMC 
Cancer, 14, 134-134. doi: 10.1186/1471-2407-14-134. 
 
Yim, E-K., Peng, G., Dai, H., Hu, R., Li, K., Lu, Y., Mills, G.B., Meric-Bernstam, 
F., Hennessy, B.T., Craven, R.J., Lin, S.Y. (2009). Rak functions as a tumor 
suppressor by regulating PTEN protein stability and function. Cancer Cell, 
15(4), 304-314. doi: 10.1016/j.ccr.2009.02.012. 
 
Yu, Q., Geng, Y., Sicinski, P. (2001). Specific protection against breast cancers by 
cyclin D1 ablation. Nature, 411(6841), 1017-1021. doi: 10.1038/35082500. 
 
Yun, J., Espinoza, I., Pannuti, A., Romero, D., Martinez, L., Caskey, 
M., Stanculescu, A., Bocchetta, M., Rizzo, P., Band, V., Band, H., Kim, 
H.M., Park, S.K., Kang, K.W., Avantaggiati, M.L., Gomez, C.R., Golde, 
T., Osborne, B., Miele, L. (2015). p53 Modulates Notch Signaling in MCF-7 





Via MAML1. Journal of Cellular Physiology, 230(12), 3115-3127. doi: 
10.1002/jcp.25052. 
 
Zagouras, P., Stifani, S., Blaumueller, C.M., Carcangiu, M.L., Artavanis-Tsakonas 
S. (1995). Alterations in Notch signaling in neoplastic lesions of the human 
cervix. Proceedings of the National Academy of Sciences, 92, 6414-6418.  
 
Zardawi, S.J., Zardawi, I., McNeil, C.M., Millar, E.K., McLeod, D., Morey, 
A.L., Crea, P., Murphy, N.C., Pinese, M., Lopez-Knowles, E., Oakes, 
S.R., Ormandy, C.J., Qiu, M.R., Hamilton, A., Spillane, A., Soon Lee, 
C., Sutherland, R.L., Musgrove, E.A., O'Toole, S.A. (2010). High Notch1 
protein expression is an early event in breast cancer development and is 
associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-
296. doi: 10.1111/j.1365-2559.2009.03475.x. 
 
Zebisch, A., Staber, P.B., Delavar, A., Bodner, C., Hiden, K., Fischereder, 
K., Janakiraman, M., Linkesch, W., Auner, H.W., Emberger, 
W., Windpassinger, C., Schimek, M.G., Hoefler, G., Troppmair, J., Sill, H. 
(2006). Two Transforming C-RAF Germ-Line Mutations Identified in 
Women with Therapy-Related Acute Myeloid Leukemia. Cancer Research, 
66(7), 3401-3408. doi: 10.1158/0008-5472.CAN-05-0115. 
 
Zeng, Q., Li, S., Chepeha, D.B., Giordano, T.J., Li, J., Zhang, H., Polverini, 
P.J., Nor, J., Kitajewski, J., Wang, C.Y. (2005). Crosstalk between tumor 
and endothelial cells promotes tumor angiogenesis by MAPK activation of 
Notch signaling. Cancer Cell, 8(1), 13-23. doi: 10.1016/j.ccr.2005.06.004. 
 
Zhang, C., Samanta, D., Lu, H., Bullen, J.W., Zhang, H., Chen, I., He, 
X., Semenza, G.L. (2016). Hypoxia induces the breast cancer stem cell 
phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation 
of NANOG mRNA. Proceedings of the National Academy of Sciences, 
113(14), E2047-E2056. doi: 10.1073/pnas.1602883113. 
 
Zhang, C.C., Paylicek, A., Zhang, Q., Lira, M.E., Painter, C.L., Yan, Z., Zheng, X., 
Lee, N.V., Ozeck, M., Qiu, M., Zong, Q., Lappin, P.B., Wong, A., Rejto, P.A., 
Smeal, T., Christensen, J.G. (2012). Biomarker and Pharmacological 
Evaluation of the γ-secretase Inhibitor PF-03084014 in Breast Cancer 
Models. Clinical Cancer Research, 18(18), 50008-5019. doi: 10.1158/1078-
0432.CCR-12-1379. 
 
Zhang, K., Wong, P., Zhang, L., Jacobs, B., Borden, E.C., Aster, J.C., Bedogni, B. 
(2011). A Notch1-neuregulin1 Autocrine Signaling Loop Contributes to 







Zhao, Y., Katzman, R.B., Delmolino, L.M., Bhat, I., Zhang, Y., Gurumurthy, 
C.B., Germaniuk-Kurowska, A., Reddi, H.V., Solomon, A., Zeng, 
M.S., Kung, A., Ma, H., Gao, Q., Dimri, G., Stanculescu, A., Miele, L., Wu, 
L., Griffin, J.D., Wazer, D.E., Band, H., Band, V. (2007). The notch 
regulator MAML1 interacts with p53 and functions as a coactivator. Journal 
of Biological Chemistry, 282(16), 11969-11981. doi: 
10.1074/jbc.M608974200. 
 
Zhou, W., Guo, S., Gonzalez-Perez, R.R. (2010). Leptin pro-angiogenic signature 
in breast cancer is linked to IL-1 signalling. British Journal of Cancer, 104(1), 
128-137. doi: 10.1038/sj.bjc.6606013. 
 
Zhuang, G., Brantley-Sieders, D.M., Vaught, D., Yu, J., Xie, L., Wells, S., Jackson, 
D., Muraoka-Cook, R., Arteaga, C., Chen, J. (2010). Elevation of receptor 
tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer 
Research, 70(1), doi: 10.1158/0008-5472.can-09-1845. 
 
Zimmermann, S., Moelling, K. (1999). Phosphorylation and Regulation of Raf by 









 Andrew Baker was born in Rochester, New York to Thomas and Jana 
Baker. He currently resides in Forest Park, Illinois with his beloved wife Anastasia 
Mousouli whom he married on November 15, 2015.  
 Andrew began his graduate research in the lab of Dr. Seiser at Roosevelt 
University. He completed his Master’s thesis on implementation of the BioBrick 
Program at Roosevelt University where he completed his Masters in 
Biotechnology. He went on to work at Valent Biosciences as well as Loyola 
University as a lab technician for the Campbell lab. Under Dr. Campbell he aided 
in the construction of the fluorescent tagged TRIM expression vector library. 
 In August of 2011, Andrew joined the Ph.D. program in the Cell Biology, 
Neurology, and Anatomy (CBNA) department of Loyola University, Chicago. 
Andrew joined the laboratory of Dr. Osipo where he studied the role of Notch-1 in 
trastuzumab resistant HER2+ breast cancer. He won the 2015 Senior Research 
Award for the Oncology Research Institute and Infectious Disease and 
Immunology Research Institute poster session at the Stritch School of medicine. 
He was awarded the Arthur J. Schmitt Dissertation Fellowship in 2016. He has had 
the opportunity to publish reviews, lecture classes, and aid in the completion of a 
number of papers. He has also acted as a research mentor for high school, 





 Andrew Baker has accepted a post-doctoral position at Harvard University 
in the Lab of Dr. Rueda where he will continue to perform research on endometrial 
cancer. He is looking forward to applying the methods and techniques he has 
learned about drug resistance in breast cancer and expounding upon them in a 
different cancer type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
